Saturday 31 August - European Society of Cardiology

ESC CONGRESS 2013
SATURDAY 31 AUGUST
SATURDAY
Browse the most up-to-date Scientific
Programme in the “ESC 2013” Mobile App.
Missed a session? Need to see it again?
Consult VOD & webcasts, slides, abstracts
& reports on ESC Congress 365, yourfree
access to ESC Congress content all year long.
www.escardio.org/365
Tweet about your favourite sessions: #ESCcongress2013

SATURDAY, 31 AUGUST 2013 – MORNING SESSIONS
09:30–10:30 | Chisinau - Central Village
CLINICAL CASES FOR PRACTITIONERS
Special Session
Chairperson(s): P.A. Sirnes (Moss, NO); R. Asteggiano (Turin, IT)
A patient with hypertension. Vascular screening and newer echocardiography techniques alter the
risk profile and treatment strategy.
09:30 Presenter. 1
– P.A. Sirnes (Moss, NO)
09:30 Panellists. 2
– S.L.M.A. Beeres (Leiden, NL), P.R.M. van Dijkman (The Hague, NL), J. Van Melle (Groningen, NL)
A very old and frail man with severe symptomatic aortic stenosis.
10:00 Presenter. 3
– R. Asteggiano (Turin, IT)
10:00 Panellists. 4
– S.L.M.A. Beeres (Leiden, NL), P.R.M. van Dijkman (The Hague, NL), J. Van Melle (Groningen, NL)
11:00–12:00 | Chisinau - Central Village
WHEN CURE IS NOT POSSIBLE: IMPROVING LIFE AND END-OF-LIFE
Clinical Seminar
Chairperson(s): D. Lehwaldt (Dublin, IE); P. Moons (Leuven, BE)
11:00 Guideline on implantable cardioverter-defibrillator deactivation. 5
– J. van Staaveren (Aalsmeer, NL)
11:18 Enhanced external counter-pulsation for refractory angina. 6
– E. Wu (Stockholm, SE)
11:36 End-stage heart failure and palliative care. 7
– J. Boyne (Maastricht, NL)
11:54 Take home messages from the chairs. 8
– D.Lehwaldt(Dublin,IE),P.Moons(Leuven,BE)
11:00–12:30 | Damascus - Central Village
THE HIGH-DENSITY LIPOPROTEIN STORY: WAITING FOR A HAPPY ENDING
Symposium
Chairperson(s): L. Tokgozoglu (Ankara, TR); J. Chapman (Paris, FR)
11:00 Dysfunctional high-density lipoprotein as a diagnostic and therapeutic target. 9
– M. Banach (Lodz, PL)
11:22 Genetic determinants of high-density lipoprotein cholesterol and risk of myocardial infarction. 10
– S. Kathiresan (Boston, US)
11:45 Effects of high-density lipoprotein on vascular function. 11
– U. Landmesser (Zurich, CH)
12:07 High-density lipoprotein lowering trials: what went wrong? 12
– J. Armitage (Oxford, GB)
11:00–12:30 | Tunis (The Hub) - Central Village
ELECTRICAL PROBLEMS – LOOK FOR THE UNDERLYING TRUTH
Clinical Cases
Chairperson(s): R. Hatala (Bratislava, SK); M. Pazdernik (Prague, CZ)
11:00 Regression of sinus node dysfunction after treatment of obstructive sleep apnea. 13
– N. Diaconu (Chisinau, MD)
11:12 Ictal bradycardia syndrome: an underdiagnosed cause of recurrent syncope and sudden
14
unexpected death in epilepsy (SUDEP).
– M.E.W. Hemels (Arnhem, NL)
11:25 Risk stratification for sudden cardiac death in a patient with dermatomyositis: the predictive role 15
of programmed ventricular stimulation.
– A.-I. Vouliotis (Athens, GR)
11:38 To ICD or not to ICD? 16
– I. Merinopoulos (Ipswich, GB)
11:51 A case of arrhythmia due to myocarditis treated by antiviral therapy: new diagnostic approaches 17
using peripheral biomarkers.
–E.M.Gupalo(Moscow,RU)
12:04 Cardiac conduction and rhythm disturbances in a patient with postinfectious polyradiculoneuritis 18
and unilateral diaphragmatic paralysis.
– M.I. Dregoesc (Cluj-Napoca, RO)
12:17 Severe right heart failure in a tunisian patient with thyrotoxicosis: a case report. 19
– A. Tounsi (Sfax, TN)
18

SATURDAY, 31 AUGUST 2013 – MORNING SESSIONS
11:00–12:30 | Baku (The Hub) - Central Village
RAPID FIRE – ACUTE CORONARY SYNDROMES IN THE FIRING LINE
Rapid Fire Abstract
Chairperson(s): M. Dalby (Harefield, GB); G. Dangas (New York, US)
11:00 Direct comparison of high-sensitivity cardiac troponin I versus T for the early diagnosis of acute 20
myocardial infarction.
– M. Rubini Gimenez, R. Twerenbold, T. Reichlin, B. Moehring, K. Wildi, B. Meller, P. Haaf, C. Zellweger,
S. Osswald, C. Mueller (Basel, CH)
11:06 Accelerated diagnostic protocol using high-sensitivity cardiac troponin T in acute chest pain
21
patients.
– B. Meller, L. Cullen, W.A. Parsonage, J. Greenslade, S. Aldous, T. Reichlin, K. Wildi, R. Twerenbold,
M. Than, C. Mueller (Basel, CH; Christchurch, NZ)
11:12 Atrial fibrillation is an independent predictor of hospital mortality in STEMI but not in NSTE-ACS in 22
clinical practice - results of the Euro heart survey ACS-registry.
– A.K. Gitt, M. Hochadel, R. Zahn, U. Zeymer, W. Wojakowski, M. Tendera, F. Schiele, J.P. Bassand
(Ludwigshafen am Rhein, DE; Katowice, PL; Besançon, FR)
11:18 Impact of statin use before the onset of acute myocardial infarction on coronary plaque
23
morphology of the culprit lesion, inflammatory response, and viable myocardium.
– H. Hikita, T. Shigeta, K. Kozima, K. Hishikari, Y. Oosaka, D. Akiyama, T. Sugiyama, S. Kimura,
A. Takahashi, M. Isobe (Yokosuka and Tokyo, JP)
11:24 Comparison of the efficacy of periprocedural rosuvastatin versus atorvastatin treatment in
24
patients with acute ST-elevation myocardial infarction undergoing primary percutaneous coronary
intervention.
– T.Q. Zhu, Q. Zhang, F.H. Ding, J.P. Qiu, H.G. Jin, L. Lu, R.Y. Zhang, J. Hu, Z.K. Yang, W.F. Shen
(Shanghai, CN)
11:30 Manual thrombectomy with platelet glycoprotein IIb/IIIa blockade is associated with lower
25
mortality in patients treated with primary PCI (9266 patients from the london heart attack group).
– M.M.Akhtar,B.N.Modi,D.A.Jones,A.Wragg(London,GB)
11:36 One-year survival according to use of thrombus aspiration for primary PCI in the real-world. The 26
FAST-MI 2010 registry.
– E. Puymirat, Y. Cottin, G. Vanzetto, D. Carrie, K. Isaaz, F. Schiele, D. Tchetche, P.G. Steg, T. Simon,
N. Danchin (Paris, Dijon, Grenoble, Toulouse, Saint-Etienne and Besançon, FR)
11:42 Ischemic postconditioning in ST-elevation myocardial infarction. Results of the POSTEMI trial. 27
– S. Limalanathan, G.O. Andersen, N.-E. Klow, M. Abdelnoor, P. Hoffmann, J. Eritsland (Oslo, NO)
11:48 Delayed stenting compared with immediate stenting in patients with ST-segment elevation
28
myocardial infarction.
– M. Chettibi, K. Yayehd, C. Ricard, A. Ghorab, M. Bouraghda, S. Bertal, R. Nedjar, M.A. Bouzid,
M.T. Bouafia, L. Belle (Blida, DZ; Annecy, FR)
11:54 Impact of intraaortic balloon counterpulsation in patients with acute myocardial infarction and 29
cardiogenic shock.
– H.W. Lee, K.S. Cha, J.H. Ahn, J.H. Kim, J.H. Oh, J.H. Choi, H.C. Lee, T.J. Hong, J.S. Park, M.H. Jeong
(Busan and Gwangju, KR)
12:00 Discussions around plasma screens outside the room.
SATURDAY – MORNING
19

SATURDAY, 31 AUGUST 2013 – MORNING SESSIONS
11:00–12:30 | Minsk (The Hub) - Central Village
RAPID FIRE – SIGNALLING IN CARDIAC HYPERTROPHY AND REMODELLING
Rapid Fire Abstract
Chairperson(s): S. Engelhardt (Munich, DE); J. Hall (Minneapolis, US)
11:00 Novel link between angiotensin II and Wnt signalling in myocardial fibrogenesis in inflammatory 30
cardiomyopathy.
– G. Kania, P. Blyszczuk, B. Mueller-Edenborn, S. Behnke, T.F. Luescher, U. Eriksson (Zurich and Eglisau,
CH)
11:06 Angiotensin-(1-9) antagonises cardiac remodelling via the angiotensin type 2 receptor. 31
– M. Flores-Munoz, D. Graham, A.H. Baker, G. Milligan, S.A. Nicklin (Glasgow, GB)
11:12 Early alterations of nuclear Ca2+-dependent signalling in cardiac hypertrophy. 32
– S. Ljubojevic, S. Radulovic, S. Sedej, J. Kockskaemper, B. Pieske (Graz, AT; Marburg, DE)
11:18 Secretoneurin regulates cardiomyocyte calcium homeostasis via CaMKII inhibition and is a potent 33
marker of mortality in patients with acute heart failure.
– A.H. Ottesen, W.E. Louch, C.R. Carlson, O.J.B. Landsverk, R.F. Johansen, M. Moe, M. Stridsberg,
T. Omland, G. Christensen, H. Rosjo (Lørenskog and Oslo, NO; Uppsala, SE)
11:24 Proliferative membrane changes of T-tubules and cell-wide network changes during cardiac
34
remodeling with orphaning of Ca2+ release sites are a general mechanism of heart failure.
– S.E. Lehnart, E. Wagner, T. Kohl, V. Westphal, U. Parlitz, S. Luther, S.W. Hell, M.S. Jafri, W.J. Lederer
(Göttingen, DE; Manassas and Baltimore, US)
11:30 Abnormal calcium handling in the progeric mouse model Zmpste24-/- is linked to reduced
35
sarcoplasmic reticulum calcium loading and depression of SERCA2 and calsequestrin-2
expression.
– A. Llach, J. Rivera, A. Herraiz, N. Cabello, C. Gonzalez, A. Vallmitjana, R. Benitez, V. Andres,
L. Hove-Madsen (Barcelona and Madrid, ES)
11:36 The tumor suppressor RAS-association domain family protein 1A (RASSF1A) regulates TNF-alpha 36
signaling in cardiomyocytes.
– T.M.A. Mohamed, M. Zi, A. Maqsood, S. Prehar, L. Neyses, D. Oceandy (Manchester, GB)
11:42 Calcineurin A stabilizes hypoxia-inducible factor-1 alpha via a heat shock protein (HSP) 90
37
dependent mechanism in myocardial hypertrophy.
– S. Eschricht, K.U. Jarr, C. Kuhn, H. Katus, N. Frey, E. Chorianopoulos (Heidelberg and Kiel, DE)
11:48 AMP-activated protein kinase dependent signaling pathways and modulation of autophagy are 38
involved in the anti-hypertrophic effect of the human beta 3 adrenoreceptor.
– E.Dubois-Deruy,J.Hammond,R.Gelinas,B.Manoury, J. Hamelet, I. Lobysheva, D. Langin, C. Dessy,
L. Bertrand, J.L. Balligand (Brussels, BE; Toulouse, FR)
11:54 G-protein coupled receptor kinase 2 (GRK-2), a new regulator in the pathological cardiac
39
hypertrophy by interacting NFAT signaling.
– J. Reinkober, H. Tscheschner, P. Schlegel, T. Wieland, J. Backs, W. Koch, H. Katus, P. Most, P. Raake
(Heidelberg and Mannheim, DE; Philadelphia, US)
12:00 Discussions around plasma screens outside the room.
11:00–12:30 | Vilnius - Village 1
PACEMAKER THERAPY IN 2013
Symposium
Chairperson(s): B. Merkely (Budapest, HU); F. Gadler (Stockholm, SE)
11:00 Can stroke prevention therapy be improved by atrial fibrillation burden detected by pacemaker 40
interrogation?
– P. Ritter (Pessac, FR)
11:22 A safe magnetic resonance imaging with conventional and conditional pacemakers. 41
– A.Roguin(Haifa,IL)
11:45 Is there a role for alternative right ventricular apical pacing? 42
– C. Butter (Bernau bei Berlin, DE)
12:07 Telemonitoring of pacemaker patients: future or futuristic? 43
– P. Mabo (Rennes, FR)
11:00–12:30 | Lisbon - Village 1
DIAGNOSTIC EVALUATION OF SYNCOPE
Clinical Seminar
Chairperson(s): R. Sutton (Monte Carlo,MC);G.Theodorakis(Athens,GR)
11:00 Patients with bundle branch block. 44
– A. Moya I Mitjans (Barcelona, ES)
11:22 The role of tilt table testing and autonomic testing. 45
– P. Flevari (Halandri, GR)
11:45 Syncope in the elderly. 46
– R.A. Kenny (Dublin, IE)
12:07 Syncope unit: a new necessity? 47
– M. Brignole (Lavagna, IT)
20

SATURDAY, 31 AUGUST 2013 – MORNING SESSIONS
11:00–12:30 | Ankara - Village 1
BURNING QUESTIONS IN CARDIAC RESYNCHRONISATION THERAPY
Abstract Session
Chairperson(s): A.S. Revishvili (Moscow, RU); H. Burri (Geneva, CH)
11:00 Cardiac resynchronization therapy in atrial fibrillation patients: a multinational registry: the certify 48
study.
– M. Gasparini, C. Leclercq, M. Lunati, M. Landolina, A. Auricchio, M. Santini, G. Boriani, A. Proclemer,
C. Klersy, F. Leyva (Rozzano, Milan, Pavia, Rome, Bologna and Udine, IT; Rennes, FR; Lugano, CH;
Birmingham, GB)
11:15 Benefit of cardiac resynchronization therapy in patients without a history of advanced heart
49
failure symptoms enrolled in MADIT-CRT.
– R. Herscovici, A.J. Moss, V. Kutyifa, A. Barsheshet, S. McNitt, W. Zareba, I. Goldenberg (Ramat Gan, IL;
Rochester, US)
11:30 Long-term outcome of cardiac resynchronization therapy in the elderly. 50
– N. Ehara, Y. Furukawa, K. Ando, T. Arita, M. Nobuyoshi, T. Kimura, S. Shizuta, K. Inoue, S. Fujii, T. Isshiki
(Kobe, Kitakyushu, Kyoto, Osaka, Kurashiki and Tokyo, JP)
11:45 The clinical benefits of atrioventricular and interventricular intervals optimization at long-term 51
follow-up in cardiac resynchronization therapy: results from CUBIC study.
– Y. Toyoshima, K. Inoue, K. Fujii, T. Isshiki, T. Kimura, M. Nobuyoshi, K. Ando, S. Shizuta, T. Arita, S. Fujii
(Osaka, Tokyo, Kyoto, Kitakyushu and Kurashiki, JP)
12:00 Intraoperative right to left ventricular interlead delay predicts outcome in CRT recipients. 52
– V.Kutyifa,E.Zima,S.Z.Szilagyi,A.Roka,G.Szucs,A.Kosztin,L.Molnar,G.Szeplaki,L.Geller,B.Merkely
(Budapest, HU)
12:15 Cardiac resynchronization therapy offers no benefits in patients with narrow QRS (

SATURDAY, 31 AUGUST 2013 – MORNING SESSIONS
11:00–12:30 | Kiev - Village 2
HEART FAILURE: NEW MECHANISMS – NEW THERAPIES
Abstract Session
Chairperson(s): J.L. Tamargo (Madrid, ES); S. Momomura (Saitama, JP)
11:00 Long-term therapy with Bendavia (MTP-131), a novel mitochondria-targeting peptide, normalizes 63
skeletal muscle fiber type composition in dogs with chronic heart failure.
– H.N. Sabbah, S. Rastogi, R.C. Gupta, K. Zhang, M. Wang (Detroit, US)
11:15 Mineralocorticoid receptor antagonists modulate ST2 signaling pathway in chronic heart failure. 64
– M.C. Asensio-Lopez, J. Sanchez-Mas, D.A. Pascual-Figal, L. Caballero, M.J. Fernandez Del Palacio,
G. Santarelli, S. Abenza, M.T. Perez-Martinez, M. Valdes-Chavarri, A.M. Lax (Murcia, ES)
11:30 Carvedilol sensitizes cardiac beta1-adrenergic receptors by increasing subsarcolemmal cAMP 65
levels through ligand-induced dissociation of PDE4 from beta1-adrenergic receptors.
– C. Maack, I. Lee, C. Molina, W. Richter, N. Wannenmacher, A. Zimmer, E. Qvigstad, R. Fischmeister,
M. Conti, M. Böhm (Homburg, DE; Chatenay-Malabry, FR; San Francisco, US; Oslo, NO)
11:45 Pro-atrial natriuretic peptide1-126 is processed in the human circulation to a mature GC-A
66
activating peptide with therapeutic potential in heart failure.
– T. Ichiki, B.K. Huntley, S.M. Sandberg, S.J. Sangaralingham, I.A. Anderson, J.C. Burnett (Rochester, US)
12:00 Galectin-3 as indicator of oxidative stress and inflammation in patients with chronic heart failure. 67
– E.A.Medvedeva,Y.V.Shchukin,E.I.Seleznev,I.I.Berezin(Samara,RU)
12:15 MiR-21 and miR-133 levels in peripheral blood mononuclear cells associate with left ventricular 68
diastolic dysfunction in patients with diastolic heart failure.
– M. Marketou, J. Kontaraki, E. Zacharis, F. Parthenakis, S. Margkoudakis, J. Logakis, P. Vardas (Heraklion,
GR)
11:00–12:30 | Podgorica - Village 3
CONTROVERSIES IN ANTITHROMBOTIC THERAPY
Debate Session
Chairperson(s): T.W. Weiss (Vienna, AT); D. Alexopoulos (Ekali, GR)
Bivalirudin is the ideal anticoagulant in percutaneous coronary intervention for high-risk acute
coronary syndrome.
11:00 Pro. 69
– H.J. Rupprecht (Ruesselsheim, DE)
11:15 Contra. 70
– G. Montalescot (Paris, FR)
Rebuttal.
11:30 Pro. 71
– H.J. Rupprecht (Ruesselsheim, DE)
11:35 Contra. 72
– G. Montalescot (Paris, FR)
11:40 Conclusion.
New oral anticoagulants are an important addition to dual antiplatelet therapy after acute
coronary syndrome.
11:45 Pro. 73
–C.Bode(Freiburg,DE)
12:00 Contra. 74
–S.Husted(Herning,DK)
Rebuttal.
12:15 Pro. 75
–C.Bode(Freiburg,DE)
12:20 Contra. 76
–S.Husted(Herning,DK)
12:25 Conclusion.
11:00–12:30 | Moscow - Village 3
WHAT IS NEW IN STENT THROMBOSIS?
Symposium
Chairperson(s): R.F. Storey (Sheffield, GB); A. Kastrati (Munich, DE)
11:00 High on-treatment platelet reactivity. 77
– D. Trenk (Bad Krozingen, DE)
11:22 Optimal duration of dual antiplatelet therapy. 78
– J.M. Ten Berg (Nieuwegein, NL)
11:45 The role of intravascular imaging. 79
– G. Guagliumi (Bergamo, IT)
12:07 Stent thrombosis in the new stent era. 80
– C. Varenhorst (Uppsala, SE)
22

SATURDAY, 31 AUGUST 2013 – MORNING SESSIONS
11:00–12:30 | Tirana - Village 3
QUALITY INDICATORS FOR ACUTE CARDIAC CARE
Chairperson(s): H. Bueno (Madrid, ES); P.M. Clemmensen (Copenhagen, DK)
Symposium
11:00 ESC-quality indicators for ST-elevation myocardial infarction; a work still in progress? 81
– F. Schiele (Besançon, FR)
11:22 ESC-quality indicators for acute heart failure: are we ready? 82
–S.Price(London,GB)
11:45 Quality indicators for acute coronary angioplasty: is it feasible? 83
– U. Zeymer (Ludwigshafen am Rhein, DE)
12:07 The dedicated European registry for quality assessment. 84
– N. Danchin (Paris, FR)
11:00–12:30 | Rabat - Village 4
STRESS AND CARDIOVASCULAR DISEASE: WHAT CAN WE DO ABOUT IT?
Chairperson(s): E. Prescott (Copenhagen, DK); S. Gupta (London, GB)
Symposium
11:00 Stress and cardiovascular disease: cause or trigger? 85
– A. Steptoe (London, GB)
11:22 The role of heart rate variability in evaluating stress. 86
– E. Clays (Ghent, BE)
11:45 Sleep patterns and cardiovascular health. 87
– H. Tiemeier (Rotterdam, NL)
12:07 Work related stress. 88
– S. Puttonen (Helsinki, FI)
SATURDAY – MORNING
11:00–12:30 | San Marino - Village 4
OUTCOME MEASURES IN SECONDARY PREVENTION – WHAT AND HOW TO MEASURE?
Chairperson(s): U. Laufs (Homburg, DE); M. Cupples (Belfast, GB)
Symposium
11:00 How to measure the effects of the components of a multidisciplinary intervention? 89
–K.Pieper(Durham,US)
11:22 Problems with surrogates: why do they not always predict patient outcomes? 90
– W.S. Weintraub (Newark, US)
11:45 Combined endpoints - source of manipulation and misinterpretations? 91
– K.K. Teo (Burlington, CA)
12:07 What are the best intermediate endpoints? 92
– T.F. Luscher (Zurich, CH)
11:00–12:30 | Algiers - Village 4
PERCUTANEOUS CORONARY INTERVENTION AND CORONARY ARTERY BYPASS GRAFTING:
THE NEXT 5 YEARS
Chairperson(s): A.P. Kappetein (Rotterdam, NL); H.K. Najm (Riyadh, SA)
Symposium
11:00 Is the absorable stent a real advance? 93
– P. Widimsky (Prague, CZ)
11:22 Which intervention and in whom? 94
– M.C.Morice(Massy,FR)
11:45 Hybrid revascularisation. 95
– C. Muneretto (Brescia, IT)
12:07 What further trials are needed? 96
– A.H. Gershlick (Leicester, GB)
23

SATURDAY, 31 AUGUST 2013 – MORNING SESSIONS
11:00–12:30 | Algiers - Village 4
THE SMOKING ROOM
Chairperson(s): E.S. Froelicher (Menlo Park, US); C. Chen-Huan (Taipei, TW)
Abstract Session
11:00 Smoking and risk of vascular and non-vascular mortality in old age: 15-year follow-up of 7000
men in the Whitehall resurvey.
– J. Emberson, N. Bhala, M. Shipley, A. Fletcher, R. Clarke (Oxford, Birmingham and London, GB)
11:15 Smoking influence on mortality: the 40 years’ follow up results of the Serbian cohorts of the seven
countries studies.
– B. Parapid, N. Milic, B. Obrenovic-Kircanski, V. Vukcevic, O.M.S. Nedeljkovic-Arsenovic, D. Simic,
I. Nedeljkovic, B. Beleslin, M.C. Ostojic (Belgrade, RS)
11:30 Cigarette smoking induces vascular damage of both conduit arteries and small vessels and
persistent elevation of plasma serotonin unresponsive to 8 weeks of smoking cessation.
– T. Sugiura, Y. Dohi, S. Yamashita, S. Tanaka, N. Ohte, Y. Hirowatari, S. Ito, S. Fujii (Nagoya and Ayase, JP)
11:45 Tobacco smoking increases leukocyte activation and decrease regulatory T cells in healthy
subjects.
– R. Mila Garcia, N. Lluberas Gonzalez, S. Grille Montauban, A.I. Gruss, A. Brugnini, N. Trias, A.I. Galan,
L. Llambi, D. Lens, R. Lluberas (Montevideo, UY)
12:00 Long-term implications on the incidence of ST-Elevation Myocardial Infarction after
implementation of a public smoking ban: a comparison between cantons in Switzerland.
– A.P. Porretta, M. Di Valentino, S. Muzzarelli, C. Limoni, G. Pedrazzini, C. Kaiser, T. Moccetti, S. Osswald,
A. Gallino (Bellinzona, Lugano and Basel, CH)
12:15 Immediate effects of electronic cigarette use on coronary circulation and blood
carboxyhemoglobin levels: comparison with cigarette smoking.
– K. Farsalinos, D. Tsiapras, S. Kyrzopoulos, C. Stefopoulos, A. Spyrou, M. Tsakalou, E. Avramidou,
D. Vasilopoulou, G. Romagna, V. Voudris (Athens, GR; Verbania, IT)
97
98
99
100
101
102
11:00–12:30 | Belgrade - Village 5
NEW ADVANCES IN THE TREATMENT OF CORONARY CHRONIC TOTAL OCCLUSION
Symposium
Chairperson(s): C. Di Mario (London, GB); T. Lefevre (Massy, FR)
11:00 Indications. 103
– G.S. Werner (Darmstadt, DE)
11:22 Antegrade approach. 104
– Y. Louvard (Massy, FR)
11:45 Retrograde approach. 105
– S. Rinfret (Quebec City, CA)
12:07 Minimally invasive off pump surgery. 106
– D.M. Holzhey (Leipzig, DE)
11:00–12:30 | Yerevan - Village 5
PERCUTANEOUS CORONARY REVASCULARISATION IN ACUTE CORONARY SYNDROMES Abstract Session
Chairperson(s): J.E.A. Appelman (Amsterdam, NL); M. Gilard (Brest, FR)
11:00 Transradial coronary intervention versus coronary artery bypass grafting for unprotected left main 107
and/or multivessel disease in patients with acute coronary syndrome.
– F. Gao, Y.J. Zhou, Z.J. Wang, S.W. Yang, X.L. Liu, D.A. Jia (Beijing, CN)
11:15 Efficacy of thrombus aspiration during percutaneous coronary intervention for stent thrombosis. 108
– S. Kubo, K. Kadota, S. Habara, T. Tada, H. Tanaka, Y. Fuku, H. Katoh, T. Goto, K. Mitsudo (Kurashiki, JP)
11:30 Non-achievement of TIMI-3-flow results in significant increase in hospital mortality of primary PCI 109
for STEMI and PCI for NSTE-ACS - findings of the Euro Heart survey PCI-registry.
– A.K. Gitt, T. Bauer, R. Zahn, U. Zeymer, C. Hamm (Ludwigshafen am Rhein and Bad Nauheim, DE)
11:45 Use and outcome of radial versus femoral approach in patients with primary PCI for acute ST 110
elevation myocardial infarction without cardiogenic shock: results of the ALKK PCI registry.
– T. Bauer, M. Hochadel, J. Brachmann, V. Schaechinger, P. Boekstegers, B. Zrenner, R. Zahn, U. Zeymer
(Ludwigshafen am Rhein, Coburg, Fulda, Siegburg and Landshut, DE)
12:00 Radial versus femoral approach in patients undergoing percutaneous coronary intervention for 111
acute coronary syndrome: meta-analysis and trial sequential analysis of randomized trials.
– R. Piccolo, T. Niglio, G. Di Gioia, C. D’Anna, R. De Rosa, T. Strisciuglio, B. Trimarco, F. Piscione,
G. Galasso (Naples and Salerno, IT)
12:15 Long-term results of multivessel and left main coronary artery stenting in comparison with
112
surgical revascularisation in patients with NSTE-ACS: the MILESTONE registry.
– P.P.Buszman,M.Gierlotka,A.Bochenek,K.Milewski,M.Gasiar,L.Polonski,R.S.Kiesz,M.Z.Zembala,
P.E. Buszman (Katowice and Zabrze, PL; San Antonio, US)
24

SATURDAY, 31 AUGUST 2013 – MORNING SESSIONS
11:00–12:30 | Valetta - Village 6
TRANSCATHETER AORTIC VALVE IMPLANTATION: AN ABC FOR THE GENERAL
CARDIOLOGIST
Chairperson(s): D. Messika-Zeitoun (Paris, FR); P. Kala (Brno, CZ)
Clinical Seminar
11:00 History of transcatheter aortic valve implantation. 113
– A. Cribier (Rouen, FR)
11:22 Referral pathways and pre-procedural evaluation. 114
– P. Tornos Mas (Barcelona, ES)
11:45 When is transcatheter aortic valve implantation appropriate and inappropriate? 115
– P.A. MacCarthy (London, GB)
12:07 Future perspectives. 116
– N. Piazza (Montreal, CA)
11:00–12:30 | Bratislava - Village 6
INFECTIVE ENDOCARDITIS – GUIDELINES ON TRIAL
Debate Session
Chairperson(s): W.H. Yin (Taipei, TW); L.A. Pierard (Liège, BE)
All patients with staphylococcal bacteraemia should undergo an urgent echocardiogram.
11:00 Pro. 117
– R.V. Rasmussen (Frederiksberg, DK)
11:15 Contra. 118
– N. Herring (Oxford, GB)
Rebuttal.
11:30 Pro. 119
– R.V. Rasmussen (Frederiksberg, DK)
11:35 Contra. 120
– N. Herring (Oxford, GB)
11:40 Conclusion.
Early surgery is mandatory in left sided infective endocarditis.
11:45 Pro. 121
– C.A. Mestres (Barcelona, ES)
12:00 Contra. 122
– M.J. Antunes (Coimbra, PT)
Rebuttal.
12:15 Pro. 123
– C.A. Mestres (Barcelona, ES)
12:20 Contra. 124
– M.J. Antunes (Coimbra, PT)
12:25 Conclusion.
SATURDAY – MORNING
11:00–12:30 | Vienna - Village 6
WHAT DETERMINES EXERCISE PERFORMANCE IN CONGENITAL HEART DISEASE
Abstract Session
Chairperson(s): L. Morales (Panama, PA); B.J.M. Mulder (Amsterdam, NL)
11:00 Myocardial deformation as provided by CMR based feature tracking is related to exercise
125
capacity and outcome in patients with repaired tetralogy of Fallot.
– S. Orwat, G.P. Diller, A. Kempny, R. Radke, B. Peters, P.B. Beerbaum, S. Sarikouch, H. Baumgartner
(Münster, Magdeburg and Hannover, DE)
11:15 Exercise capacity correlates with ventricle size in adult operated tetralogy of Fallot. 126
– J. Yap, R.S. Tan, F. Gao, T.T. Le, L. Zhong, Y.Y. Go, R. Liew, J.L. Tan, S.Y. Tan (Singapore, SG)
11:30 The impact of pulmonary valve replacement on left ventricular mechanical efficiency in adult 127
patients with tetralogy of fallot: a study with cardiac energetics.
– K. Yamamura, Y. Tanoue, I. Sakamoto, K. Uike, Y. Hirata, H. Nagata, Y. Shiokawa, K. Sunagawa,
R. Tominaga, T. Hara (Fukuoka, JP)
11:45 Exercise capacity in children after total cavopulmonary connection; lateral tunnel versus
128
extracardiac conduit technique.
– S.S.M. Bossers, W.A. Helbing, N. Duppen, I.M. Kuipers, A.D.J. Ten Harkel, T. Takken (Rotterdam,
Amsterdam, Leiden and Utrecht, NL)
12:00 Impaired preload reserve during exercise limits exercise capacity in the better Fontan patients. 129
– A. Van De Bruaene, A. La Gerche, G. Claessen, P. De Meester, S. Devroe, J. Bogaert, P. Claus,
H. Heidbuchel, W. Budts, M. Gewillig (Leuven, BE; Melbourne, AU)
12:15 Cardiac index, left ventricular longitudinal systolic function and atrialised right ventricle size affect 130
exercise capacity in adults with Ebsteins anomaly.
– Y.Shiina,W.Li,B.Bouzas,R.Rydman,A.Kempny,T.Karonis,O.Tutarel,M.A.Gatzoulis,P.J.Kilner,
S.V. Babu-Narayan (London, GB)
25

SATURDAY, 31 AUGUST 2013 – MORNING SESSIONS
11:00–12:30 | Warsaw - Village 7
HYPERTENSION AND THE HEART
Chairperson(s): P. Sleight (Oxford, GB); R.O. Darabont (Bucharest, RO)
Clinical Seminar
11:00 Left ventricular hypertrophy. 131
– G.deSimone(Naples,IT)
11:22 Heart failure. 132
– F. Ruschitzka (Zurich, CH)
11:45 Ischaemic heart disease. 133
– A.M. Heagerty (Manchester, GB)
12:07 Atrial fibrillation. 134
– G.Y.H. Lip (Birmingham, GB)
11:00–12:30 | Madrid - Village 7
THE HEART AND THE GUT. THE USE OF PROTON PUMP INHIBITORS IN PATIENTS WITH
CARDIOVASCULAR DISEASE AND ANTITHROMBOTIC THERAPY
Chairperson(s): S. Agewall (Oslo, NO); S. Levy (Marseille, FR)
Symposium
11:00 Bleeding risk associated with antithrombotic therapy. 135
– S. Wassmann (Munich, DE)
11:22 Acute coronary syndromes and proton pump inhibitors. 136
– F.W.A. Verheugt (Amsterdam, NL)
11:45 Platelet inhibition and proton pump inhibitors: pharmacokinetics and clinical evidence. 137
– D. Tsekoura (Athens, GR)
12:07 Warfarin and proton pump inhibitors. 138
– F. Andreotti (Rome, IT)
11:00–12:30 | Bern - Village 7
NEW FRONTIERS IN LIPID LOWERING
Chairperson(s): F. Martinez (Cordoba, AR); K. Hirata (Kobe, JP)
Abstract Session
11:00 No genetic determinants of differential cardiovascular event reduction by pravastatin in the
PROSPER/PHASE study.
– I.Postmus,S.Trompet,A.J.M.DeCraen,D.Shiffman,J.J.Devlin,I.Ford,N.Sattar,D.J.Stott,
P.E. Slagboom, J.W. Jukema (Leiden, NL; Alameda, US; Glasgow, GB)
11:15 SLCO1B1 polymorphisms affect atorvastatin pharmacokinetics and cholesterol-lowering effects in
patients with hypercholesterolemia in a microdosing approach.
– K. Kajinami, K. Takeda, K. Maeda, Y. Sugiyama, I. Ieiri, T. Masaugi, N. Fukizawa (Uchinada, Tokyo and
Fukuoka, JP)
11:30 HMG-CoA-reductase inhibitor co-therapy lowers the risk for incident heart failure in farmorubicin
recipients for two cancer locations.
– A.G. Tase, A. Tase, O. Tetiu, G. Savoiu, G. Stanciulescu, M. Mihaila (Pitesti, RO)
11:45 Homogeneity of treatment effect of REGN727/SAR236553, a fully human monoclonal antibody
against PCSK9, in lowering LDL-C: data from three phase 2 studies.
– P. Moriarty, G. Lecorps, C. Hanotin, R. Pordy, E.M. Roth (Kansas City, Tarrytown and Cincinnati, US; Paris,
FR)
12:00 The ABCA1 gene variant and heart disease risk reduction in the elderly during pravastatin
treatment.
– H. Akao, E. Polisecki, K. Kajinami, S. Trompet, I. Ford, J.W. Jukema, A.J.M. De Craen, R.G.J. Westendorp,
C. Packard, E.J. Schaefer (Boston and Framingham, US; Uchinada, JP; Leiden, NL; Glasgow, GB)
12:15 Effect of coenzyme Q 10 supplementation on myalgia induced by HMG-CoA reductase inhibitors.
A randomized, double-blind,placebo controlled study.
– D. Rott, D. Leibowitz (Jerusalem, IL)
139
140
141
142
143
144
11:00–12:30 | Oslo - Village 8
PITFALLS IN DETERMINING THE SEVERITY OF HEART VALVE DISEASE
Clinical Seminar
Chairperson(s): S. Rahimtoola (Los Angeles, US); R. Sicari (Pisa, IT)
11:00 Low flow low gradient aortic stenosis. 145
– R. Rosenhek (Vienna, AT)
11:22 Pressure recovery in aortic stenosis. 146
– S. Ray (Manchester, GB)
11:45 Mitral regurgitation in low cardiac output. 147
–J.L.MoyaMur(Madrid,ES)
12:07 Patient prosthesis mismatch. 148
– M. Galderisi (Naples, IT)
26

SATURDAY, 31 AUGUST 2013 – MORNING SESSIONS
11:00–12:30 | Ljubljana - Village 8
NON-INVASIVE IMAGING IN PULMONARY HYPERTENSION
Chairperson(s): A. Manes (Bologna, IT); L.M. Rincon (Madrid, ES)
Clinical Seminar
11:00 Right heart non-invasive haemodynamics: how reliable is it? 149
– A. Linhart (Prague, CZ)
11:22 A multimodality approach to assess right ventricular remodelling. 150
– D. Muraru (Padua, IT)
11:45 How to rule out pulmonary hypertension secondary to left heart disease? 151
– J.L. Vachiery (Brussels, BE)
12:07 Non-invasive prognostic parameters: old and new. 152
– V. Delgado (Leiden, NL)
11:00–12:30 | Stockholm - Village 8
NUCLEAR AND COMPUTED TOMOGRAPHY CARDIAC IMAGING TO PREDICT CORONARY Abstract Session
RISK
Chairperson(s): P. Knaapen (Amsterdam, NL); H. Sakuma (Tsu, JP)
11:00 Assessing the pretest likelihood of coronary artery disease - maximizing clinical information in the 153
age of high tech.
– A. Silva Ferreira, C.M. Santos, P. De Araujo Goncalves, H. Marques, H. Dores, M.S. Carvalho, N. Cardim,
F.P. Machado (Lisbon, PT)
11:15 Augmented inflammation in pericoronary adipose tissue is associated with future acute coronary 154
syndrome in patients with coronary artery disease.
– K. Nakanishi, S. Fukuda, A. Tanaka, T. Ikuta, K. Otsuka, K. Matsumoto, H. Inanami, J. Yoshikawa,
K. Shimada, M. Yoshiyama (Osaka, Tanabe, Higashiosaka and Nishinomiya, JP)
11:30 Coronary computed angiography screening on asymptomatic type 2 diabetic patients. 155 (W)
– M. Chang, I.J. Choi, S. Lim, M. Kang, B.H. Hwang, Y.S. Koh, J.M. Lee, S.H. Ihm, K. Chang, K.B. Seung
(Seoul, KR)
11:45 Prognostic value of routine cardiac stress imaging 5 years after percutaneous coronary
156
intervention.
– M.J. Zellweger, G. Fahrni, C.A. Kaiser, M.E. Pfisterer (Basel, CH)
12:00 Long term outcome of patients with high -risk exercise testing and normal myocardial perfusion 157
imaging.
– M.R. Wanderley, C.L. Pereira Da Cunha, C. Cunha, J.A. Da Silva, A. Stier, O. Franca Neto, O.J. Kormann,
I. Shin Ike, R. Cerci, J. Vitola (Curitiba, BR)
12:15 Prognostic value of coronary CT angiography for the prediction of major cardiovascular events. 158
– P. De Araujo Goncalves, A. Silva Ferreira, H. Marques, H. Dores, M.S. Carvalho, M.S. Santos, N. Cardim
(Lisbon, PT)
SATURDAY – MORNING
27

SATURDAY, 31 AUGUST 2013 – LUNCH TIME SESSIONS
13:00–14:00 | Chisinau - Central Village
NURSE-LED INITIATIVES IN THE NETHERLANDS
Chairperson(s): J.M.L. Hendriks (Maastricht, NL); T. Van Hecke (Ghent, BE)
Clinical Seminar
13:00 Renal failure, a complicating factor in cardiology patients. 159
– K. De Haan (Rotterdam, NL)
13:18 Responsible steps to expand the field of cardiovascular nursing. 160
– A. Van Goor (Utrecht, NL)
13:36 Is there a role for allied professionals in pacemaker implantation? 161
– J. Elders (Nijmegen, NL)
13:54 Comments from the chairs. 162
– J.M.L. Hendriks (Maastricht, NL), T. Van Hecke (Ghent, BE)
13:00–14:00 | Skopje - Village 5
RECENT ADVANCES IN MANAGEMENT OF ATRIAL FIBRILLATION
Sponsored by Cardiome Pharma Development AG
Chairperson(s): H.J.G.M. Crijns (Maastricht, NL); J.L. Merino (Madrid, ES)
Satellite Symposium
13:00 The 2012 ESC Guidelines for atrial fibrillation. 163
– D.Atar(Oslo,NO)
13:20 Economic aspects of atrial fibrillation. 164
– P. Kirchhof (Birmingham, GB)
13:40 Real-life experience with vernakalant – What is the right patient for this drug? 165
– J. Hartikainen (Kuopio, FI)
13:00–14:30 | Warsaw - Village 7
NEW FRONTIERS, NOVEL MECHANISMS, AND EVOLVING PARADIGMS FOR OPTIMIZING Satellite Symposium
CARDIOVASCULAR RISK REDUCTION IN PATIENTS WITH TYPE 2 DIABETES AND ACUTE
CORONARY SYNDROME
Sponsored by Roche
Chairperson(s): A.M. Lincoff (Cleveland,US);P.G.Steg(Paris,FR)
13:00 Cardiovascular risk reduction in patients with type 2 diabetes: unique challenges for the
166
cardiovascular specialist.
– A.M. Lincoff (Cleveland, US)
13:15 Mechanisms of macrovascular disease in high risk type 2 diabetes: critical, time-dependent
167
pathobiologic processes affecting atherogenic and thrombogenic heart disease in the setting of
type 2 diabetes.
– B. Staels (Lille, FR)
13:35 The pivotal roles of insulin resistance, glycemic target goal attainment, and lipid profile
168
management in the setting of type 2 diabetes: identifying optimal cardiometabolic target goals to
maximize cardiovascular risk reduction in patients with ACS and CAD.
–P.G.Steg(Paris,FR)
13:50 The potential foundation role of dual peroxisome proliferator-activated receptor agonists for 169
cardiovascular risk reduction in the diabetic patient with acs: addressing insulin resistance,
glycemic regulation, and dyslipidemia to optimize atheroprotection in T2D.
– A.M. Lincoff (Cleveland, US)
14:20 New therapeutic paradigms for optimizing cardiovascular risk reduction in patients with type 2 170
diabetes: the pivotal role of multifactorial cardiometabolic-focused interventions.
– G. Montalescot (Paris, FR)
13:00–14:30 | Ljubljana - Village 8
STATE OF THE ART AND FUTURE DIRECTIONS IN ADVANCED CARDIAC IMAGING Satellite Symposium
Sponsored by Toshiba Medical Systems
Chairperson(s): K. Nieman (Rotterdam, NL); J.L. Zamorano Gomez (Madrid, ES)
13:00 2D wall motion tracking in non-STEMI. 171
– S.I. Sarvari (Gjettum, NO)
13:20 Coronary subtraction on 2nd generation 320 row detector CT. 172
– K.F. Kofoed (Copenhagen, DK)
13:40 CORE320 in clinical practice. 173
– J.A.C. Lima (Baltimore, US)
14:00 Bringing it all together - Realtime fusion of ultrasound and CT. 174
– J.L. Zamorano Gomez (Madrid, ES)
14:20 Panel discussion: state of the art and future directions in advanced cardiac imaging. 175
– K. Nieman (Rotterdam, NL), J.L. Zamorano Gomez (Madrid, ES)
28

SATURDAY, 31 AUGUST 2013 – AFTERNOON SESSIONS
14:00–15:30 | Damascus - Central Village
GENOMICS OF CONGENITAL HEART DISEASE
Chairperson(s): D. Franco (Jaen, ES); R. Kelly (Marseille, FR)
Symposium
14:00 Genomic approaches to laterality in congenital heart defects. 176
– M. Brueckner (New Haven, US)
14:22 Functional genomics of cardiac development. 177
– L.A. Larsen (Copenhagen, DK)
14:45 Population genetics and congenital heart disease. 178
–A.Postma(Amsterdam,NL)
15:07 Systems biology to probe cardiac disease genes. 179
– H. Schunkert (Munich, DE)
14:30–16:00 | Chisinau - Central Village
TAKE HOME MESSAGE FOR PRACTITIONERS
In collaboration with the Council for Cardiology Practice
Chairperson(s): G. Baron Esquivias (Seville, ES); M. Guenoun (Plan-De-Cuques, FR)
Symposium
14:30 Prevention, hypertension and peripheral artery disease - update 2013. 180
– D.L. Clement (Ghent, BE)
14:48 Heart failure update 2013. 181
– K. Dickstein (Stavanger, NO)
15:06 Coronary artery disease update 2013. 182
– S. Silber (Munich, DE)
15:24 Cardiovascular imaging update 2013. 183
– L.A. Pierard (Liège, BE)
15:42 Arrhythmia and pacing update 2013. 184
– A. Moya I Mitjans (Barcelona, ES)
SATURDAY – AFTERNOON
14:45–16:15 | Vilnius - Village 1
WHY DO GOAL RATES IN HYPERTENSION URGENTLY NEED TO IMPROVE?
Sponsored by Daiichi Sankyo Europe GmbH and The Menarini Group
Chairperson(s): S. Laurent (Paris, FR); B. Williams (London, GB)
Satellite Symposium
14:45 Chairperson’s introduction: why do goal rates in hypertension urgently need to improve? 185
– S. Laurent (Paris, FR)
15:00 How to effectively and simply treat your patients to goal. 186
– R. Schmieder (Erlangen, DE), M. Volpe (Rome, IT)
15:30 Highlights from the new European Guidelines on arterial hypertension: what is new? 187
– J. Redon (Valencia, ES)
15:45 No guts, no glory: how to get 70% of patients to goal. 188
– J.-J. Mourad (Bobigny, FR)
16:05 Discussion and summary: why do goal rates in hypertension urgently need to improve? 189
– B. Williams (London, GB)
14:45–16:15 | Lisbon - Village 1
STROKE PREVENTION IN ATRIAL FIBRILLATION 2013: REGISTRY INSIGHTS AND Satellite Symposium
PERSPECTIVES
Sponsored by Thrombosis Research Institute London
Chairperson(s): A. Kakkar (London, GB); J.-P. Bassand (Thise, FR)
14:45 Introduction and status update of GARFIELD. 190
– A. Kakkar (London, GB)
14:55 Value of registries in understanding atrial fibrillation. 191
– D. Fitzmaurice (Birmingham, GB)
15:05 Coronary artery disease and atrial fibrillation. 192
– A.G.G. Turpie (Dundas, CA)
15:15 INRs in context of today’s clinical practice. 193
– S. Haas (Munich, DE)
15:25 The reality of persistence and compliance in atrial fibrillation. 194
– S. Goto (Isehara, JP)
15:35 Lessons learned from venous thromboembolism prevention. 195
– S.Z. Goldhaber (Boston, US)
15:45 Panel discussion: stroke prevention in atrial fibrillation 2013. 196
– J.-P. Bassand (Thise, FR), A. Kakkar (London, GB), D. Fitzmaurice (Birmingham, GB), S.Z. Goldhaber
(Boston, US), S. Goto (Isehara, JP), S. Haas (Munich, DE), W. Hacke (Heidelberg, DE), A.G.G. Turpie
(Dundas, CA)
29

SATURDAY, 31 AUGUST 2013 – AFTERNOON SESSIONS
14:45–16:15 | Luxembourg - Village 2
ANTIPLATELET THERAPY IN ACUTE CORONARY SYNDROMES: EBAC Accredited Educational Programme
TRANSLATING EVIDENCE INTO CLINICAL PRACTICE TO IMPROVE
OUTCOMES
Organised by the Sahlgrenska Academy – University of Gothenburg. Course Director: Prof. Karl Swedberg
Chairperson(s): C.B. Granger (Durham, US); F. Van de Werf (Leuven, BE)
14:45 Evolving evidence: bridging the gaps among clinical trials, registries, and clinical practice. 197
– F. Van de Werf (Leuven, BE)
15:10 Appropriate risk stratification in the management of acute coronary syndromes. 198
– A. Budaj (Warsaw, PL)
15:25 Combining antiplatelet and anticoagulant therapy: is more necessarily better? 199
–C.Bode(Freiburg,DE)
15:40 Assessing variability of response to antiplatelet therapy: is there a role for platelet function and 200
generic testing in clinical practice.
– P.A. Gurbel (Baltimore, US)
15:55 Panel and general discussion: antiplatelet therapy in acute coronary syndromes. 201
– C.B. Granger (Durham, US)
“This educational programme is accredited by the European Board for Accreditation in Cardiology (EBAC) for one
hour of External CME credits. Each participant should claim only those hours of credit that have actually been spent
in the educational activity. EBAC works in cooperation with the European Accreditation Council for Continuing
Medical Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS).”
Supported by an unrestricted educational grant from AstraZeneca
14:45–16:15 | Bucharest - Village 2
CLINICAL CROSSROADS IN THROMBOSIS: STROKE PREVENTION IN AF; SECONDARY Satellite Symposium
PREVENTION IN ACS
Sponsored by theheart.org / Medscape Education
Chairperson(s): E. Braunwald (Boston, US); F.W.A. Verheugt (Amsterdam, NL)
14:45 Acute coronary syndrome: atrial fibrillation - an update from TIMI. 202
– E.Braunwald(Boston,US)
15:05 Management of the patient with atrial fibrillation: is there still a role for vitamin K antagonists? 203
– A.J. Camm (London, GB)
15:20 Should CT angiography be routine in patients with suspected acute coronary syndrome? 204
– J.J. Bax (Leiden, NL)
15:35 Key clinical decisions in patients with acute coronary syndromes. 205
– C.W. Hamm (Bad Nauheim, DE)
15:50 Case presentation: the approach to the patient with chronic atrial fibrillation who develops an 206
acute coronary syndrome.
– F.W.A. Verheugt (Amsterdam, NL)
14:45–16:15 | Belgrade - Village 5
COMPLEX INTERVENTIONAL CARDIAC THERAPIES
Satellite Symposium
Sponsored by Siemens AG Healthcare Sector
Chairperson(s): O. Bruder (Essen, DE); U. Sechtem (Stuttgart, DE)
14:45 Without imaging no cardiac interventions - Opening remarks. 207
– U. Sechtem (Stuttgart, DE)
14:50 Stent enhancement in clincal practice. 208
– K. Cornelis (Gent, BE)
15:10 How to identify the patient that will benefit from coronary revascularization? 209
– C. Tillmanns (Berlin, DE)
15:30 Non-invasive imaging for structural heart disease interventions. 210
– S. Achenbach (Erlangen, DE)
15:50 Intracardiac volume echocardiography for guidance of transcatheter aortic valve implantation 211
(TAVI).
– T. Bartel (Innsbruck, AT)
16:10 The role of imaging for patient management - Closing remarks. 212
– O. Bruder (Essen, DE)
30

SATURDAY, 31 AUGUST 2013 – AFTERNOON SESSIONS
14:45–16:15 | Bern - Village 7
CAN WE IMPROVE MORBIDITY AND MORTALITY WITH TAILORED STRATEGIES IN Satellite Symposium
ACUTE HEART FAILURE?
Sponsored by theheart.org / Medscape Education
Chairperson(s): S.D. Anker (Berlin, DE); A.A. Voors (Groningen, NL)
14:45 Introduction: can we improve morbidity and mortality with tailored strategies in acute heart
213
failure?
– S.D. Anker (Berlin, DE)
14:55 Reality of AHF treatments today: lesson from observational data. 214
– D.Atar(Oslo,NO)
15:10 Vascular mechanism of acute heart failure. 215
– G.M. Felker (Durham, US)
15:25 Profiling and strategizing care in AHF: what the clinician needs to know. 216
– P. Ponikowski (Wroclaw, PL)
15:40 New evidence on morbidity and mortality: future prospects and strategies. 217
– A.A. Voors (Groningen, NL)
15:55 Panel discussion: can we improve morbidity and mortality with tailored strategies in acute heart 218
failure?
– A.A. Voors (Groningen, NL)
SATURDAY – AFTERNOON
14:45–16:15 | Oslo - Village 8
NEW METHODS TO ADDRESS COMMON 2D AND 3D ECHO CHALLENGES. PANEL Satellite Symposium
DISCUSSIONS ILLUSTRATED BY CLINICAL CASES.
Sponsored by Philips Healthcare
Chairperson(s): M.J. Monaghan (London, GB); J.-L. Vanoverschelde (Brussels, BE)
14:45 How anatomical intelligence can help assess the heart function. Panel discussion illustrated by 219
clinical cases.
– T. Buck (Essen, DE), R.M. Lang (Chicago, US), J.L. Zamorano Gomez (Madrid, ES)
15:45 Latest advances in periinterventional imaging. Panel discussion illustrated by clinical cases. 220
– K. Tiemann (Munich, DE), R.S. Von Bardeleben (Mainz, DE)
14:45–15:45 | Ljubljana - Village 8
PCSK9: THE NEW LIPID TARGET IN PREVENTIVE CARDIOLOGY? EBAC Accredited Educational Programme
Organised by University College London. Course Director: Prof. John Deanfield
Chairperson(s): J.J.P. Kastelein (Amsterdam, NL); E. Stein (Cincinnati, US)
14:45 Introduction: familial hypercholesterolemia: why are we not reaching goals in these patients? 221
– J.J.P. Kastelein (Amsterdam, NL)
14:55 PCSK9 inhibition: mechanistic insights into a new therapeutic approach for the lowering of LDL-c. 222
– G. Lambert (Le Kremlin-Bicêtre, FR)
15:10 Monoclonal antibodies that target PCSK9: what the first clinical trial data are telling? 223
– E. Stein (Cincinnati, US)
15:25 The roadmap of PCSK9 inhibitors towards the clinic: an overview of current development
224
programs & outcome studies.
–H.N.Ginsberg(NewYork,US)
15:40 Discussion & summary: PCSK9 – the new lipid target in preventive cardiology? 225
– J.J.P. Kastelein (Amsterdam, NL)
“This educational programme is accredited by the European Board for Accreditation in Cardiology (EBAC) for one
hour of External CME credits. Each participant should claim only those hours of credit that have actually been spent
in the educational activity. EBAC works in cooperation with the European Accreditation Council for Continuing
Medical Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS).”
Supported by an unrestricted educational grant from Amgen, Lilly, Regeneron/Sanofi
31

SATURDAY, 31 AUGUST 2013 – AFTERNOON SESSIONS
15:30–16:30 | Moderated Posters - Village 9
CHALLENGING CLINICAL ISSUES IN PULMONARY HYPERTENSION
Moderated Posters
Chairperson(s): O. Kozan (Izmir, TR);H.Shimokawa(Sendai,JP)
Posters are on display from 14:00 to 18:00 and moderated by two Chairpersons between 15:30 and 16:30. The following
abstracts were chosen for their outstanding quality – Presenters are in competition for the “best Moderated Poster” to win a free
registration for next year’s ESC Congress.
15:30 Demythologizing pulmonary artery aneurysm: prevalence and associated complications in a large P226
pulmonary arterial hypertension population.
– J.M. Montero Cabezas, M.J. Ruiz Cano, L. Alvarez Acosta, B. Barrios Garrido-Lestache, J. Delgado
Jimenez, M.A. Gomez Sanchez, A. Jurado Roman, J. Molina Martin De Nicolas, E. Gomez Mariscal,
P. Escribano Subias (Madrid, ES)
15:37 Genotype to phenotype correlations in heritable pulmonary arterial hypertension. P227
– F. Terzi, M. Palazzini, C. Bachetti, A. Albini, E. Monti, F. Dardi, G. Mazzanti, A. Manes, A. Branzi, N. Galie’
(Bologna, IT)
15:45 Myocardial and micro-vascular inflammation/infection in HIV/HCV associated pulmonary artery P228
hypertension.
– A. Frustaci, R. Verardo, F. Scopelliti, M. Francone, C. Grande, R. Badagliacca, D. Vizza, F. Fedele,
N. Petrosillo, C. Chimenti (Rome, IT)
15:52 Baseline hemodynamic predictors of treatment response in pulmonary arterial hypertension. P229
– C. Gerges, M. Gerges, Y. Zhou, L. Zhang, M.B. Lang, I.M. Lang (Vienna, AT; Research Triangle Park, US)
16:00 Right ventricular work increase during strenuous exercise is greater than for the left ventricle: P230
results from a real-time exercise cardiac magnetic resonance study.
– A. La Gerche, G. Claessen, A. Van De Bruaene, J. Bogaert, J. Van Cleemput, M. Gewillig, P. Claus,
H. Heidbuchel (Leuven, BE)
16:07 Shift in relative contribution of radial and longitudinal mechanics to right ventricular ejection P231
fraction between normal subjects and patients with pulmonary hypertension.
– A. Kovacs, D. Peluso, D. Muraru, L. Badano, S. Casablanca, L. Dal Bianco, G. Zoppellaro, S. Iliceto (Padua,
IT)
16:15 Diagnosis of right ventricular myocardial fibrosis using right ventricular myocardial CT
P232
attenuation, wall thickness and motion on ECG-gated 320 slice CT in subjects with pulmonary
hypertension.
– K. Ozawa, N. Funabashi, A. Kataoka, N. Yanagawa, N. Tanabe, K. Tatsumi, Y. Kobayashi (Chiba, JP)
16:22 Standardized fluid-challenge testing to distinguish Pulmonary Arterial Hypertension (PAH) from P233
pulmonary hypertension secondary to heart failure.
– F.P.T. Oosterveer, K.M. Marques, C.P. Allaart, F.S. De Man, H.J. Bogaard, A.C. Van Rossum,
N. Westerhof, A. Vonk-Noordegraaf, M.L. Handoko (Amsterdam, NL)
32

SATURDAY, 31 AUGUST 2013 – AFTERNOON SESSIONS
15:30–16:30 | Moderated Posters - Village 9
ANTITHROMBOTIC THERAPY: UNSOLVED PROBLEMS
Moderated Posters
Chairperson(s): J.A.C. Morais (Leiria, PT); B. Rocca (Rome, IT)
Session moderated by two Chairpersons between 15:30 and 16:30. The following abstracts were chosen for their outstanding
quality and will be discussed in a special area in the Poster Area (Village 9) – Presenters are in competition for the “best
Moderated Poster” to win a free registration for next year’s ESC Congress. Posters are on display from 14:00 to 18:00 (set up
13:30 – removed 18:00).
15:30 Randomized trial to examine the effect of ASA dose or ASA dosing frequency on ASA resistance P234
after coronary artery bypass graft surgery.
– J.S. Paikin, J.W. Eikelboom, R.P. Whitlock, J.S. Ginsberg, J.I. Weitz, G. Pare, J. Hirsh (Hamilton, CA)
15:37 The risk for stent thrombosis after discontinuation of clopidogrel for PCI patients waiting for P235
surgery.
– T.C. Godschalk, J.C. Kelder, J.M. Ten Berg (Nieuwegein, NL)
15:45 The predictors of discharge without clopidogrel following admission with acute coronary
P236
syndrome in australia - the concordance registry.
– M. Anastasius, J.K. Lau, K. Hyun, A. Patel, J. Rankin, D. Walters, C. Juergens, B. Costa, D. Brieger
(Sydney, Perth and Brisbane, AU)
15:52 Duration of dual anti-platelet therapy after acute myocardial infarction and impact on mortality. P237 (W)
Landmark analyses from the 5 year follow-up of the FAST-MI 2005 registry.
– F. Schiele, E. Puymirat, S. Cattan, P. Coste, Y. Cottin, B. Livarek, N. Meneveau, J. Ferrieres, T. Simon,
N. Danchin (Besançon, Paris, Montfermeil, Bordeaux, Dijon, Versailles and Toulouse, FR)
16:00 Intracranial hemorrhage in acute coronary syndrome: incidence, predictors, and outcomes from P238
APPRAISE-2, PLATO, and TRACER.
– K.W. Mahaffey, J. Horton, J.H. Alexander, P. Tricoci, R.A. Harrington, L. Wallentin (Durham and Stanford,
US; Uppsala, SE)
16:07 Clinical validation of BARC definitions of bleeding after an ACS in the TRACER trial. P239
– P. Vranckx, P. Tricoci, Z. Huang, F. Van De Werf, L. Wallentin, P. Aylward, P.W. Armstrong, D.J. Moliterno,
K.W. Mahaffey, H.D. White (Hasselt and Leuven, BE; Durham and Lexington, US; Uppsala, SE; Adelaide,
AU; Edmonton, CA; Auckland, NZ)
16:15 Lack of concordance between angiographic core laboratory and CEC in the assessment of stent P240
thrombosis: results from the TRACER angiographic substudy.
– C.M. Gibson, P. Tricoci, C. Abueg, K. Feeney, Z. Huang, M. Smith, E. Chen, K.W. Mahaffey (Boston,
Durham and Whitehouse Station, US)
16:22 PRT064445 reverses rivaroxaban induced anticoagulation in a rabbit liver laceration "treatment" P241
model.
– S. Hollenbach, S. Tan, F. Deguzman, J. Malinowski, A. Hutchaleelaha, M. Inagaki, J. Curnutte, G. Lu (South
San Francisco, US)
SATURDAY – AFTERNOON
17:00–18:00 | Amsterdam - Central Village
INAUGURAL SESSION
We invite all delegates to join this Special Session which will be immediately
followed by a networking reception in the ESC Plaza.
Special Event
Live from ESC Congress
33

SATURDAY, 31 AUGUST 2013 – AFTERNOON POSTERS
14:00–18:00 | Posters - Village 9
POSTER SESSION 1
Presenters will be by their poster during the coffee break from 15:30 to 16:30 for posters viewing time and discussant
interventions. Posters are on display from 14:00 to 18:00.
COMPUTERS
Poster Session
Discussant(s): Computers.
– T. Nieminen (Lahti, FI)
A data-driven clinical prediction rule for pulmonary embolism.
– L.G. Falsetti, E. Merelli, M. Rucco, C. Nitti, T. Gentili, M. Pennacchioni, A. Salvi (Ancona and Camerino, IT)
Association of electronic order set usage for heart failure and early post hospital outcomes.
– J. Howlett, A. Pattullo, J. Mandolesi, S. Aggarwal (Calgary, CA)
The wealth of nations and the dissemination of cardiovascular research.
– S.Winnik,D.A.Raptis,M.Komajda,J.J.Bax,M.Tendera,K.Fox,F.VanDeWerf,T.F.Luescher,
B.K. Nallamothu, C.M. Matter (Zurich, CH; Paris, FR; Leiden, NL; Katowice, PL; London, GB; Leuven, BE;
Ann Arbor, US)
Association between endothelial shear stress and neointimal formation in bioresorbable vascular
scaffolds. An OCT study.
– C. Bourantas, M.I. Papafaklis, A. Kotsia, T. Muramatsu, K.K. Naka, R. Rapoza, H.M. Garcia-Garcia,
Y. Onuma, L.K. Michalis, P.W. Serruys (Rotterdam, NL; Boston and Santa Clara, US; Ioannina, GR)
Vascular modelling and wall motion analysis of ascending and descending aorta with 3D-ultrasound
speckle tracking and finite element analysis.
– K. Karatolios, A. Wittek, C. Blase, A. Shelke, R. Moosdorf, S. Vogt (Marburg and Frankfurt, DE)
Finite element models of the left ventricle based on 3D speckle tracking echocardiography.
– K. Karatolios, A. Wittek, C. Blase, B. Schieffer, R. Moosdorf, S. Vogt (Marburg and Frankfurt, DE)
Is it important to monitor the percentage of cardiac resynchronization day by day?
– M. Mazurek, A. Liberska, K. Przybylska, J. Boidol, T. Podolecki, E. Jedrzejczyk-Patej, J. Kowalczyk,
R. Lenarczyk, O. Kowalski, Z. Kalarus (Zabrze, PL)
Exploring the impact of telemonitoring on prescription of guideline-recommended heart failure
medication.
– R. Dierckx, J. Zhang, T. Mabote, P. Pellicori, R. Antony, Y. Zhang, P. Atkin, C. Whitehead, K. Goode,
J.G.F. Cleland (Hull and York, GB)
Utility of the ST-segment deviation score in the risk prediction of patients with suspected acute
myocardial infarction.
– R. Twerenbold, T. Reichlin, R. Abaecherli, S. Sou, K. Wildi, P. Haaf, T. Hochgruber, M. Reiter, S. Osswald,
C. Mueller (Basel, CH)
QRS duration overweighs the LBBB morphology to predict response to cardiac resynchronization
therapy.
– L.E. Sade, I. Atar, B. Ozin, S. Demirtas, H. Muderrisoglu (Ankara, TR)
Selvester QRS score: an automated algorithm for the quantification of myocardial scar.
– G. Giannakakis, P. Flevari, M. Dafni, D. Leftheriotis, E. Iliodromitis, M. Anastasiou-Nana (Athens, GR)
Changes in spatial ventricular gradient and QRS-T angle induced by strict 5-days immobilization, and
effects of exercise countermeasure.
– E.G. Caiani, A. Pellegrini, J. Bolea, P. Vaida (Milan, IT; Zaragoza, ES; Bordeaux, FR)
Non-invasive mapping of endocardial and epicardial activation: a validation study.
– P. Oosterhoff, I.H. Gerrits, P.F.H.M. Van Dessel, A.C. Linnenbank, J.M.T. De Bakker, R. Coronel,
T.F. Oosterndorp, P.M. Van Dam (Amsterdam and Nijmegen, NL)
P242
P243
P244
P245
P246
P247
P248
P249
P250
P251
P252
P253
P254
P255
IMAGING OTHERS
Discussant(s): Imaging others.
– E.T. van der Velde (Leiden, NL)
Detection of coronary artery disease in postmenopausal women: the significance of integrated stress
imaging tests in a 4-year prognostic study.
Top Score Poster
– M.-M. Becker, C. Zwicker, E. Altiok, F.M. Mottaghy, J. Schroeder, N. Marx, R. Hoffmann (Aachen, DE)
Noninvasive compound ultrasound elastography for vulnerable plaque detection: in vivo validation.
– H.H.G. Hansen, G.J. De Borst, M.L. Bots, F. Moll, G. Pasterkamp, C.L. De Korte (Nijmegen and Utrecht,
NL)
Impact of chronic kidney disease on carotid atherosclerotic plaque prevalence and morphology: results
from the high-risk plaque bioimage study.
– U. Baber, S. Sartori, R. Mehran, E. Falk, M. Garcia, H. Sillesen (New York, US; Aarhus and Copenhagen,
DK)
Age- and gender-related differences in non-culprit versus culprit coronary plaques assessed with
intravascular ultrasound.
– A.W. Schoenenberger, N. Urbanek, S. Toggweiler, A.E. Stuck, T.J. Resink, P. Erne (Berne, Lucerne and
Basel, CH)
P256
P257
P258
P259
P260
34

SATURDAY, 31 AUGUST 2013 – AFTERNOON POSTERS
Cardiac iodine-123-Metaiodobenzylguanidine imaging predicts cardiac events in heart failure patients
evaluated for implantable cardiac defibrillator.
– P. Garcia-Gonzalez, O. Fabregat-Andres, P. Cozar-Santiago, J. Estornell-Erill, M. Ferrando-Beltran,
B. Bochard-Villanueva, A. Quesada-Dorador, R. Paya-Serrano, J. Ferrer-Rebolleda, F. Ridocci Soriano
(Valencia, ES)
The Near Infra-Red (NIRF) molecular imaging of oxidised LDL in atherosclerosis with the native
autoantibody LO1, and its molecularly expressed cysteine-tagged Fab construct (LO1-Fab-cys).
– R. Khamis, K. Woollard, S.H. Chang, D.W. Granger, J.J.Boyle,M.Johns,P.M.Matthews,D.O.Haskard
(London and Stevenage, GB)
Non-invasive assessment of microvascular dysfunction in families with premature coronary artery
disease.
– T.A. Mulders, M. Nieuwdorp, E.S.G. Stroes, H. Vink, S.J. Pinto-Sietsma (Maastricht and Amsterdam, NL)
Diabetic patients with cardiac syndrome x: methods to investigate coronary microvascular function and
new angiography indexes.
– V. Sucato, S. Evola, E. Bronte, G. Novo, S. Novo (Palermo, IT)
Clinical evaluation of dynamic layer separation for coronary DSA and enhancement in fluoroscopic
sequences.
– J. Rieber, H. Rittger, S. Henrichs, M. Ostermeier, M. Baylacher, M. Schmidt, E. Hoffmann (Munich, Coburg
and Forchheim, DE)
Total costs and outcomes of bare metal stent placement with intravascular ultrasound compared with
angiography alone: a cost-effectiveness analysis from the perspective of the Italian health system.
– M.Wasserman,V.Priest,A.Alberti,A.Gelera,L.Stefanini,M.Simmonds(London,GB;Singapore,SG;
Milan, IT)
Fatal and non-fatal cancer and medical radiation exposure in a population hospitalized for cardiovascular
disease.
– C. Carpeggiani, P.L. Landi, C.M. Michelassi, E.P. Picano (Pisa, IT)
Validation of the aortic dissection detection risk score in the emergency department.
– F. Morello, M. Castelli, S. Vanni, F. Giachino, A. Bono, D. Forno, F. Soardo, P. Nazerian, L. Betti, S. Grifoni
(Turin and Florence, IT)
P261
P262
P263
P264
P265
P266
P267
P268
SATURDAY – AFTERNOON
MULTIMODALITY IMAGING VALVE
Discussant(s): Multimodality imaging valve.
– R. Sicari (Pisa, IT)
Impact of angle between interventricular septum and ascending aorta on ellipsoid-shaped aortic annuls
evaluated by three-dimensional transthoracic echocardiography.
– N.Harada,Y.Wada,S.Okuda,Y.Nose,K.Uchida,W.Murakami,T.Ariyoshi,H.Tsutsumi,M.Yano(Ube,
JP)
Aortic annulus eccentricity before and after transcatheter aortic valve implantation: comparison of
balloon-expandable and self-expandable prostheses.
– A. Schuhbaeck, C. Weingartner, M. Arnold, J. Schmid, T. Pflederer, M. Marwan, H. Nef, M. Uder,
M. Weyand, S. Achenbach (Erlangen and Giessen, DE)
Accuracy of aortic root annulus assessment with cardiac magnetic resonance in patients referred for
transcatheter aortic valve implantation: a comparison with multidetector computed tomography.
– G. Pontone, D. Andreini, E. Bertella, S. Mushtaq, P. Gripari, S. Cortinovis, M. Loguercio, A. Baggiano,
E. Conte, M. Pepi (Milan, IT)
Advanced diffuse fibrosis is associated with mid-wall fibrosis in patients with aortic stenosis.
– C.W.L. Chin, S. Semple, T. Malley, A. White, S. Prasad, D.E. Newby, M.R. Dweck (Edinburgh and London,
GB)
Independent predictor CMR of mortality in patient with surgical aortic stenosis.
– G. Barone-Rochette, S. Pierard, C. De Meester De Ravensteen, J. Melchior, F. Maes, A.-C. Pouleur,
D. Vancraeynest, A. Pasquet, J.-L. Vanoverschelde, B.L. Gerber (Grenoble, FR; Brussels, BE)
Optimization of T1 mapping at 3T in patients with aortic stenosis.
– C.W.L. Chin, S. Semple, T. Malley, A. White, S. Prasad, D. Newby, M. Dweck (Edinburgh and London, GB)
Inconsistent grading of severe chronic aortic and mitral regurgitation by cardiovascular magnetic
resonance using current guideline cut-off values.
– C.L. Polte, K.M. Lagerstrand, S. Gao, U. Cederbom, O. Bech-Hanssen (Gothenburg and Trollhattan, SE)
Aortic valve area, stroke volume,left ventricular hypertrophy, remodeling and fibrosis in aortic stenosis
assessed by cardiac MRI.
– G. Barone-Rochette, S. Pierard, S. Seldrum, C. De Meester De Ravensteen, J. Melchior, A.-C. Pouleur,
D. Vancraeynest, A. Pasquet, J.-L. Vanoverschelde, B.L. Gerber (Grenoble, FR; Brussels, BE)
Aortic valve sclerosis: an early marker of systemic atherosclerosis and coronary microvascular
dysfunction.
– A. Fisicaro, V. Tufaro, M. Loffi, A. Cappelletti, P.G. Camici, A. Margonato, E. Agricola (Milan, IT)
Doppler-derived left ventricular negative dp/dt as a predictor of atrial fibrillation or ischemic stroke in
patients with degenerative mitral regurgitation and normal ejection fraction.
– J.E. Yi, J.Y. Chin, D.H. Lee, C.H.O. Ej, H.K. Jeon, H.O. Jung, H.J. Youn (Seoul, KR)
Paravalvular leaks after double valve replacement with reconstruction of the mitral aortic intervalvular
fibrosa for infective endocarditis.
– F. De Torres Alba, T. Lopez Fernandez, S. Valbuena Lopez, U. Ramirez Valdris, A. Iniesta Manjavacas,
N. Montoro Lopez, I. Moreno Gomez Limon, M. Moreno Yanguela, J.M. Mesa Garcia, J.L. Lopez Sendon
(Madrid, ES)
P269
P270
P271
P272
P273
P274
P275
P276
P277
P278
P279
P280
35

SATURDAY, 31 AUGUST 2013 – AFTERNOON POSTERS
Prosthetic meCHAnical mitral ring clot: clinical implication of utility of Serial real time three dimensional
transesophageal Echocardiography in the evaluation of THRombus evolution (CHASE-THR trial).
– M.O. Gursoy, S. Karakoyun, M. Kalcik, Z. Bayram, B. Cakal, M. Yesin, G. Kahveci, N. Eksi Duran, M. Yildiz,
M. Ozkan (Istanbul, TR)
Projected aortic valve area reflects true severity in patients with paradoxical low-flow low-gradient
severe aortic stenosis: a Multicenter Aortic Stenosis Assessment (MASA) study.
– M. Izumo, M. Takeuchi, Y. Seo, E. Yamashita, K. Suzuki, T. Ishizu, S. Oshima, K. Aonuma, F. Miyake,
Y. Otsuji (Kawasaki, Kitakyusyu, Tsukuba and Maebashi, JP)
Clinical utility and prognostic value of appropriateness criteria in stress echocardiography for evaluation
of valvular heart disease.
– S. Bhattacharyya, V. Kamperidis, B. Shah, I. Roussin, N. Chahal, W. Li, R. Khattar, R. Senior (London and
Harrow, GB)
P281
P282
P283
CHRONIC PULMONARY HYPERTENSION
Discussant(s): Chronic pulmonary hypertension.
– R.N. Naeije (Brussels, BE), M. Beghetti (Geneva, CH), To be announced
The role of vascular obstruction site on pulsatile afterload in patients with pulmonary hypertension.
– M.J. Ruiz Cano, M. Vicente, L. Dos Subira, M. Lazaro, A. Lara, J.A. Barbera Mir, A. Roman Broto,
M.J. Castillo, P. Escribano Subias (Madrid, Barcelona, Toledo, Santa Cruz de Tenerife and Seville, ES)
Enhanced [18F]fluorodeoxyglucose accumulation in the right ventricular free wall predicts long-term
prognosis of patients with pulmonary hypertension.
– S. Tatebe, Y. Fukumoto, K. Sugimura, K. Satoh, Y. Miura, K. Nochioka, M. Miura, M. Oikawa-Wakayama,
Y. Kagaya, H. Shimokawa (Sendai, JP)
Long-term survival of patients with repaired Congenital Heart Disease associated Pulmonary Arterial
Hypertension (CHD-PAH) in the modern management era.
– M.-L. Sun, C.-Y. Cheng, D.-C. Wu, Q.-H. Zhao, Q.-Q. Liu, R. Jiang, X. Jiang, Z.-C. Jing (Shanghai, CN)
In vivo assessment of pulmonary arterial vasculopathy by intravascular ultrasound in patients evaluated
for lung transplantation.
– G. Zavala, E. Domingo, C. Arredondo, G. Marti, M. Vazquez, M. Lopez-Messeguer, A. Roman (Barcelona,
ES)
Correlation between serum matrix metalloproteinase-2/tissue inhibitors of metalloproteinase-2 ratio and
elevated pulmonary vascular resistance.
– K. Hisazaki, H. Uzui, K. Arakawa, N. Amaya, K. Kaseno, K. Ishida, T. Morishita, T. Sato, J.D. Lee, H. Tada
(Fukui, JP)
Plasma cxc-chemokine ligand 10, 12 and 16 levels correlate significantly with patients’ clinical
characteristics in idiopathic pulmonary arterial hypertension.
– T. Yang, Z.N. Li, G. Chen, Q. Gu, X.H. Ni, Z.H. Zhao, Z.H. Liu, C.M. Xiong, J.G. He (Beijing, CN)
Potential involvement of functional tricuspid regurgitation in the diagnostic error to assess pulmonary
arterial pressure by doppler echocardiography.
– S. Yamamoto, Y. Matsumoto, K. Nochioka, M. Miura, S. Tatebe, K. Sugimura, T. Suzuki, Y. Fukumoto,
H. Shimokawa (Sendai, JP)
Formation of typical vascular lesions in a new experimental model of pulmonary arterial hypertension.
Top Score Poster
– M.-P. Winter, A. Alimohammadi, A. Panzenboeck, M.K. Frey, M. Sibilia, S. Alias, D. Santer, B. Podesser,
F. Nagel, I.M. Lang (Vienna, AT)
Beta-3 adrenoreceptor stimulation reduces pulmonary vascular resistance in experimental models of
acute and chronic pulmonary hypertension in pigs.
– A. Garcia-Alvarez, D. Pereda, M. Nuno-Ayala, R. Fernandez-Jimenez, D. Sanz-Rosa, J. Garcia-Prieto,
L. Fernandez-Friera, J.M. Garcia-Ruiz, V. Fuster, B. Ibanez (Madrid, ES)
The role of gas exchange measurements during exercise in the detection of early pulmonary arterial
hypertension in scleroderma patients - a multi-center analysis.
– D. Dumitrescu, G. Kovacs, C. Nagel, M. Halank, J. Winkler, E. Gruenig, H. Olschewski, R. Ewert,
S. Rosenkranz (Cologne, Heidelberg, Dresden, Leipzig and Greifswald, DE; Graz, AT)
Pulmonary vascular reactivity in pulmonary hypertension due to left heart disease.
– C. Gerges, M. Gerges, M.B. Lang, J. Mascherbauer, I.M. Lang (Vienna, AT)
Specific targeting of Egr-1 reduces neointimal lesions and improves RV remodeling in PAH.
– M.G.Dickinson,B.Bartelds,M.A.J.Borgdorff,P.Kowalski, J.A.A.M. Kamps, G. Molema, R.M.F. Berger
(Groningen, NL)
Troponin elevation correlates with pulmonary hypertension and hemolytic burden in sickle cell pain crisis.
– S. Rajpal, J. Hilbun, A. Dwary, T. Smith, G. Mina, P.C. Reddy, N.I. Akkus (Shreveport, US)
Efficacy of sildenafil therapy in children with pulmonary hypertension secondary to congenital
systemic-to-pulmonary shunts.
– I. Palii, E. Vataman, P. Stratulat (Chisinau, MD)
Mode of death in patients with pulmonary arterial hypertension.
– C.D.Vizza,B.Pezzuto,R.Poscia,M.Mezzapesa,M.Nocioni,M.D’Alto,S.Ghio,L.Scelsi,P.Vitulo,
F. Fedele (Rome, Naples, Pavia and Palermo, IT)
Role of mitochondrial dysfunction in cachexia secondary to pulmonary arterial hypertension.
– J. Justino, A.I. Padrao, A.F. Silva, R. Nogueira-Ferreira, T. Henriques-Coelho, R. Ferreira, F. Amado,
J.A. Duarte, A. Leite-Moreira, D. Moreira-Goncalves (Porto and Aveiro, PT)
Pulmonary venous hypertension in end-stage chronic obstructive pulmonary disease with preserved
systolic left ventricular function.
– K.H. Andersen, J. Kjaergaard, M.P. Iversen, S. Boesgaard, J. Carlsen (Copenhagen, DK)
P284
P285
P286
P287
P288
P289
P290
P291
P292
P293
P294
P295
P296
P297
P298
P299
P300
P301
36

SATURDAY, 31 AUGUST 2013 – AFTERNOON POSTERS
Survivin role in pulmonary arterial hypertension.
– M.J. Ferreira-Pinto, A.F. Silva, R. Nogueira-Ferreira, A.I. Padrao, D. Moreira-Goncalves, F. Carneiro,
R. Costa, L. Ribeiro, A.F. Leite-Moreira, T. Henriques-Coelho (Porto and Aveiro, PT)
Protective effect of right ventricular mitochondrial damage by cyclosporine A in monocrtaline-induced
pulmonary hypertension.
– D. Lee, Y.W. Jung (Kyeongju, KR)
Children with pulmonary arterial hypertension (PAH) associated with congenital heart disease are treated
less intensively with PAH-targeted drugs compared to children with idiopathic/hereditary PAH.
– W.M.H. Zijlstra, J.M. Douwes, E.B. Rosenzweig, S. Schokker, U. Krishnan, M.T.R. Roofthooft,
K. Miller-Reed, H.L. Hillege, D.D. Ivy, R.M.F. Berger (Groningen, NL; New York and Aurora, US)
Sildenafil add-on therapy to ERA mono-therapy is effective in paediatric pulmonary arterial hypertension.
– J.M. Douwes, M.T.R. Roofthooft, B. Bartelds, M.D. Talsma, H.L. Hillege, R.M.F. Berger (Groningen, NL)
Preliminary results of the determination of BMPR2 mutations and clinical implications in a Spanish
population of patients with pulmonary arterial hypertension.
– E. Barrios, J. Tenorio, P. Lapunzina, M. Vicente, N. Ochoa, A. Parra, M.J. Ruiz-Cano, J. Delgado,
M.A. Gomez-Sanchez, P. Escribano (Madrid, ES)
EPITOME-4, an open-label phase 3b study evaluating a new formulation of epoprostenol sodium in
Japanese pulmonary arterial hypertension patients following switch from Flolan.
– Y. Tamura, T. Ono, K. Fukuda, T. Satoh, S. Sasayama (Tokyo and Kyoto, JP)
Hemodynamic assessment of patients with pulmonary hypertension due to lung disease and/or hypoxia.
– M.Gerges,C.Gerges,M.B.Lang,I.M.Lang(Vienna,AT)
Cardiovascular risk factors are associated with a reduced response to drug therapies in pulmonary
arterial hypertension.
– A.C. Charalampopoulos, I. Tzoulaki, L.S. Howard, R. Davies, W. Gin-Sing, M.R. Wilkins, J.S.R. Gibbs
(London, GB)
Geometry of the right heart and tricuspid regurgitation to exclude elevated pulmonary artery pressure:
new insights.
– P. De Meester, A. Van De Bruaene, P. Herijgers, J.-U. Voigt, M. Delcroix, W. Budts (Leuven, BE)
Prevalence of iron deficiency in pulmonary hypertension and comparison according etiology.
– N. Moreira, R. Baptista, G. Castro, A. Marinho, M.J. Ferreira, M. Pego (Coimbra, PT)
Pulmonary artery wave reflection: observations in pulmonary hypertension.
– S.D. Murch, T. Roberts, A. La Gerche, A.I. Macisaac, D.L. Prior, A.T. Burns (Melbourne, AU)
Hypertrophy of right ventricular septomarginal trabeculation by cardiac magnetic resonance imaging
predicts presence and severity of pulmonary hypertension and outcome.
– G. Karakus, B.A. Marzluf, C. Tufaro, S. Pfaffenberger, J. Babayev, G. Maurer, D. Bonderman,
J. Mascherbauer (Istanbul, TR; Vienna, AT)
Clinical prediction rule for identifying patients with pulmonary veno-occlusive disease/pulmonary capillary
hemangiomatosis.
– A. Ogawa, K. Miyaji, H. Matsubara (Okayama, JP)
The impairment of pulmonary function is related to the development of pulmonary hypertension in
patients with cystic fibrosis?
– M.A. Prioli, R. Scarsini, G. Pesarini, A. Cristofaletti, C. Castellani, B. Assael, G. Tridello, E.G. Milano,
G. Dolci, C. Vassanelli (Verona, IT)
Predicting survival in pulmonary hypertension with echocardiography: insights from a French single
centre cohort.
– P. Moceri, O. Chiche, D. Baudouy, C. Checler, C. Sanfiorenzo, S. Leroy, R. Saady, P. Cerboni, E. Ferrari
(Nice, FR)
Left ventricular mass and volume in patients with idiopathic pulmonary arterial hypertension and
Eisenmenger’s syndrome.
– G. Kopec, D. Moertl, M. Waligora, A. Tyrka, T. Miszalski-Jamka, P. Podolec (Krakow, PL; St Poelten, AT)
Thrombocytopenia in pulmonary hypertension, does it predict survival?
– H. Weaver, R. Tulloh (Bristol, GB)
A significant difference between survival estimates predicted by National Institutes of Health and
Pulmonary Hypertension Connection equations in comparison to five-year observed survival.
– S.Ozturk,C.Kaymaz,O.Akbal,H.C.TokgozDemircan,N.Poci,F.Yilmaz,T.Aktemur,N.Kirca,
S. Kulahcioglu, N. Ozdemir (Istanbul, TR)
Prognostic value of C-reactive protein in patients with Eisenmenger syndrome.
– G. Scognamiglio, A. Kempny, R. Alonso-Gonzalez, R. Agra-Bermejo, A. Uebing, P. Marino, L. Swan,
M.A. Gatzoulis, K. Dimopoulos, S.J. Wort (London, GB)
Absence of acute vasoreactivity response in patients with pulmonary arterial hypertension associated
with toxic oil syndrome.
– E. Barrios, M.A. Gomez-Sanchez, C. Hernandez, M.T. Velazquez, N. Ochoa, J.M. Montero, J. Delgado,
M.J. Ruiz-Cano, P. Escribano, J. Tascon (Madrid and Las Palmas de Gran Canaria, ES)
Pulmonary artery size and intrinsic wall properties in patients with pulmonary hypertension.
– C.-D. Botezatu, R. Enache, O. Nastase, B.A. Popescu, M. Rosca, C. Beladan, A. Calin, M.M. Gurzun,
C. Ginghina (Bucharest, RO)
Comparison of hemodynamic parameters in treatment-naive and pretreated patients with pulmonary
arterial hypertension (PAH) in the Phase III PATENT-1 study.
Top Score Poster
– Z.-C. Jing, N. Galie, H.-A. Ghofrani, M. Humbert, D. Langleben, L.J. Rubin, M.M. Hoeper, A. Fritsch,
N. Davie, A.M. Keogh (Shanghai, CN; Bologna, IT; Giessen, Hannover and Wuppertal, DE; Le
Kremlin-Bicêtre, FR; Montreal, CA; La Jolla, US; Sydney, AU)
P302
P303
P304
P305
P306
P307
P308
P309
P310
P311
P312
P313
P314
P315
P316
P317
P318
P319
P320
P321
P322
P323
SATURDAY – AFTERNOON
37

SATURDAY, 31 AUGUST 2013 – AFTERNOON POSTERS
Echocardiographic evaluation of the impact of exercise training at different time points of the
development of experimental pulmonary hypertension.
– N. Moreno, D. Moreira-Goncalves, C. Shmidt, A. Bovolini, T. Henriques-Coelho, A. Leite-Moreira (Porto, PT)
Right heart deformation mechanics in patients with pulmonary hypertension.
– K. Keramida, N. Kouris, V. Kostopoulos, V. Karidas, D. Damaskos, C. Kairis, G. Makavos, C.D. Olympios
(Athens, GR)
Prognostic evaluation of patients with pulmonary hypertension by combined non-invasive assessment of
pulmonary vascular resistance and right ventricular function.
– M. Kawamukai, M. Koyama, J. Nishida, H. Kouzu, A. Muranaka, N. Kokubu, S. Yuda, A. Hashimoto,
K. Tsuchihashi, T. Miura (Sapporo, JP)
The right to left atrial and ventricular area ratio, left ventricular area,TAPSE and right ventricular global
strain can predict three-year survival in patients with pulmonary hypertension.
– C. Kaymaz, S. Ozturk, N. Poci, T. Aktemur, O. Akbal, H.C. Tokgoz Demircan, T. Bezgin, F. Yilmaz,
I.H. Tanboga, N. Ozdemir (Istanbul, TR)
Plasma levels of soluble P-selectin predict survival in CTEPH.
– R. Sadushi-Kolici, C. Ay, M.P. Winter, S. Panzer, A. Panzenboeck, N. Skoro-Sajer, W. Klepetko,
I.Pabinger,I.M.Lang(Vienna,AT)
Long-term survival and functional status of adult patient with Eisenmenger syndrome.
– H. Joly, A. Soufi, R. Henaine, F. Sassolas, J. Ninet, A. Bozio, O. Metton, S. Di Filippo (Lyon, FR)
Utility of acute improvement of peak oxygen consumption after adding bosentan for predicting
hemodynamic parameters at mid-term follow-up in patients with pulmonary arterial hypertension.
– R. Nishio, H. Tanaka, Y. Tsuboi, M. Shigeru, T. Sawa, H. Kinutani, Y. Taniguchi, Y. Sakai, N. Emoto,
K. Hirata (Kobe, JP)
Doppler echocardiography pulmonary artery flow acceleration time: an adjunctive parameter to select
candidates with suspected pulmonary hypertension to proceed to right heart catheterization.
– A.Fontana,A.Vincenzi,G.Paciocco,G.DeVito,A.Marinari,G.Trocino,A.Ciro’,C.DeCarlini,M.R.Pozzi,
F. Achilli (Monza, Milan and Merate, IT)
Myeloperoxidase, osteopontin and asymmetrical dimethylarginine as biomarkers of pulmonary
hypertension severity.
– A.V. Kazimli, A.V. Ryzhkov, N.S. Goncharova, A.V. Naymushin, O.M. Moiseeva (St. Petersburg, RU)
Left ventricular rotational deformation is impaired in pulmonary hypertension: a speckle tracking- based
study.
– S. Yurdakul, Z.K. Bingol, T. Sahin, B. Cengiz, A. Bozkurt, E. Kiyan, S. Aytekin (Istanbul, TR)
Can echocardiography discriminate between pulmonary arterial hypertension and pulmonary
hypertension related to left heart disease in patients with cardiovascular risk factors?
– A.C. Charalampopoulos, I. Tzoulaki, L.S. Howard, R. Davies, W. Gin-Sing, M.R. Wilkins, J.S.R. Gibbs
(London, GB)
Right ventricular wall hypertrophy predicts functional capacity in pulmonary hypertension. A cardiac
magnetic resonance study.
– S.A. Mouratoglou, G. Giannakoulas, A. Kallifatidis, V. Kamperidis, S. Hatjimiltiadis, H. Karvounis
(Thessaloniki, GR)
Diagnostic accuracy of the 100% oxygen method in detecting pulmonary right-to-left shunts compared to
transthoracic contrast echocardiography.
– S. Velthuis, V.M.M. Vorselaars, C.J.J. Westermann, R.J. Snijder, J.J. Mager, M.C. Post (Nieuwegein, NL)
Pre-test probability of having a pre-capillary rather than a post-capillary pulmonary hypertension: an easy
and integrated echocardiographic score.
– M. D’Alto, E. Romeo, P. Argiento, A. D’Andrea, R. Vanderpool, A. Correra, N. Borrelli, M.G. Russo,
R. Calabro’, R. Naeije (Naples, IT; Brussels, BE)
Long-term safety and survival outcomes of patients with pulmonary arterial hypertension enrolled in an
open label continuation study with tadalafil 40mg daily.
– N. Galie, R.J. Barst, R.J. Oudiz, B. Li, A. Esler, G. Simonneau (Bologna, IT; New York, Torrance,
Indianapolis and Ann Arbor, US; Clamart, FR)
P324
P325
P326
P327
P328
P329
P330
P331
P332
P333
P334
P335
P336
P337
P338
CHRONIC THROMBO EMBOLIC PULMONARY HYPERTENSION
Discussant(s): Chronic trombo embolic pulmonary hypertension.
– I.M. Lang (Vienna, AT)
Hemodynamic improvement through beneficial vessel reaction following balloon pulmonary angioplasty
for distal-type chronic thromboembolic pulmonary hypertension.
– H. Kinutani, T. Shinke, H. Otake, Y. Taniguchi, N. Emoto, K. Nakayama, K. Hirata (Kobe, JP)
The cause of lumen enlargement after balloon pulmonary angioplasty for patients with chronic
thromboembolic pulmonary hypertension-intravascular ultrasound assessment.
– H. Shimokawahara, A. Ogawa, H. Mizoguchi, S. Ikemiyagi, K. Miyaji, M. Munemasa, H. Matsubara
(Okayama, JP)
Assessment of right ventricular function by three-dimensional myocardial strain echocardiography in
chronic thromboembolic pulmonary hypertension before and after balloon pulmonary angioplasty.
– T. Onishi, H. Tanaka, Y. Fukuda, Y. Motoji, Y. Taniguchi, T. Shinke, N. Emoto, J. Gorcsan, H. Kawai,
K. Hirata (Kobe, JP; Pittsburgh, US)
Hemodynamic parameters during exercise in patients with chronic thromboembolic disease after
pulmonary endarterectomy. Is there a complete normalization of pulmonary vascular wall after surgery?
– E. Barrios, P. Escribano, M. Vicente, M. Paradinas, C. Garcia, M.J. Martinez, N. Ochoa, J. Delgado,
M.A. Gomez-Sanchez, M.J. Ruiz-Cano (Madrid, ES)
P339
P340
P341
P342
P343
38

SATURDAY, 31 AUGUST 2013 – AFTERNOON POSTERS
D-dimer in chronic thromboembolic pulmonary hypertension.
– A. Kurz, N. Skoro-Sajer, R. Ristl, I. Lang (Vienna, AT)
Splenectomy delays thrombus resolution.
– M.K. Renner, S. Alias, M.P. Winter, B. Redwan, G. Stuebiger, A. Panzenboeck, J. Jakowitsch,
H. Bergmeister, K.T. Preissner, I.M. Lang (Vienna, AT; Münster and Giessen, DE)
P344
P345
INTERVENTION – PERIPHERAL CIRCULATION – SURGERY
Discussant(s): Intervention – peripheral circulation – surgery.
– A.F. Gallino (Bellinzona, CH), E. Van Belle (Lille, FR), H. Gamra (Monastir, TN)
One year clinical and angiographic outcomes after everolimus- and paclitaxel-eluting stent implantation
for small coronary vessels in diabetic patients: sub-analysis from PLUM and SACRA registries.
– K. Nasu, Y. Oikawa, M. Suzuki, H. Ota, Y. Nakagawa, T. Ozaki, Y. Takeuchi, J. Yamashita, T. Suzuki,
M. Muto (Toyohashi, Tokyo, Sapporo, Hamamatsu and Koriyama, JP)
Medial degenerative disease and atherosclerosis in bicuspid and tricuspid aortic valve-associated
thoracic aortic aneurysm.
– E. Malev, E. Luneva, V. Uspensky, L. Mitrofanova, M. Paydimirova, E. Zemtsovsky (St. Petersburg, RU)
Bilateral retrograde radial approach in stenting of occluded subclavian artery.
– D. Petkoska, B. Zafirovska, A. Jovkovski, S. Kedev (Skopje, MK)
The impact of peripheral arterial disease on outcome after percutaneous transluminal angioplasty for
arteriovenous fistula: a 1-year retrospective analysis.
– M.M. Balci, K.G. Balci, A. Kirkpantur, A. Turkvatan, O. Er, S.K. Acikgoz (Ankara and Yozgat, TR)
Gene therapy in peripheral arterial disease: a systematic review and meta-analysis of randomized,
controlled trials.
– S. Steiner, A. Hammer (Vienna, AT)
Vascular flow reserve immediately after infrapopliteal intervention as a predictor of wound healing in
patients with critical limb ischemia.
– M. Fukunaga, K. Fujii, D. Kawasaki, K. Miki, H. Tamaru, T. Imanaka, M. Ohyanagi, T. Masuyama
(Nishinomiya, JP)
Long-term clinical outcome and predictors after femoropopliteal stenting with self-expandable nitinol
stent for critical limb ischemia.
– Y. Tomoi, Y. Soga, O. Iida, K. Hirano, K. Suzuki, Y. Miyashita, N. Suematsu, Y. Shintani, M. Nobuyoshi
(Kitakyushu, Amagasaki, Yokohama, Sendai, Matsumoto, Fukuoka and Kurume, JP)
Temporal profile of brain injury and inflammatory serum markers in carotid artery stenting.
– F.DellaPina,A.Rizza,M.S.Parri,G.Basta,C.Prontera,A.Mazzone,A.Clemente,S.Berti(Massaand
Pisa, IT)
Impact of 2010 Ghent criteria and subgroups definition to optimize diagnosis, avoid aortic dissection and
choose the right surgical timing in the experience of the Tor Vergata Marfan Centre registry.
– S. Grego, M. Russo, F. Versaci, P. Polisca, P. Nardi, L. Chiariello (Rome and Isernia, IT)
The evaluation of pulse wave velocity using Arteriograph and Complior apparatus across different
cardiovascular-related diseases.
– I. Ikonomidis, K. Ntai, N.P.E. Kadoglou, I. Papadakis, C. Koukoulis, B. Tritakis, P. Trivilou, H. Triantafyllidi,
M. Anastasiou-Nana, J. Lekakis (Athens, GR)
Differences between short- and long-term outcome of type b acute aortic dissection vs intramural
haematoma.
– S. Moral Torres, A. Evangelista, D. Gruosso, H. Cuellar, V. Galuppo, A. Carro, J.A. Urbano-Moral,
M.T. Gonzalez-Alujas, J.F. Rodriguez-Palomares, D. Garcia-Dorado (Barcelona, ES)
Acute anemia and cardiovascular events after vascular surgery.
– D. Calderaro, S.M. Gualandro, D.M. Gualandro, P.C. Yu, G.L.A. Carmo, A.C. Marques, E.A. D‘Amico,
T.R.F. Rocha, B. Caramelli, A.F. Pastana (São Paulo, BR)
Transfer metrics for patients with suspected acute aortic syndrome.
– B. Aggarwal, C.E. Raymond, E. Roselli, J. Jacob, D.D. Holloway, K. Kormos, D. Kralovic, V. Menon
(Cleveland, US)
Reliability of the abdominal aortic aneurysm screening by novice physicians using handheld ultrasound
device. A prospective study.
– T. Bonnafy, T. Cautres, A. Labrunie, I. Desormais, P. Vignon, P. Lacroix, V. Aboyans (Limoges, FR)
Drug-eluting stent for revascularization of infrapopliteal arteries: a meta-analysis of randomized trials.
– S. Cassese, G. Ndrepepa, G. Tepe, I. Ott, L. King, T. Tada, A. Kastrati, M. Fusaro (Munich and Rosenheim,
DE)
Platelet aggregation decrease after vascular surgery and is related to cardiovascular events.
– D. Calderaro, A.F. Pastana, T.R.F. Rocha, P.C. Yu, D.M. Gualandro, G.A.L. Carmo, E. D‘Amico,
P. Puech-Leao, N. De Luccia, B. Caramelli (São Paulo, BR)
Impact of stent placement compared with balloon angioplasty in small vessel of femoropopliteal disease.
– N. Kamioka, Y. Soga, H. Aihara, H. Yokoi, M. Iwabuchi, M. Nobuyoshi (Kitakyushu, JP)
Aortic stiffness assessed by pulse wave velocity is predictive of outcome after coronary artery bypass
grafting: a prospective study.
– T. Cautres, P. Lacroix, T. Bonnafy, A. Leclerc, M. Laskar, V. Aboyans (Limoges, FR)
Clinical-pathogical correlation in surgically resected ascending aorta aneurysms.
– S. Rizzo, M. Martin, R. Razzolini, G. Gerosa, G. Thiene, C. Basso (Padua, IT)
Perivascular adipose tissue supresses superoxide production in internal mammary artery grafts by
regulating Rac1-mediated activation of vascular NADPH-oxidase.
– M. Margaritis, A. Antonopoulos, S. Reilly, R. Sayeed, R. Desilva, M. Petrou, D. Tousoulis, C. Stefanadis,
K.M. Channon, C. Antoniades (Oxford, GB; Athens, GR)
P346
P347
P348
P349
P350
P351
P352
P353
P354
P355
P356
P357
P358
P359
P360
P361
P362
P363
P364
P365
P366
SATURDAY – AFTERNOON
39

SATURDAY, 31 AUGUST 2013 – AFTERNOON POSTERS
Long-term follow-up after endovascular treatment in patients with femoropopliteal TASC II class A and B
lesion.
– N. Kamioka, Y. Soga, H. Aihara, Y. Kobayashi, K. Ichihashi, S. Hiramori, N. Murata, Y. Tomoi, H. Yokoi
(Kitakyushu, JP)
Characteristics and outcome of patients over 75 years old hospitalized for lower extremity peripheral
artery disease in France.The COPART registry.
– T.Mirault,C.Chamoin,J.P.Cambou,V.Aboyans,P.Lacroix,J.Constans,A.Rossi,A.Stansal,
A. Bura-Riviere, E. Messas (Paris, Toulouse, Limoges and Bordeaux, FR)
Characteristics and outcome of patients hospitalized for lower extremity peripheral artery disease in
France and receiving betablockers. The COPART registry.
– T.Mirault,A.Galloula,J.P.Cambou,V.Aboyans,P.Lacroix,J.Constans,A.Rossi,A.Stansal,
A. Bura-Riviere, E. Messas (Paris, Toulouse, Limoges and Bordeaux, FR)
Long-term experience in patients undergoing endovascular revascularisation procedures for Takayasu
arteritis.
– L. Wrotniak, A. Kablak-Ziembicka, T. Przewlocki, P. Pieniazek, M. Trystula, A. Roslawiecka, J. Podolec,
P. Podolec (Krakow, PL)
How long should cilostazol be prescribed following endovascular therapy in patients with peripheral
artery disease?
– K. Nanto, O. Iida, S. Okamoto, T. Dohi, T. Iida, T. Shiraki, Y. Soga, M. Uematsu (Amagasaki and Kokura, JP)
Long-term results after endovascular therapy for femoropopliteal artery disease in patients with chronic
heart failure.
– Y.Kobayashi,Y.Soga(Kitakyushu,JP)
Factors determining long term survival and risk of cardiovascular events in patients treated with
subclavian artery angioplasty.
– L. Wrotniak, T. Przewlocki, A. Kablak-Ziembicka, P. Pieniazek, A. Roslawiecka, P. Musialek, A. Kozanecki,
L. Tekieli, P. Podolec (Krakow, PL)
The impact of statin after endovascular treatment or surgical reconstruction for infrainguinal disease in
patients with critical limb ischemia.
– Y.Kobayashi,Y.Soga(Kitakyushu,JP)
Direct flow utilizing the angiosome concept is valuable for salvaging limbs in critical limb ischemia
patients.
– T. Nishijima, T. Ono, K. Morihisa, F. Kugimiya, H. Fukushima, H. Sumida, K. Noda, S. Oshima (Kumamoto,
JP)
A ten year experience resolving traumatic endovascular pathology by firearms in cervical region.
– S. Rizzone, S. Zolorsa, A. Bordenave, D. Di Nanno (Ciudad Autonoma de Buenos Aires, AR)
Carotid artery stenting in clinical practice: first results of the multidisciplinary GECAS registry.
– N. Werner, H. Mudra, U. Blacha, P. Von Flotow, I. Janicke, M. Leschke, V. Geist, M. Hochadel, R. Langhoff,
R. Zahn (Ludwigshafen am Rhein, Munich, Bad Rothenfelde, Kaiserslautern, Duisburg, Esslingen, Bad
Segeberg and Berlin, DE)
Perioperative complications following aorto-iliac stenting in patients with peripheral artery disease.
– O. Iida, S.O. Okamoto, K.N. Nanto, T.I. Iida, T.S. Shiraki, M.U. Uematsu (Amagasaki, JP)
Endothelial dysfunction as a link between renal and coronary microvascular dysfunction in type II diabetic
patients with normal coronary arteries: a transthoracic echocardiographic doppler study.
– F. Lo Iudice, M. Galderisi, C. D’Amore, G. Savarese, C. Marciano, L. Casaretti, A.M. Pellegrino, I. Fabiani,
L. La Mura, P. Perrone Filardi (Naples, IT)
P367
P368
P369
P370
P371
P372
P373
P374
P375
P376
P377
P378
P379
STROKE
Discussant(s): Stroke.
– S. Kownator (Thionville, FR), A. Kastrati (Munich, DE)
Mitral and aortic calcifications are associated with cerebrovascular ischemic episodes in coronary
patients.
– I. Palka, M. Mostowik, A. Gackowski, J. Nessler (Krakow, PL)
Temporal trends for cerebrovascular event in patients admitted with acute coronary syndrome 1997
-2012.
– D. Radovanovic, P. Erne, G. Pedrazzini, J.-C. Stauffer, R. Jeger, M. Essig, P. Urban (Zurich, Lucerne,
Lugano, Fribourg, Basel, Zweisimmen and Geneva, CH)
High-sensitivity troponin T is predictive of adverse outcome after acute ischemic stroke.
– M. Furtner, A. Hammerer-Lercher, S. Kiechl, J. Mair (Innsbruck, AT)
Early statin therapy reduces all-cause mortality in acute hemorrhagic stroke patients without prior statin
use.
– P.-S. Chen, Y.-H. Li, C.-L. Chang, Y.-H. Kao Yang (Tainan City, TW)
Risk factors for ipsi- and contralateral cerebral ischemic lesions after carotid artery stenting with embolic
protection.
– K. Bijuklic, A. Wandler, T. Tuebler, J. Schofer (Hamburg, DE)
One-year outcomes in atrial fibrillation patients with versus without a previous stroke or transient
ischaemic attack: findings from the international prospective GARFIELD registry.
– A.K. Kakkar, J.-P. Bassand, S.Z. Goldhaber, G. Agnelli, D. Atar, E. Berge, F. Cools, S. Haas,
S.K. Rushton-Smith, W. Hacke (London, GB; Besançon, FR; Boston, US; Perugia, IT; Oslo, NO;
Brasschaat, BE; Munich and Heidelberg, DE)
P380
P381
P382
P383
P384
P385
P386
40

SATURDAY, 31 AUGUST 2013 – AFTERNOON POSTERS
Atrial fibrillation and treatment changes in cryptogenic stroke patients with an implantable loop recorder
for continuous cardiac rhythm monitoring.
– A. Ungar, G. Rieger, T. West, H. Purerfellner, J. Bucx, R.F. Topper, S. Kuster, H. Nagele, M. De Melis,
F. Duru (Florence, IT; Maastricht and Utrecht, NL; Linz, AT; Hamburg, Ratzeburg and Reinbek, DE; Zurich,
CH)
Treatment with cilostazol prevents incidence of stroke in haemodialysis patients with peripheral artery
disease: propensity score-adjusted analysis.
– H. Ishii, T. Aoyama, Y. Kumada, D. Kamoi, T. Sakakibara, Y. Kawamura, S. Suzuki, M. Tanaka,
D. Yoshikawa, T. Murohara (Nagoya, JP)
Clinical characteristics of atrial fibrillation patients with anemia: from the Fushimi AF registry.
– K. Takabayashi, T. Unoki, H. Ogawa, M. Esato, Y.H. Chun, H. Tsuji, H. Wada, K. Hasegawa, M. Abe,
M. Akao (Kyoto, JP)
Pulse wave velocity independently predicts incidence of stroke in patients with essential hypertension:
data from a Greek 6-year-follow-up study.
– I. Bafakis, C. Tsioufis, K. Dimitriadis, I. Andrikou, K. Kintis, L. Lioni, A. Kasiakogias, P. Vasileiou, A. Kordalis,
C. Stefanadis (Athens, GR)
Evaluation with optimal coherence tomography for vulnerable plaque detected by black-blood MRI for
carotid artery stenting.
– M. Suzuki, N. Doi, Y. Hashimoto, K. Hirai, Y. Dote, Y. Goryo, T. Isojima, M. Naito, H. Iwama, T. Nakai (Nara,
JP)
Fibrin monomers improves stroke risk stratification in chronic anticoagulated non-valvular atrial
fibrillation patients.
– V.Roldan,P.Gallego,M.Romera,V.Dominguez,J.A.Vilchez,M.Valdes,V.Vicente,G.Y.Lip,F.Marin
(Murcia, ES; Birmingham, GB)
Differences of morphological and functional characteristics of patent foramen ovale between patients
with and without cryptogenic brain ischemia.
– J. Dubrava (Bratislava, SK)
Array-based profiling reveals biomarker and therapeutic potential for different microRNAs in patients with
symptomatic carotid stenosis.
– S.M.Eken,C.Osterholm,E.Chernogubova,H.Jin,A.Razuvajev,L.Perisic,U.Hedin,J.Roy,P.Eriksson,
L. Maegdefessel (Stockholm, SE)
Simultaneous or staged carotid artery stenting and coronary artery bypass grafting as the
revascularization strategy for severe, concurrent carotid and coronary disease in TARGET-CAS study
population.
– K. Dzierwa, P. Pieniazek, L. Tekieli, P. Musialek, T. Przewlocki, J. Piatek, J. Konstanty-Kalandyk,
M. Trystula, R. Kosobucka-Peszat, P. Podolec (Krakow, PL)
ABCS2 risk scores and cardiovascular risk factors do not predict cerebral microemboli in patients with
critical carotid artery stenosis.
– M. Saedon, C. Hutchinson, C. Imray, D.R. Singer (Coventry, GB)
Incidence and clinical features of stroke in HIV patients in HAART era: a meta-analysis.
– G. Quadri, F. D’Ascenzo, E. Cerrato, P. Omede’, A. Calcagno, S. Bonora, A. Abbate, G. Biondi Zoccai,
C. Moretti, F. Gaita (Turin and Rome, IT; Richmond, US)
Female patients with non-valvular atrial fibrillation are susceptible to cardioembolic stroke because of
their left atrial enlargement.
– M. Wanezaki, H. Tamura, T. Watanabe, C. Sato, S. Sasaki, M. Ishino, S. Nishiyama, I. Kubota (Yamagata,
JP)
Metabolic syndrome deteriorates aortic arch plaque in atherothrombotic stroke.
– S. Nishiyama, T. Watanabe, H. Tamura, M. Ishino, S. Sasaki, M. Wanezaki, C. Sato, T. Shishido, I. Kubota
(Yamagata, JP)
Primary Sjogren’s syndrome and risk of ischemic stroke: a nationwide study.
– C.-H. Chiang (Hsin-Chu, TW)
Rationale and preliminary results of the Imaging of the plaque (IMPLAC) study. A multi-modality approach
to identify vulnerable carotid plaques in relation to brain damage in asymptomatic patients.
– E.Ammirati,A.C.Vermi,M.Magnoni,I.Scotti,E.Busnardo, M. Marrocco Trischitta, N. Anzalone, A. Falini,
O.E. Rimoldi, P.G. Camici (Milan, IT)
Decreased left atrial peak systolic strain evaluated by two-dimensional speckle tracking reflects left atrial
appendage dysfunction in sinus rhythm patients with acute ischemic stroke.
– S. Sasaki, H. Tamura, T. Watanabe, S. Nishiyama, M. Wanezaki, M. Ishino, C. Sato, I. Kubota (Yamagata,
JP)
The role of microwave radiometry in the prediction of concomitant carotid and coronary artery disease.
– M. Drakopoulou, K. Toutouzas, G. Benetos, E. Tolis, A. Synetos, G. Latsios, E. Tsiamis, H. Grassos,
E. Siores, C.H. Stefanadis (Athens, GR; Bolton, GB)
Rheological differences of the pathogenetic variants of stroke.
– M.V. Kruchinina, A.A. Gromov, V.M. Generalov, A.V. Rabko (Novosibirsk, RU)
BNP but not Troponin is associated with cardioembolic aetiology and poor outcome after acute ischemic
stroke or TIA.
– K.S. Wildi, N. Nigro, C. Mueller, P. Schuetz, B. Mueller, F. Fluri, M. Christ-Crain, M. Katan (Basel, Aarau and
Zurich, CH)
Risk factors and clinical outcome in a stroke event depend on the patient’s age and sex.
– J. Kolasa, M. Faryan, A. Lasek-Bal, P. Puz, K. Mizia-Stec (Katowice, PL)
Left atrial appendage closure for stroke prevention - long term results from high volume center.
– Y. Matsuo, S. Moebius-Winkler, M. Sandri, N. Mangner, N. Majunke, I. Daehnert, G. Schuler,
M. Kurabayashi (Maebashi, JP; Leipzig, DE)
P387
P388
P389
P390
P391
P392
P393
P394
P395
P396
P397
P398
P399
P400
P401
P402
P403
P404
P405
P406
P407
SATURDAY – AFTERNOON
41

SATURDAY, 31 AUGUST 2013 – AFTERNOON POSTERS
Serum 100B protein in detection of brain injury in patients undergoing transcatheter aortic valve
implantation.
– R. Pudil, M. Vasatova, J. Stasek, J. Bis, P. Polansky, J. Harrer, J. Vojacek (Hradec Kralove, CZ)
Thoracic aortic circumferential strain and atherosclerosis in patients with cerebral infarction.
– M.S. Shin, J.G. Kang, B.R. Kim, J. Moon, W.J. Chung, T.H. Ahn (Incheon and Seoul, KR)
Platelet count, mean platelet volume and plasma fibrinogen level in the acute phase of different types of
stroke.
– I. Scuric, F. Baborski, D. Cerovec (Krapinske Toplice, HR)
P408
P409
P410
INFARCTION ACUTE PHASE NON STEMI
Discussant(s): Infraction acute phase non STEMI.
– L.M. Biasucci (Rome, IT), H.A. Katus (Heidelberg, DE)
Differences in incidence of hospital admissions for acute coronary syndromes in five Western countries.
Top Score Poster
– U. Zeymer, L. Eckert, I. Dubroca (Ludwigshafen am Rhein, DE; Paris, FR)
Renal failure but not diabetes determines hospital mortality in patients with NSTE-ACS - results of the
Euro heart survey ACS-registry.
– A.K. Gitt, M. Hochadel, W. Wojakowski, U. Zeymer, M. Tendera, F. Schiele, R. Zahn, J.P. Bassand
(Ludwigshafen am Rhein, DE; Katowice, PL; Besançon, FR)
Blood transfusion per se does not impact survival in AMI patients. A propensity-score analysis from the
French FAST-MI 2005 registry.
– G. Ducrocq, E. Puymirat, N. Danchin, P. Henry, M. Martelet, P.V. Ennezat, F. Schiele, P.G. Steg,
J. Ferrieres, T. Simon (Paris, Langres, Grenoble, Besançon and Toulouse, FR)
Impact of early reperfusion therapy in patients with NSTEMI - results of the OPTAMI registry.
– J.C. Karcher, K. Kouraki, T. Limbourg, U. Zeymer, R. Zahn, A. Gitt (Ludwigshafen am Rhein, DE)
The effect of weekend admission on outcomes in patients with non-ST-segment elevation acute coronary
syndrome.
– Y.S.Cho,H.J.Kim,K.I.Kim,D.J.Choi(SeongnamandSeoul,KR)
Optimal timing of coronary invasive strategy in non-st elevation acute coronary syndromes:
a comprehensive meta-analysis of current evidence.
– E.P. Navarese, F. Andreotti, P.A. Gurbel, G. Di Pasquale,D.Ardissino,G.W.Stone,J.Kubica(Bydgoszcz,
PL; Rome, Bologna and Parma, IT; Baltimore and New York, US)
Incidence of serious arrhythmias after successful revascularization in patients with NSTEMI.
– K.S. Wildi, F. Cuculi, T. Reichlin, R. Twerenbold, K. Murray, B. Meller, M. Rubini-Gimenez, C. Mueller (Basel
and Lucerne, CH; Boston, US)
Rapid rule-out of NSTEMI using sensitive cardiac troponin I: evaluation of the safety of the ESC 2011
guidelines.
– K. Murray, B. Moehring, R. Twerenbold, M. Mueller, M. Rubini Gimenez, S.M. Sou, B. Meller, P. Haaf,
T. Reichlin, C. Mueller (Basel, CH; Freiburg and Bad Krozingen, DE; Boston, US)
Release kinetics of early ischemic biomarkers in patients undergoing transcoronary ablation of septal
hypertrophy.
– C. Liebetrau, O. Doerr, L. Gaede, S. Szardien, J. Rixe, A. Rolf, J. Hoffmann, H. Nef, C. Hamm,
H. Moellmann (Bad Nauheim and Giessen, DE)
Myocardial injury after noncardiac surgery and short-term mortality.
– J.A.R. Van Waes, H.M. Nathoe, J.C. De Graaff, H. Kemperman, G.J. De Borst, L.M. Peelen, W.A. Van Klei
(Utrecht, NL)
Invasive treatment strategy in elderly patients with non ST elevation acute coronary syndromes.
A sensitivity analysis of a large monocentric retrospective study.
– J.Passerini,E.Conti,M.B.Musumeci,D.Fusco,L.Zezza,M.Ventura,A.Romaniello,A.Berni,M.Volpe,
C. Autore (Rome, IT)
High-sensitivity troponin in evaluation of acute coronary syndrome: application of gender specific
diagnostic thresholds.
– A. Shah, M. Griffiths, K. Lee, D. McAllister, A. Hunter, F. Strachan, S. Walker, K. Fox, D. Newby, N. Mills
(Edinburgh, GB)
One-hour rule-out and rule-in of acute myocardial infarction using Siemens high-sensitivity cardiac
troponin T.
– R. Twerenbold, T. Reichlin, M. Rubini-Gimenez, M. Mueller, K. Wildi, P. Haaf, C. Mueller (Basel, CH)
Optimal cutoff-value of Siemens cardiac troponin I assay in patients with kidney disease for the early
diagnosis of acute myocardial infarction.
– R. Twerenbold, S. Sou, M. Mueller, T. Reichlin, M. Rubini-Gimenez, T. Hochgruber, C. Mueller (Basel, CH)
Chronic kidney disease epidemiology collaboration equations and global registry for acute coronary
events risk score for the prediction of mortality in non-ST elevation acute coronary syndromes.
– M. Navarro-Penalver, P.J. Flores-Blanco, A. Lopez-Cuenca, F. Marin, M. Sanchez-Martinez,
M. Sanchez-Galian, A. Romero-Aniorte, J.A. Vilchez, M. Valdes, S. Manzano Fernandez (Murcia, ES)
Baseline red cell distribution width and long term clinical outcomes in patients treated with primary
percutaneous coronary intervention.
– T. Akgun, V. Oduncu, C.Y. Karabay, A. Erkol, A. Guler, O. Tasar, A. Kalayci, O. Ozveren, M. Akcakoyun,
C. Kirma (Istanbul, TR)
Patients with NSTEMI have increased QT prolongation as compared to patients with acute coronary
syndrome without MI.
– R. Jubeh, D. Tzivoni, M. Moriel, M. Klutstein, S. Mtour, R. Farkash, A. Medina (Jerusalem, IL)
P411
P412
P413
P414
P415
P416
P417
P418
P419
P420
P421
P422
P423
P424
P425
P426
P427
P428
42

SATURDAY, 31 AUGUST 2013 – AFTERNOON POSTERS
Electrocardiogram in Non-ST Elevation Myocardial Infarction: will always have the same meaning on
prognosis?
– B.C. Picarra, A.R. Santos, A.F. Damasio, M. Celeiro, A. Bento, J. Aguiar, SPC RNSCA (Évora, PT)
The incidence of troponin elevation in non AMI patients in the unselected emergency room population.
– P. Collinson, D.C. Gaze, S. Goodacre (London and Sheffield, GB)
The clinical introduction of high sensitivity cardiac troponin will redefine patient categories in acute
coronary syndromes and increase prognostic information.
– M. Schoos, K. Iversen, M. Nielsen, J. Thode, S. Hansen, P. Clemmensen, R. Steffensen (Copenhagen and
Hillerød, DK)
Release kinetics of circulating micrornas in patients undergoing transcoronary ablation of septal
hypertrophy.
– C. Liebetrau, O. Doerr, H. Moellmann, S. Szardien, C. Troidl, L. Gaede, M. Willmer, J. Rixe, C. Hamm,
H. Nef (Bad Nauheim and Giessen, DE)
Derivatives of enzymatic injury kinetics in acute ST-elevation myocardial infarction. Cardiac magnetic
resonance imaging validation study.
– J. Zalewski, K. Zmudka, P. Lech, M. Durak, J. Nessler (Krakow, PL)
One-hour rule-out and rule-in of acute myocardial infarction using siemens sensitive cardiac Troponin I
ultra.
– R. Twerenbold, B. Meller, M. Rubini, K. Wildi, M. Mueller, T. Reichlin, S. Osswald, C. Mueller (Basel, CH)
Stem cell mobilization by granulocyte-colony Stimulating Factor in patients with acute myocardial
infarction: five-year results of the REVIVAL-2 trial.
– I. Ott, S. Schulz, M. Fusaro, S. Cassese, R. Byrne, M. Joner, A. Kastrati (Munich, DE)
Copeptin as a part of the dual biomarker strategy for early diagnosis of non ST segment elevation
myocardial infarction WILCOP study.
– M. Tajsic, R. Jarai, M.A. Schwarz, J. Kitzbrecht, J. Koch, J. Wojta, K. Huber (Vienna, AT)
Coronary artery plaque burden is a predictor of myocardial ischemia in non-ST elevation myocardial
infarction in both genders.
– I. Eskerud, E. Gerdts, J.E. Nordrehaug, M.T. Lonnebakken (Bergen, NO)
P429
P430
P431
P432
P433
P434
P435
P436
P437
SATURDAY – AFTERNOON
INFARCTION ACUTE PHASE STEMI
Discussant(s): Infarction acute phase STEMI.
– A. Parkhomenko (Kiev, UA), A.K. Gitt (Ludwigshafen, DE), S. Agewall (Oslo, NO)
P438
Current use and clinical benefit of intraaortic balloon support in patients with ST-elevation myocardial
infarction complicated by cardiogenic shock.
– O. Koeth, S.K.G. Maier, C. Fleischmann, G.S. Werner, L.S. Maier, H.G. Olbrich, J. Jung, K.H. Scholz
(Worms,Straubing,Wolfsburg,Darmstadt, Göttingen, Langen and Hildesheim, DE)
Progress seen after the first year of "stent for life" Initiative in Portugal.
– H. Pereira, R. Cale, E. Pereira, J. Marques, L. De Sousa, M. De Sousa Almeida, S. De Mello (Almada, Braga
and Lisbon, PT)
Gender-related mortality trends among diabetic patients with STEMI: insights from a nationwide registry
1997- 2010.
– M. Roffi, D. Radovanovic, P. Erne, P. Urban, S. Windecker, F.R. Eberli (Geneva, Zurich, Lucerne and Berne,
CH)
Effect of ischemic postconditioning on microvascular obstruction in reperfused myocardial infarction.
Results of a randomized multicenter study in patients and data of an experimental model.
– C. Bonanad, J.M. Ruiz-Nodar, E. Feliu, J. Nunez, J. Sanchis, J.M. Martinez-Elvira, G. Minana,
J.V. Monmeneu, F.J. Chorro, V. Bodi Peris (Valencia and Alicante, ES)
Acute kidney injury in the setting of acute ST-elevation myocardial infarction.
– A. Sinkovic, M. Marinsek, F. Svensek (Maribor, SI)
The effect of older age on receipt and outcomes of care in patients with acute coronary syndromes: a
cohort study of 68,025 patients from the national acute coronary syndrome register of England/Wales.
– M.J. Zaman, L. Shepstone, S. Stirling, M. Bachmann, P.K. Myint (Norwich, GB)
GP IIb/IIIa inhibitors improve outcome in patients with primary PCI for STEMI. Results of the prospective
ALKK-Registry.
– U. Zeymer, M. Hochadel, A. Gitt, J. Brachmann, H. Schuehlen, R. Zahn (Ludwigshafen am Rhein, Coburg
and Berlin, DE)
Delayed postconditioning in STEMI patients.
– F. Roubille, N. Mewton, O. Lairez, G. Rioufol, H. Thibaut, M. Elbaz, P. Croisille, F. Prunier, O. Roth, M. Ovize
(Montpellier, Lyon, Toulouse, Angers and Mulhouse, FR)
Intrapulmonary artery balloon counterpulsation (PABC) improves outcome in post-ischemic cardiogenic
shock.
– S. Nour, N. Magkoutis, G. Sideris, S. Voicu, R. Ouardani, C. Kang, M. Bonneau, O. Bailliart (Jouy-en-Josas
and Paris, FR)
The assessment of edema in magnetic resonance imaging in patients with acute myocardial infarction.
– M. Lanocha, A. Kociemba, K. Karmelita-Katulska, A. Siniawski, M. Janus, M. Pyda, S. Grajek (Poznan, PL)
Coronary artery bypass graft patients treated with primary percutaneous coronary intervention have high
long-term adverse event rates (10,920 STEMI patients from the London heart attack group).
– B.N. Modi, M.M. Akhtar, D.A. Jones, A. Wragg (London, GB)
Microvascular integrity indexes were predictor of long-term adverse cardiac events in acute myocardial
infarction.
– M.H. Yoon, S.J. Tahk, H.S. Lim, J.S. Park, H.M. Yang, J.E. Her, Y.S. Kwon, B.J. Choi, S.Y. Choi, J.H. Shin
(Suwon, KR)
P439
P440
P441
P442
P443
P444
P445
P446
P447
P448
P449
P450
43

SATURDAY, 31 AUGUST 2013 – AFTERNOON POSTERS
AVR the ignored lead in pre hospital management of STEMI patients.
– F. Boutot, S. Da Costa, S. Parisse, J. Moro, K. Milojevic, J.M. Caussanel, Y. Lambert (Versailles, FR)
Reducing door-to-balloon time in patients with ST-segment elevation myocardial infarction affect
in-hospital and one-year mortality: a network experience in Italy.
– U.Paradossi,U.Palmieri,M.Ravani,M.Vaghetti,G.Trianni,A.Rizza,A.M.Mazzone,A.Taddei,S.Maffei,
S. Berti (Massa, IT)
CD4+CD28null T-cell enrichment at the culprit lesion site in STE-ACS.
– A. Mangold, T. Scherz, A. Falkinger, T. Hofbauer, C. Adlbrecht, I.M. Lang (Vienna, AT)
Gender differences in the use of invasive strategies and recommended medications for AMI in the EHS
2009 snapshot registry.
– B.Parapid,E.Puymirat,A.Battler,J.Birkhead,H.Bueno,K.A.A.Fox,B.Lindhal,F.Schiele,M.Tubaro,
N. Danchin (Belgrade, RS; Paris and Besançon, FR; Tel Aviv, IL; London and Edinburgh, GB; Madrid, ES;
Uppsala, SE; Rome, IT)
The randomized physiologic assessment of thrombus aspirtion in patients with ST-segment Elevation
acute Myocardial Infarction trial (PATA STEMI).
– D. Orlic, M. Ostojic, B. Beleslin, D. Sobic-Saranovic, M. Tesic, V. Vukcevic, S. Stojkovic, M. Dobric,
M. Nedeljkovic, G. Stankovic (Belgrade, RS)
Trend of decreased incidence and mortality of right ventricular infarction in association with increased
use of reperfusion therapy; results from over 30-year database of acute myocardial infarction.
– S. Honda, S. Yasuda, T. Yamane, T. Adachi, T. Nagai, T. Miyagi, J. Kotani, H. Sakamoto, M. Ishihara,
H. Ogawa (Suita, JP)
Comparison of 30-day outcome in ST-elevation myocardial infarction patients treated in Sweden or
Hungary: results from SWEDEHEART and the Hungarian myocardial infarction registry.
– K. Szummer, A. Janosi, T. Breuer, P. Ofner, J. Sundstrom, T. Jernberg (Stockholm, SE; Budapest, HU;
Sydney, AU)
Impact of thrombectomy on the outcome of ST-segment elevation myocardial infarction patients treated
with primary percutaneous coronary intervention.
– P.S. Mateus, C. Ferreira, A. Ferreira, S. Carvalho, J.I. Moreira (Vila Real, PT)
Low specificity of ST-segment elevation or left bundle branch block in the activation for primary
percutaneous coronary interventions.
– H. Reuter, S. Scholz, C. Wegmann, A. Markhof, H.W. Hoepp, R. Pfister (Cologne, DE)
Novel potential biomarkers for ST-elevation myocardial infarction identified by proteomic analysis of
plasma-derived microparticles.
– P. Velez, A. Parguina, I. Rosa, L. Grigorian, R. Ocaranza, S. Alonso-Orgaz, M. Barderas, J. Moreu,
R. Gonzalez-Juanatey, A. Garcia (Santiago de Compostela, Vigo and Toledo, ES)
Takotsubo cardiomiopathy: incidence, clinical features and prognosis in all comers patients referred for
acute coronary syndrome.
– D. Grosseto, S. Carigi, A. Santarelli, F. Baldazzi, N. Franco, S. Amati, D. Santoro, L. Marinelli, M. Marconi,
G. Piovaccari (Rimini and Riccione, IT; San Marino, SM)
Sedation with sevoflurane improves reperfusion in acute myocardial infarction.
– S. Lavi, D. Bainbridge, S. Dalfonso, P. Teefy, G. Jablonsky, P. Garg, J. Syed, P. Diamantouros, K. Sridhar,
R. Lavi (London, CA)
The effect of esmolol on left ventricular haemodynamic, rotational mechanics and strain in intact and
infracted myocardium. Experimental study.
– J.A. Agrios, A.K. Kaladaridou, E.S. Skaltsiotes, D.B. Bramos, J.M. Matheos, C.P. Pamboucas,
E.P. Papadopoulou, G.K. Kottis, S.T. Toumanidis (Athens, GR)
Standard (180mg) vs high (360mg) loading dose of ticagrelor in patients with STEMI undergoing primary
PCI.
– D. Alexopoulos, I. Xanthopoulou, S. Patsilinakos, V. Gizas, A. Perperis, G. Makris, S. Karanikas,
I. Chiladakis, G. Hahalis, P. Davlouros (Patras and Athens, GR)
Automatic remote ischemic preconditioning procedure reduces reperfusion arrhythmias and
contrast-induced nephropathy in patients with ST-elevation myocardial infarction.
– T. Yamanaka, Y. Kawai, T. Mima, H. Ito (Imabari, Matsuyama and Okayama, JP)
Impact of intraaortic counterpulsation on microcirculatory impairment in cardiogenic shock complicating
myocardial infarction - an IABP-Shock II substudy.
– C. Jung, G. Fuernau, M. Ferrari, B. Goebel, H.R. Figulla, S. Desch, G. Schuler, H. Thiele (Jena and Leipzig,
DE)
Intensive glucose regulation does not reduce enzymatic infarct size in hyperglycemic acute coronary
syndromes: results of the randomized BIOMArCS-2 glucose trial.
– M.DeMulder,V.A.Umans,J.H.Cornel,F.M.VanDer Zant, F. Stam, R.M. Oemrawsingh, K.M. Akkerhuis,
E. Boersma (Alkmaar and Rotterdam, NL)
Circumflex artery-related ST-elevation myocardial infarction is associated with an increased delay in
primary PCI: data from the Austrian acute PCI registry.
– J. Doerler, H. Alber, W. Benzer, G. Grimm, M. Juhasz, D.V. Levinski, F.X. Roithinger, H. Schuchlenz,
P. Siostrzonek, F. Weidinger (Vienna, AT)
Treatment delay in primary PCI in relation to marital status and distance from acute medical care.
– D. Austin, A.T. Yan, S. Jamieson, A.G. Zaman, V. Kunadian, A.J. Bagnall (Middlesbrough and
Newcastle-upon-Tyne, GB; Toronto, CA)
Longitudinal strain provides prognositic value, incremental to that of cardiac magnetic resonance at the
acute phase in patients with st-segment elevation myocardial infarction.
– L. Biere, E. Donal, G. Terrien, G. Kervio, A. Furber, F. Prunier (Angers and Rennes, FR)
P451
P452
P453
P454
P455
P456
P457
P458
P459
P460
P461
P462
P463
P464
P465
P466
P467
P468
P469
P470
44

SATURDAY, 31 AUGUST 2013 – AFTERNOON POSTERS
Determinants of infarct mass, assessed by cardiac magnetic resonance, in STEACS revascularized by
primary-PCI: findings of the PROMISE randomized clinical trial.
– I. Ferreira Gonzalez, B. Garcia-Del-Blanco, S. Moral, J. Barrabes, G. Marti, I. Otaegui, E. Domingo,
J. Elizaga, H. Gutierrez, D. Garcia-Dorado (Barcelona, Madrid and Valladolid, ES)
Can we improve duration of hospital stay in angioplasty treated ST-segment elevation acute myocardial
infarction? The Zwolle risk score.
– A. Tralhao, S. Madeira, M. Borges Santos, I. Rosario, M. Castro, A. Miguel Ferreira, J. Ferreira, M. Trabulo,
M. Mendes (Carnaxide, PT)
Survival rates and causes of death in contemporary primary percutaneous intervention for ST-segment
elevation myocardial infarction - a mega-center experience.
– S.B.E.W. Rader, F. Pedersen, K. Saunamaki, S. Helqvist, T. Engstroem, H. Kelbaek, L. Holmvang,
J. Kastrup, P. Clemmensen, E. Joergensen (Copenhagen, DK)
Left circumflex artery lesions in acute myocardial infarction.
– H. Waziri, E.L. Fosbol, U.M. Mogensen, F. Pedersen, E. Jorgensen, H. Kelbaek, L. Kober, K. Wachtell
(Copenhagen and Glostrup, DK)
High cholesteryl ester transfer protein (CETP) activity in acute phase of myocardial infarction predicts
short-term mortality by inducing endothelial dysfunction and reduced microvascular perfusion.
– L.S.F. Carvalho, N.B. Panzoldo, S. Santos, V.V. Wilson, F. Amaral, E.C. De Faria, A.C. Sposito (Campinas
and Brasilia, BR)
Functional mitral regurgitation after a first non-st elevation acute coronary syndrome: very long term
follow-up, prognosis, and contribution to left ventricular enlargement and atrial fibrillation.
– I. Nunez-Gil, I. Estrada, G. Feltes Guzman, L. Perez De Isla, A. De Agustin, D. Vivas, A. Viana, P. Jimenez
Quevedo, C. Macaya, A. Fernandez Ortiz (Madrid, ES)
The relationship between preinfarction angina and serum sphingosine 1 phosphate levels.
– E. Kiziltunc, A. Abaci, S. Ozkan, Y. Alsancak, S. Unlu, E.S. Simsek, S. Elbeg, M. Cemri (Ankara, TR)
In-hospital mortality prediction for STEMI patients submitted to primary PCI.
– M. Sladojevic, K. Pavlovic, L. Velicki, N. Cemerlic-Adjic, T. Popov, S. Tadic, S. Sladojevic, D. Culibrk (Novi
Sad, RS)
Epicardial adipose tissue thickness independently predicts myocardial infarction, and it is related to
impaired coronary perfusion in patients with coronary artery disease.
– A. Tanindi, S.A. Kocaman, A.F. Erkan, M. Ugurlu, H.F. Tore (Ankara, TR)
Impact of glucose fluctuation and monocyte subsets on coronary plaque rupture.
– I. Teraguchi, T. Imanishi, Y. Ozaki, T. Tanimoto, T. Yamano, Y. Ino, T. Yamagichi, K. Hirata, T. Kubo,
T. Akasaka (Wakayama, JP)
P471
P472
P473
P474
P475
P476
P477
P478
P479
P480
SATURDAY – AFTERNOON
ACUTE CARDIAC CARE, OTHER
Discussant(s): Acute cardiac care, other.
– R.F.Storey(Sheffield,GB)
Copeptin and troponin in patients with acute cardiac chief complaints in the emergency department.
– A. Slagman, J. Searle, T. Lauterbach, J.O. Vollert, F. Holert, R. Muller, C. Mueller, M. Mockel (Berlin, DE;
Townsville, AU)
Copeptin in everyday clinical practice of an emergency department.
– D. Menhofer, A. Sandhofer, A. Hammerer-Lercher, J. Mair (Innsbruck, AT)
Diagnostic accuracy of highly sensitive troponin I versus highly sensitive troponin T assays for acute
myocardial infarction within two hours of emergency department presentation.
– L. Cullen, W. Parsonage, J. Greenslade, S. Aldous, P. George, A. Lamanna, J. Ungerer, M. Richards,
C.J. Pemberton, M. Than (Brisbane, AU; Christchurch, NZ)
Adherence to guidelines on management of acute coronary syndrome in Russian hospitals is better in
lower risk patients and this is associated with better outcomes of hospitalization.
– A. Erlikh, N.A. Gratsiansky (Moscow, RU)
ARRHYTHMIAS – PACING – RESYNCHRONISATION
Discussant(s): Arrhythmias – pacing – resynchronisation.
– S. Ernst (London, GB), F. Arribas (Madrid, ES), A. Da Costa (Saint-Etienne, FR), G. Marinskis (Vilnius, LT)
The incidence of new-onset atrial fibrillation in patients with stroke of unknown etiology is similar to the
age- and gender-matched stroke-free population during 10-year follow up.
– M.A. Baturova, A. Lindgren, J. Carlson, Y.V. Shubik, B. Olsson, P.G. Platonov (Lund, SE; St. Petersburg,
RU)
Focal impulse and rotor modulation for AF ablation: acute response in initial vs. rescue procedures.
– D. Musat, S. Mittal, S. Narayan, K. Shivkumar, J.M. Miller, E. Buch, J. Gima, K. Mills, J.S. Steinberg
(Ridgewood, San Diego, Los Angeles and Indianapolis, US)
Left atrium regional voltage analysis in sinus rhythm in patients undergoing atrial fibrillation ablation.
– I. Menduina, E. Caballero, M. Diaz-Escofet, P. Martin, J. Novoa, A. Garcia, N. Castro, D. Valdivia, M. Leon,
A. Medina (Las Palmas de Gran Canaria, ES)
Significant decrease of pulmonary veins activity by stand-alone atrial-substrate ablation strategy in
persistent atrial fibrillation.
– J. Seitz, C. Bars, A. Maluski, G. Penaranda, J. Faure, M. Bremondy, A. Ferracci, L. Curel, A. Pisapia
(Marseille and Paris, FR)
P481
P482
P483
P484
P485
P486
P487
P488
P489
P490
45

SATURDAY, 31 AUGUST 2013 – AFTERNOON POSTERS
Comparison of lesion formation between contact force-guided and non-guided circumferential pulmonary
vein isolation.
– M.Kimura,S.Sasaki,D.Horiuchi,K.Sasaki,S.Owada,Y.Ishida,T.Kinjo,K.O.Okumura(Hirosaki,JP)
Long-term (>10 years) clinical results and electroanatomic correlations of persistent atrial fibrillation
ablation with a hybrid approach in patients with valvular heart disease.
– F. Gaita, E. Ebrille, D. Caponi, L. Garberoglio, L. Vivada, A. Barbone, R. Gallotti, M. Scaglione (Turin, Asti
and Rozzano, IT)
Predictors of complete arrhythmia free survival in patients undergoing MAZE surgery. PRAGUE-12
randomized study subanalysis.
– P.Osmancik,P.Budera,Z.Straka,P.Cervinka,M.Hulman,T.Vanek,P.Widimsky(PragueandÚstínad
Labem, CZ; Bratislava, SK)
Ganglionated plexi ablation plus antral pulmonary vein isolation for paroximal atrial fibrillation: clinical
outcome after a single procedure at one-year follow-up.
– K. Yamashiro, Y. Sakamoto, K. Satoh, T. Suzuki (Toyohashi, JP)
Mechanisms of pulmonary vein reconnection: insufficient catheter tissue contact and long
lesion-to-lesion distance.
– C.I. Park, H. Lehrmann, C. Keyl, R. Weber, J. Allgeier, J. Schiebeling, C. Herrera-Siklody, T. Arentz,
A. Jadidi (Freiburg and Bad Krozingen, DE)
Long-term radio frequency scar behavior after ablation of atrial fibrillation: lessons learned from LGE-MRI
analysis.
– K. Higuchi, M. Koopmann, A. Morris, M. Macgrath, N. Burgon, E. Kholmovski, R. Macleod, N. Marrouche
(Salt Lake City, US)
Is lone AF lonely yet? What about the atrial fibrosis in lone AF and implications on the cryoablation
success?
– U. Canpolat, A. Oto, H. Yorgun, M. Sahiner, H. Sunman, E.B. Kaya, L. Tokgozoglu, G. Kabakci, N. Ozer,
K. Aytemir (Ankara, TR)
New cryoballoon generation enhances procedural efficacy without compromising safety.
– U. Dorwarth, M. Schmidt, F. Straube, M. Wankerl, J. Krieg, E. Hoffmann (Munich, DE)
Does termination predict the outcome at long term follow-up in patients with long standing persistent
AF? results from a prospective randomized study.
– L. Di Biase, P. Santangeli, R. Bai, P. Mohanty, G. Gallinghouse, R. Horton, J.E. Sanchez, S. Beheiry,
J.D. Burkhardt, A. Natale (Austin and San Francisco, US)
Initial impedance decrease as an indicator of good catheter contact: insights from radiofrequency
ablation with two different force sensing catheters.
– T. Reichlin, S. Knecht, C. Lane, M. Kuehne, W.G. Stevenson, B. Schaer, S. Osswald, G.F. Michaud,
C. Sticherling (Basel, CH; Boston, US)
The COR trial: a randomized study with continuous rhythm monitoring comparing the efficacy of
cryoenergy and radiofrequency for pulmonary vein isolation.
– N. Perez Castellano, R. Fernandez, J. Moreno, A. Conde, V. Canadas, J.J. Gonzalez-Ferrer, J.M. Aguirre,
R. Bover, C. Macaya, J. Villacastin (Madrid, ES)
Atrial fibrillation ablation using magnetic navigation: comparison with conventional approach during long
term follow up.
– P. Adragao, F. Moscoso Costa, D. Cavaco, H. Dores, P. Santos, P. Carmo, K. Santos, L. Parreira,
F. Morgado, M. Mendes (Lisbon, PT)
Left atrial radiofrequency isolation for surgical treatment of persistent AF: the value of entrance block as
procedural end-point on mid-term rhythm outcome.
– C. Muneretto, G. Bisleri, F. Rosati, L. Bontempi, A. Curnis (Brescia, IT)
AF ablation using novel non-fluoroscopic catheter tracking - experience of the first 100 patients treated
with sensor-equipped ablation catheters.
– S. Rolf, S. John, S. Kircher, T. Gaspar, S. Richter, A. Arya, B. Dinov, C. Piorkowski, G. Hindricks,
P. Sommer (Leipzig, DE)
The effect of treating dormant pulmonary vein conduction on the outcome of cryoballoon ablation.
– M.G. Compier, K. Zeppenfeld, M. De Riva Silva, K. Dyrda, M.J. Schalij, S.A. Trines (Leiden, NL)
Clinical experience with a diaphragmatic electromyographic-guided approach to monitor phrenic nerve
integrity during cryoballoon-based atrial fibrillation ablation.
– B.Mondesert,J.G.Andrade,P.G.Guerra,L.Rivard,L.Macle,B.Thibault,M.Talajic,D.Roy,P.Khairy,
M. Dubuc (Montreal, CA)
Renal dysfunction and stroke risk stratification scores as predictors of thromboembolic events in
patients with atrial fibrillation after catheter ablation.
– J. Kornej, J. Kosiuk, A. Arya, C. Piorkowski, D. Husser, G. Hindricks, G. Lip, A. Bollmann (Leipzig and
Dresden, DE; Birmingham, GB)
Incidence and characteristics of phrenic nerve palsy following pulmonary vein isolation with the novel
second-generation cryoballoon as compared to the first-generation balloon.
– A. Fuernkranz, S. Bordignon, B. Schmidt, A. Konstantinou, V. Urban, M.C. Boehmer, B. Schulte-Hahn,
B. Nowak, J.K.R. Chun (Frankfurt, DE)
Changes in pulmonary arterial pressure after atrial fibrillation ablation: incidence, causes, and
implications on the stiff left atrial syndrome.
– C. Witt, S.S. Kushwaha, G.C. Kane, Y.M. Cha, S.J. Asirvatham, J.K. Oh, D.L. Packer, B.D. Powell
(Rochester, US)
Evaluation of left atrial contractile function after successful ablation of long standing persistent atrial
fibrillation utilizing combined epicardial and endocardial approach.
– D.E. Pajitnev, T. Neumann, S.W. Zaltsberg, H. Greiss, J. Sperzel, Z. Szalay, M. Schoenburg, T. Walther,
C.W. Hamm, M. Kuniss (Bad Nauheim, DE)
P491
P492
P493 (W)
P494
P495
P496
P497
P498
P499
P500
P501
P502
P503
P504 (W)
P505
P506
P507 (W)
P508
P509
P510
46

SATURDAY, 31 AUGUST 2013 – AFTERNOON POSTERS
Catheter ablation for atrial arrhythmia recurrence following surgical atrial fibrillation ablation.
– R.J. Beukema, A. Adiyaman, J.J.J. Smit, P.P.H.M. Delnoy, A.R. Ramdat Misier, A. Elvan (Zwolle, NL)
Does extensive defragmentation really improve the success rate of long-lasting persistent atrial
fibrillation: a study from a randomized controlled study.
– Y.-J. Lin, S.-L. Chang, L.-W. Lo, Y.-F. Hu, C.-H. Li, T.-F. Chao, S.-A. Chen (Taipei, TW)
Association of renal dysfunction and stroke risk stratification scores with rhythm outcomes in patients
after catheter ablation of atrial fibrillation.
– J.Kornej,J.Kosiuk,A.Arya,P.Sommer,S.Rolf,D.Husser,C.Piorkowski,G.Hindricks,G.Lip,
A. Bollmann (Leipzig and Dresden, DE; Birmingham, GB)
Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation: results on health-related quality
of life and symptom burden (The MANTRA-PAF trial).
Top Score Poster
– H. Walfridsson, J. Cosedis Nielsen, A. Johannessen, P. Raatikainen, J. Hartikainen, U. Walfridsson,
L.A. Levin, M. Janzon, M. Aronsson, P.S. Hansen (Linköping, SE; Aarhus, Hellerup and Varde, DK;
Tampere and Kuopio, FI)
Pulmonary vein isolation in paroxysmal atrial fibrillation: comparison of three different techniques.
– R.A. Providencia, J.P. Albenque, S. Fazaa, S. Combes, N. Combes, A. Bouzeman, B. Casteigt, H. Hireche,
S. Boveda (Toulouse, FR)
Real time assessment of pulmonary vein isolation using the novel Achieve mapping catheter during
cryoablation.
– R.P. Martins, O. Cesari, N. Behar, R. Bacquelin, J. Lacaze-Gadonneix, A. Behagel, P. Mabo, D. Pavin
(Rennes and Tours, FR)
AF ablation: evaluation of procedural parameters and acute results comparing ablation catheters with
traditional and new irrigation design.
– C. Raimondo, E. Ebrille, D. Caponi, P. Di Donna, F. Di Clemente, M. Appendino, A. Giorgetti, A. Battaglia,
F. Gaita, M. Scaglione (Turin and Asti, IT)
Preservation of luminal coronary artery diameter after epicardial irreversible electroporation ablation.
– K. Neven, V. Van Driel, H. Van Wessel, P. Doevendans, F. Wittkampf (Utrecht, NL)
Real-life treatment persistence with newer oral anticoagulants and potential strokes avoided in patients
with atrial fibrillation.
– T. Evers, A. Diamantopoulos (Wuppertal, DE; Elstree, GB)
Evaluation of edoxaban in patients with atrial fibrillation and severe renal impairment.
– Y. Koretsune, T. Yamashita, M. Yasaka (Osaka, Tokyo and Fukuoka, JP)
Should we recommend oral anticoagulation therapy in patients with atrial fibrillation undergoing coronary
artery stenting with a low-moderate CHADS2 score?
– M. Mutuberria Urdaniz, A. Sambola, E. Bosch, B. Garcia Del Blanco, A. Alonso, F. Alfonso, A. Cequier,
H. Bueno, J.A. Barrabes, D. Garcia-Dorado (Barcelona and Madrid, ES)
Platelet reactivity monitoring in patients with atrial fibrillation treated with dabigatran.
– K. Kalantzi, M. Tsoumani, K. Pappas, P. Tatsidou, J. Goudevenos, A. Tselepis (Ioannina, GR)
Identification of thrombus in left atrial appendage by 320-row ADCT is superior beyond CHADS2 score for
initiating anticoagulation treatment in patients with atrial fibrillation.
– M. Sato, Y. Abe, O. Yamaguchi, M. Takiguchi, N. Fujii, H. Moriya, T. Ishibashi (Fukushima, JP)
Safety of dabigatran etexilate in frail older old patients with non-valvular atrial fibrillation.
– C. Rodriguez Pascual, E. Paredes-Galan, A. Vilches-Moraga, M.C. Basalo-Carbajales, A. Guitian (Vigo, ES)
The safety and efficacy of oral anticoagulation in non-valvular atrial fibrillation patients with liver
cirrhosis.
– S.J. Lee, J.Y. Kim, H.N. Pak, M.H. Lee, B.Y. Joung (Seoul, KR)
Gender differences in the management of antithrombotic prescriptions among patients with atrial
fibrillation by general practitioners in France.
– P. Sabouret, L. Depret-Bixio, F.E. Cotte, P. Marie, N. Bedira, P. Blin (Paris, Rueil-Malmaison and Bordeaux,
FR)
Oral anticoagulation therapy during catheter ablation for atrial fibrillation: J-CARAF registry.
– Y. Murakawa, A. Nogami, M. Shoda, S. Naito, K. Kumagai, K. Inoue, Y. Miyauchi, T. Yamane, N. Morita,
K. Okumura (Kawasaki, Yokohama, Tokyo, Maebashi, Fukuoka, Osaka and Hirosaki, JP)
Should we recommend triple therapy in elderly patients with atrial fibrillation submitted to coronary
stenting?
– M. Mutuberria Urdaniz, A. Sambola, E. Bosch, B. Garcia Del Blanco, A. Alonso, J.A. Zueco, A. Cequier,
H. Bueno, J.A. Barrabes, D. Garcia-Dorado (Barcelona, Santander and Madrid, ES)
Substantial differences in initiation of antithrombotic treatment and clinical outcome among non-valvular
atrial fibrillation patients treated in inpatient and outpatient settings: a nationwide cohort.
– A.P. Mikkelsen, M.L. Hansen, J.B. Olesen, M.W. Hvidtfeldt, S. Husted, S.P. Johnsen, A. Brandes,
G. Gislason, C. Torp-Pedersen, M. Lamberts (Gentofte, Herning, Aarhus, Odense and Aalborg, DK)
Use of anticoagulants and antiplatelet agents in stable outpatients with coronary artery disease and atrial
fibrillation. Data from the international CLARIFY registry.
– L. Fauchier, N. Greenlaw, R. Ferrari, I. Ford, K. Fox, J.C. Tardif, M. Tendera, P.G. Steg (Tours and Paris, FR;
Glasgow and London, GB; Ferrara, IT; Montreal, CA; Katowice, PL)
Comparative efficacy and safety of novel oral anticoagulants in patients with atrial fibrillation: a network
meta-analysis with the adjustment for the possible bias from open label studies.
– T. Morimoto, B. Crawford, K. Wada, S. Ueda (Nishinomiya, Tokyo and Nishihara, JP)
Predictors of left atrial appendage thrombosis in patients with atrial fibrillation.
– A. Rubanenko, Y. Shchukin, A. Germanov, O. Tereshina (Samara, RU)
P511
P512
P513
P514
P515
P516
P517
P518
P519
P520
P521
P522
P523
P524
P525 (W)
P526
P527
P528
P529
P530
P531
P532
SATURDAY – AFTERNOON
47

SATURDAY, 31 AUGUST 2013 – AFTERNOON POSTERS
Incidence of thromboembolic events in patients with atrial fibrillation in Japan: one-year follow-up from
the Fushimi AF registry.
– M. Akao, H. Ogawa, N. Masunaga, M. Ishii, M. Abe, M. Esato, Y.H. Chun, H. Tsuji, H. Wada, K. Hasegawa
(Kyoto, JP)
Vitamin e serum level, a new tool to stratify bleeding risk in patients receiving oral anticoagulant therapy.
– D. Pastori, R. Carnevale, R. Cangemi, C. Nocella, S. Bartimoccia, T. Vicario, M. Saliola, F. Violi, P. Pignatelli
(Rome, IT)
Use of apixaban and warfarin in patients undergoing invasive procedures: insights from ARISTOTLE.
– R.D. Lopes, D.A. Garcia, D. Wojdyla, P. Dorian, J.H. Alexander, L. Wallentin, F. Lanas, M. Hanna, C. Held,
C.B. Granger (Durham, Seattle and Princeton, US; Toronto, CA; Uppsala, SE; Temuco, CL)
Risk of events in the 30 days following a major bleed with Apixaban or Warfarin - experiences from the
ARISTOTLE trial.
– C. Held, E.B. Hylek, J.H. Alexander, M. Hanna, R.D. Lopes, D. Wojdyla, C.B. Granger, L. Wallentin
(Uppsala, SE; Boston, Durham and Princeton, US)
A 10-year prospective study of estimated glomerular filtration rate and outcomes with oral
anticoagulation in patients with atrial fibrillation.
– L. Fauchier, A. Banerjee, J.M. Halimi, S. Taillandier, D. Angoulvant, P. Vourc’h, D. Babuty, G.Y.H. Lip
(Tours, FR; Birmingham, GB)
Oral anticoagulant therapy management after successful atrial fibrillation ablation.
– C. Gallo, A. Battaglia, D. Sardi, E. Toso, D. Castagno, M. Scaglione, F. Gaita (Turin and Asti, IT)
Safety and efficacy of continuous periprocedural rivaroxaban for patients undergoing catheter ablation
procedures: a retrospective registry analysis.
– R. Dillier, S. Ammar, T. Reents, H. Pavaci, A. Buiatti, V. Semmler, C. Lennerz, C. Kolb, G. Hessling,
I. Deisenhofer (Munich, DE)
Early recurrence is a predictor of recurrence after catheter ablation in the patients with persistent atrial
fibrillation.
– Y. Ito, M. Igarashi, H. Yamasaki, K. Kuroki, T. Machino, N. Murakoshi, Y. Sekiguchi, K. Aonuma (Ibaraki, JP)
Arrhythmia recurrence after pulmonary vein isolation for paroxysmal atrial fibrillation: there is more than
the pulmonary veins.
– S. Ammar, A. Buiatti, T. Reents, R. Dillier, S. Kathan, M. Hofmann, V. Semmller, C. Kolb, G. Hessling,
I. Deisenhofer (Munich, DE)
Successful non-surgical treatment of esophagopericardial fistulas following atrial fibrillation catheter
ablation - a case series.
– C. Eitel, S. Rolf, M. Zachaeus, S. John, P. Sommer, A. Bollmann, C. Piorkowski, G. Hindricks, U. Halm
(Leipzig, DE)
Patient characteristics associated with the initiation of novel oral anticoagulants versus warfarin in
patients with atrial fibrillation.
– X. Pan, H. Kawabata, M. Hamilton, X. Liu (Princeton and New York, US)
Use of simultaneous multielectrode single-beat electrocardiography for mapping of complex arrhythmias.
– I. Suman Horduna, L. Mantziari, S. Ernst (London, GB)
Diabetes as a comorbidity of atrial fibrillation in brady tachy syndrome: what impact on arrhythmia
occurrence and outcome?
– G. Boriani, M. Santini, L. Padeletti, A. Capucci, G.L. Botto, M. Gulizia, M. Biffi, R. Ricci, M. Vimercati,
A. Grammatico (Bologna, Rome, Florence, Ancona, Como, Catania and Milan, IT)
What is the optimal antithrombotic therapy of atrial fibrillation patients after coronary artery stent
deployment?
– H. Kawai, E. Watanabe, M. Yamamoto, T. Ichikawa, H. Harigaya, K. Okuda, Y. Sobue, S. Motoyama,
M. Sarai, Y. Ozaki (Toyoake, JP)
Triple therapy for all patients with atrial fibrillation undergoing coronary stenting?
– M. Mutuberria Urdaniz, A. Sambola, E. Bosch, B. Garcia Del Blanco, A. Alonso, A. Cequier, H. Bueno,
O. Rodriguez, J.A. Barrabes, D. Garcia-Dorado (Barcelona and Madrid, ES)
Catheter ablation of atrial fibrillation in patients with hypertrophic cardiomyopathy.
– Q. Yan, J.Z. Dong, D.Y. Long, R.H. Yu, R.B. Tang, X. Du, R. Bai, C.S. Ma (Beijing, CN)
Management of dyspepsia symptoms on dabigatran during RELY-ABLE: long-term follow up study after
RE-LY.
– R. Nieuwlaat, J.S. Healey, M. Ezekowitz, P. Reilly, S. Formella, L. Wallentin, S. Yusuf, S. Connolly (Hamilton,
CA; New York and Ridgefield, US; Ingelheim am Rhein, DE; Uppsala, SE)
A novel morphology based algorithm for prediction of antitachycardia pacing success.
– R. Matia Frances, A. Hernandez-Madrid, G. Sanchez-Huete, L. Carrizo, C. Pindado, S. Fernandez-Santos,
C. Lazaro, L. Moran, C. Moro, J. Zamorano (Madrid, ES)
Outcomes after rhythm versus rate control in patients with atrial fibrillation: the international prospective
GARFIELD registry.
– E. Berge, D. Atar, J.-Y. Le Heuzey, S. Connolly, D.A. Fitzmaurice, A.J. Camm, P. Jansky,
S.K. Rushton-Smith, G. Kayani, A.K. Kakkar (Oslo, NO; Paris, FR; Hamilton, CA; Birmingham, London and
St.Albans,GB;Prague,CZ)
Hybrid ablation of long standing persistent atrial fibrillation utilizing minimally invasive surgical and
endocardial catheter approach: one year results.
– D.E. Pajitnev, M. Kuniss, M. Schoenburg, Z. Szalay, S.W. Zaltsberg, H. Greiss, J. Sperzel, T. Walther,
C.W. Hamm, T. Neumann (Bad Nauheim, DE)
Primary prevention of ischemic stroke: implication of multiple risk factors in patients with and without
atrial fibrillation.
Top Score Poster
– C. Benn Christiansen, G. Gislason, C. Torp-Pedersen, M. Lamberts, S.L. Kristensen, J.B. Olesen
(Copenhagen and Aalborg, DK)
P533
P534
P535
P536
P537
P538
P539
P540
P541
P542
P543
P544
P545
P546
P547
P548
P549
P550
P551
P552
P553
48

SATURDAY, 31 AUGUST 2013 – AFTERNOON POSTERS
Role of delayed enhancement MRI and detection of esophageal complication.
– L. Navaravong, N.W. Akoum, N. Burgeon, N.F. Marrouche (Salt Lake City, US)
Combined interventional cardiac procedures in pediatric patients with congenital heart abnormalities and
cardiac arrhythmias.
– I. Khamnagadaev, L. Kokov, S. Termosesov, I. Il‘Ich, I. Miklashevich, M. Shkolnikova (Moscow, RU)
Adenosine-sensitive reentrant atrial tachycardia arising from atrioventricular annulus and atrial septum.
– H. Miyazaki, M. Nakajima, K. Ashikaga, E. Nakano, T. Sasaki, K. Mizuno, T. Harada, F. Miyake (Kawasaki,
JP)
P554
P555
P556
DRUGS AND DEVICES
Discussant(s): Drugs and devices.
– M.J. Schalij (Voorschoten, NL), S. Rahimtoola (Los Angeles, US)
Anti-hypertensive effect of statins among NAFLD patients.
– A. Laurinavicius, F.C. Nary, R.D.O. Conceicao, J.A.M. Carvalho, R.D. Santos (São Paulo, BR)
Renal artery denervation affects the circulating microRNA profile in patients with resistant arterial
hypertension.
– S.H.Schirmer,T.C.T.VanDerPouw-Kraan,S.I.Bettink,F.Mahfoud,U.Laufs,A.J.G.Horrevoets,M.Böhm
(Homburg, DE; Amsterdam, NL)
Beta-Blockade does not exert heart rate-independent effects on pulse wave reflection in men with high
cardiovascular risk.
– U. Fischer-Rasokat, J. Honold, D. Lochmann, C. Liebetrau, J. Leick, C.W. Hamm, S. Fichtlscherer,
H. Moellmann, I. Spyridopoulos (Bad Nauheim and Frankfurt, DE)
Renal denervation improves left ventricular efficiency by reducing afterload and contractility while
increasing diastolic capacity - results of single beat pressure volume analysis.
– J.-C. Reil, D. Lavall, T. Donate, G.-H. Reil, M. Hohl, S.H. Schirmer, F. Mahfoud, M. Böhm (Homburg/Saar
and Oldenburg, DE)
Acute endovascular stimulation of the carotid baroreceptors.
– K. Fan, H.F. Tse, V. Splett, M. Wong, R.L. Lieberman (Hong Kong, HK; Minneapolis and Detroit, US)
Renal sympathetic denervation inhibits postapneic blood pressure rises and renal hypoperfusion in a pig
model for obstructive sleep apnea.
– D. Linz, F. Mahfoud, M. Loehn, W. Linz, K. Wirth, M. Böhm (Homburg and Frankfurt, DE)
Percutaneous renal denervation (RDN) improves central hemodynamics and arterial stiffness - results of
24h ambulatory measurements.
– K.F. Franzen, K. Mortensen, T. Graf, J. Koester, J. Weil, M. Reppel (Lübeck, DE)
Decrease of the norepinephrine release due to disconnection of sympathetic nerves during renal
denervation.
– K. Tiroch, J. Szymanski, A. Sause, M. Seyfarth (Wuppertal, DE)
The effect of catheter based renal denervation on nocturnal blood pressure and nocturnal pulse pressure
in patients with true resistant hypertension: National heart institute Malaysia experience.
– A. Arshad, G.C. Lau, S.Z. Idris, A. Husin, A. Rahman, R. Zambahari (Kuala Lumpur, MY)
Renal sympathetic denervation significantly reduces blood pressure but not cause orthostatic
dysregulation in patients with resistant hypertension.
– C. Gisbertz, C. Fatum, T. Graf, F. Bode, M. Reppel, K. Mortensen, J. Weil (Lübeck, DE)
Persistent resistant hypertension during long term follow-up is related with lack of regression of left
ventricular hypertrophy in essential hypertensives.
– D. Tsiachris, C. Tsioufis, A. Kasiakogias, K. Dimitriadis, I. Andrikou, A. Kordalis, I. Bafakis, K. Kintis,
D. Tousoulis, C. Stefanadis (Athens, GR)
Prognostic values of different patterns of resistant hypertension for the incidence of new-onset atrial
fibrillation.
– K. Kintis, C. Tsioufis, D. Tsiachris, A. Kasiakogias, C. Thomopoulos, D. Flessas, I. Andrikou, I. Bafakis,
D. Tousoulis, C. Stefanadis (Athens, GR)
Usefulness of plasma renin activity value for therapeutic decisions among hypertensive subjects; is
Laragh and Alderman idea helpful?
– M. Rajzer, T. Pizon, D. Czarnecka (Krakow, PL)
More drugs and better blood pressure control lead to improved cardiovascular outcomes: evidence from
the "ACTION" database.
– P. Meredith, S. Lloyd, I. Ford, H.L. Elliott (Glasgow, GB)
Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT-EXT): a randomized,
double-blind, placebo-controlled trial.
– J. Vaclavik, R. Sedlak, J. Jarkovsky, E. Kocianova, M. Taborsky (Olomouc, Prostejov and Brno, CZ)
Pharmacological inhibition of NHE3-mediated sodium absorption in the gut reduces blood pressure and
attenuates impairment of left ventricular compliance.
– D. Linz, H. Heuer, W. Frick, A. Hofmeister, U. Heinelt, P. Arndt, U. Schwahn, W. Linz, M. Böhm, H. Ruetten
(Homburg and Frankfurt, DE)
Renal denervation reduces blood pressure and attenuates impairment of left ventricular compliance in
obese spontaneously hypertensive rats.
– D. Linz, M. Hohl, F. Mahfoud, J. Schuetze, S. Ewen, D. Urban, H.P. Juretschke, C. Neumann-Haeflin,
W. Linz, M. Böhm (Homburg and Frankfurt, DE)
Medetomidine can selectively activate cardiac vagal nerve without vagal activation in gastrointestinal
tract.
– S. Shimizu, T. Akiyama, T. Kawada, Y. Sata, T. Shishido, A. Kamiya, M. Sugimachi (Osaka, JP)
Dopamine withdrawal causes chemoreflex-related increase in minute ventilation.
– S. Tubek, P. Niewinski, W. Banasiak, P. Ponikowski (Wroclaw, PL)
P557
P558
P559
P560
P561
P562(W)
P563
P564
P565
P566
P567
P568
P569
P570
P571
P572
P573
P574
P575
P576
49
SATURDAY – AFTERNOON

SATURDAY, 31 AUGUST 2013 – AFTERNOON POSTERS
ENDOTHELIAL FUNCTION AND VASCULAR REMODELING
Discussant(s): Endothelial function and vascular remodeling.
– M. Volpe (Rome, IT), A. Pathak (Toulouse, FR), A.M. Heagerty (Manchester, GB)
The EPA:DHA 6:1-evoked endothelium-dependent NO-mediated relaxation in the coronary artery involves
a copper-dependent pro-oxidant response triggering the PI3-kinase/Akt-mediated activation of eNOS.
– F.Zgheel,M.Alhosin,S.Rashid,C.Auger,V.B.Schini-Kerth(Illkirch,FR)
A role of eNOS dimer stability in essential hypertension?
– S. Pick, T. Suvorava, M. Oppermann, M. Weber, G. Kojda (Düsseldorf, DE; Atlanta, US)
Contribution of extra-endothelial eNOS in regulation of blood pressure.
Top Score Poster
– T. Suvorava, J. Stegbauer, S. Friedrich, C. Rump, T. Hohlfeld, G. Kojda (Düsseldorf, DE)
Erythropoiesis-stimulating agent improves flow-mediated dilation via reduction of oxidative stress in
chronic kidney disease rats.
– K. Serizawa, K. Yogo, Y. Tashiro, M. Hirata, K. Endo (Gotemba Shizuoka, JP)
Shear stress and nitric oxide transport affect NFkB dynamics in endothelial cells.
– S.M. Bovens, N. Foin, N. O’Clery, K. Van Der Heiden, S. Cuhlmann, H. Carlsen, M. Barahona, P.C. Evans,
R. Krams (London and Sheffield, GB; Rotterdam, NL; Oslo, NO)
Hydroxyamine chloridrate reduces oxidative-stress damage subsequent to balloon-injury rat model.
– S. Muscoli, M. Macrini, D. Della Rocca, V. Cammalleri, C. Muscoli, V. Mollace, F. Romeo (Rome and
Catanzaro, IT)
Perfusion and microvascular adaptation in a rabbit model of developing heart failure assessed with a 3D
imaging cryomicrotome.
– M.G.J.T.B. Van Lier, N. Hakimzadeh, R. Coronel, J.A.E. Spaan, M. Siebes, J.P.H.M. Van Den Wijngaard
(Amsterdam, NL)
Effects of heart rate and selective heart rate reduction on vascular wall morphology and elastic
properties in dyslipidemic mice.
– F. Custodis, P. Fries, A. Mueller, C. Stamm, A. Sander, A. Ott, S.H. Schirmer, M. Böhm, U. Laufs
(Homburg/Saar and Saarbrücken, DE)
Hemodynamic shear stress regulates the apelin/APJ system in human endothelial cells.
– A. Strohbach, S. Lang, S.B. Felix, R. Busch (Greifswald, DE)
Acetyltransferase gene non-derepressible 5 mediates hyperglycemia-induced endothelial oxidative
stressin patients with type 2 diabetes.
– S. Costantino, F. Paneni, R. Battista, L. Castello, G. Capretti, S. Chiandotto, M. Volpe, T.F. Luscher,
F. Cosentino (Zurich, CH; Sora and Rome, IT)
Gene deletion of protein tyrosine phosphatase 1B limits cardiovascular dysfunction and mortality during
endotoxinic shock.
– D. Coquerel, E. Gomez, X. Marechal, D. Montaigne, I. Remi-Jouet, S. Renet, P. Mulder, R. Neviere,
V. Richard, F. Tamion (Rouen and Lille, FR)
High glucose-induced increased expression of endothelin-1 in human endothelial cells is mediated by
activated CCAAT/enhancer-binding proteins.
– S.-A. Manea, A. Todirita, C. Heltianu, A. Manea (Bucharest, RO)
Pioglitazone prevents endothelial dysfunction induced by ischemia and reperfusion via up-regulating
anti-oxidative effects: a human study.
– Y. Sakatani, T. Miyoshi, H. Oe, K. Nakamura, Y. Saito, H. Morita, K. Kohno, S. Nagase, K. Kusano, H. Ito
(Okayama, JP)
Active vitamin D3 analog, eldecalcitol, improves flow-mediated dilation via PPAR gamma/NF-kappaB
signaling pathway in ovariectomized rats.
– K. Serizawa, K. Yogo, Y. Tashiro, S. Takeda, K. Endo (Gotemba, Shizuoka, Japan, JP)
Isolation and characterisation of endothelial outgrowth from coronary arteries in patients with acute
myocardial infarction.
– M. Brittan, S. Gallogly, N.L. Mills (Edinburgh, GB)
RNA-binding motif protein 38 inhibits re-endothelialization following vascular injury.
– K. Sonnenschein, J. Fiedler, A. Just, J. Bauersachs, T. Thum (Hannover, DE)
Deletion of peroxisome proliferator coactivator-1alpha accelerates angiotensin II induced endothelial
dyfunction by increasing mitochondrial oxidative stress.
– S. Kroeller-Schoen, T. Jansen, M. Hausding, M. Oelze, A. Daiber, T. Muenzel, E. Schulz (Mainz, DE)
Genetic ablation of Platelet-Derived Growth Factor (PDGF) signaling protects from hypoxia-induced
vascular remodeling and pulmonary hypertension.
– H. Ten Freyhaus, E.M. Berghausen, W. Janssen, M. Leuchs, M. Zierden, A. Klinike, M. Vantler,
R.T. Schermuly, M.D. Tallquist, S. Rosenkranz (Cologne and Giessen, DE; Dallas, US)
Involvement of ephrinA1 in TNF-alpha-mediated monocyte adhesion.
– G. Ende, D.M. Poitz, A. Augstein, E. Wiedemann, J. Friedrichs, C. Werner, R.H. Strasser, S. Jellinghaus
(Dresden, DE)
An adipokine omentin prevents pathological vascular remodeling.
– Y. Uemura, R. Shibata, K. Ohashi, T. Enomoto, Y. Kataoka, M. Miyabe, D. Yuasa, K. Matsuo, N. Ouchi,
T. Murohara (Nagoya, JP)
AMPK preserves endothelial tight junctions in the coronary microcirculation during sepsis.
– D. Castanares-Zapatero, C. Bouleti, T. Mathivet, L. Bertrand, J.-L. Vanoverschelde, P.F. Laterre,
S.Horman,C.H.Beauloye(Brussels,BE;Paris,FR)
P577
P578
P579
P580
P581
P582
P583
P584
P585
P586
P587
P588
P589
P590
P591
P592
P593
P594
P595
P596
P597
P598
50

SATURDAY, 31 AUGUST 2013 – AFTERNOON POSTERS
Role of class IA PI 3-kinase isoforms in neointima formation following balloon angioplasty: only
p110alpha is important.
– M. Vantler, J. Jesus, O. Leppaenen, X. Chen, M. Vantler, H. Ten Freyhaus, E. Caglayan, F. Blaschke,
J.J. Zhao, S. Rosenkranz (Cologne and Berlin, DE; Uppsala, SE; Boston, US)
Connection between myocardial oedema, inflammation and function during sepsis: role of alpha1
AMP-activated protein kinase.
– D. Castanares-Zapatero, B. Gerber, D. Communi, C. Oury, C. Lecut, J.-L. Vanoverschelde, L. Bertrand,
P.F. Laterre, S. Horman, C.H. Beauloye (Brussels and Liège, BE)
Hyperuricemia induces endothelial dysfunction by increasing reactive oxygen species.
– A.H.P. Linke, A. Oberbach, N. Jehmlich, N. Schlichting, G. Schuler, V. Adams (Leipzig and Greifswald, DE)
Inhibition of Sonic hedgehog signaling impedes perivascular stem cell signaling and prevents neointimal
lesion formation.
– J.-M. Daniel, J. Dutzmann, A. Koch, J. Bauersachs, D. Sedding (Hannover, DE)
Vildagliptin, a dipeptidyl peptidase-4 inhibitor, ameliorates the development of CaCl2-induced abdominal
aortic aneurysm in mice via anti-inflammatory effects.
– Y. Noda, T. Miyoshi, T. Yonezawa, H. Oe, N. Toh, Y. Oono, K. Nakamura, H. Morita, K. Kusano, H. Ito
(Okayama, JP)
Macrohage depletion using clodronate liposomes delays exercise-induced collateral artery growth.3.
– D.N. Millenaar, A. Degen, M. Böhm, U. Laufs, S.H. Schirmer (Homburg/Saar, DE)
The protective effects of regulatory T cells in cardiac and skeletal muscles ischemia: reduce infarct size,
improve LV remodeling and function and improve flow recovery.
– R. Sharir, Y. Semo, S. Maysel-Auslender, N. Landa-Rouben, A. Shaish, R. Holbova, D. Kain, M. Entin-Meer,
G. Keren, J. George (Tel Aviv, Ramat Gan and Rehovot, IL)
Osteoprotegerin and osteopontin serum levels are associated with vascular function and inflammatory
process in coronary artery disease.
– K. Maniatis, G. Siasos, D. Tousoulis, E. Oikonomou, M. Zaromitidou, S. Kioufis, E. Kokkou,
N. Gouliopoulos, S. Mazaris, C. Stefanadis (Athens, GR)
Effects of the DPP-4 inhibitor saxagliptin on early vascular changes in the retinal and systemic circulation.
– R. Schmieder, U. Raff, S. Schmidt, I. Kistner, S. Friedrich, P. Bramlage, C. Ott (Erlangen and Mahlow, DE)
Bone marrow derived cells with defective c-Myb activity protect against neointimal remodeling following
injury.
– E. Shikatani, A. Momen, M. Husain (Toronto, CA)
Reversal of age-related vascular dysfunction through dietary nitrate supplementation.
– C.Rammos,U.B.Hendgen-Cotta,M.Totzeck,A.Bernard,J.Sobierajski,P.Stock,A.Goedecke,M.Kelm,
T. Rassaf (Düsseldorf, DE)
Circulating microRNAs in patients with myocardial bridging.
– J. Wang, J.W. Wang, Y.Z. Zhong, Y.H.P. Pei, S.S.J. Jiang, J.B.G. Gong (Nanjing, CN)
Effects of CYP2C19 genotype on vascular function in patients with coronary artery disease receiving
clopidogrel.
– M. Zaromitidou, D. Tousoulis, G. Siasos, S. Kioufis, E. Oikonomou, K. Maniatis, E. Kokkou, S. Mazaris,
P. Tourikis, C. Stefanadis (Athens, GR)
Current smoking aggravates intimal hyperplasia after arterial injury following transradial catheterization.
– R. Sansone, E. Stegemann, D. Schuler, G. Oezaslan, M. Kelm, R. Westenfeld, T. Lauer, C. Heiss
(Düsseldorf, DE)
Elevated parathyroid hormone predicts high asymmetric dimethylarginine (ADMA) concentrations;
independent of vitamin D status.
– A.T. Amarasekera, A.L. Sverdlov, M.S. Roberts, J.D. Horowitz, D.T. Ngo (Adelaide, AU)
Association of LpPLA2 activity with coronary and LV function in patients with coronary artery disease and
coexistent rheumatoid arthritis: effects of Interleukin-1 inhibition.
– I. Ikonomidis, S. Tzortzis, C. Tellis, I. Andreadou, P. Katsimbri, I. Paraskevaidis, J. Parissis,
M. Anastasiou-Nana, A. Tselepis, J. Lekakis (Athens and Ioannina, GR)
The interaction between circadian rhythms of endothelial function: resting versus recruitable endothelial
function.
– T. Gori, M. Vosseler, A. Al-Shazly, T. Munzel (Mainz, DE)
Bone morphogenetic protein receptor activation plays a crucial role in endothelial dysfunction and
osteogenic differentiation in mice with chronic kidney disease.
– H. Kajimoto, H. Kai, H. Aoki, H. Uchiwa, Y. Aoki, Y. Iwamoto, T. Imaizumi (Kurume, JP)
Increased plasma Glucagon Like Peptide-1 improves endothelial dysfunction immediately after Roux-en-Y
gastric bypass prior to body weight loss inhibiting the c-Jun N-terminal Protein Kinase Signaling.
– E. Osto, P. Doytcheva, C. Corteville, K. Spliethoff, M. Bueter, L. Rohrer, U. Landmesser, C. Matter, T. Lutz,
T. Luscher (Zurich, CH)
Does cellular sex matter? Dimorphic transcriptional differences between female and male endothelial
cells.
– M. Lorenz, J. Koschate, K. Kaufmann, C. Kreye, M. Mertens, W.M. Kuebler, G. Baumann, G. Gossing,
K. Stangl, V. Stangl (Berlin and Bergisch Gladbach, DE)
P599
P600
P601
P602
P603
P604
P605
P606
P607
P608
P609
P610
P611
P612
P613
P614
P615
P616
P617
P618
SATURDAY – AFTERNOON
51

SATURDAY, 31 AUGUST 2013 – AFTERNOON POSTERS
MECHANISMS OF HEART FAILURE DETERIORATION
Discussant(s): Mecanisms of heart failure deterioration.
– E. Roig (Barcelona, ES), J. Nanas (Athens, GR)
Natriuretic peptide/cyclic guanosine monophosphate pathway exerts compensatory roles against
endothelin system in the pulmonary circulation of left heart disease.
– Y. Ohashi, J. Ejiri, S. Hirayama, H. Kato, K. Yamawaki, K. Hyogo, D. Kashiwagi, K. Nakayama, N. Emoto,
K. Awano (Miki City and Kobe, JP)
Left ventricular contraction pattern in asymptomatic patients with moderate to severe aortic
regurgitation.
– S. Urheim, K. Broch, R. Massey, S. De Marchi, S. Aakhus, L. Gullestad (Oslo, NO; Berne, CH)
Radial function correlates with heart failure symptoms in hypertrophic cardiomyopathy with normal
ejection fraction.
– D. Muraru, C. Calore, L.P. Badano, P. Melacini, S. Mihaila, S. Casablanca, U. Cucchini,
M. Haertel-Miglioranza, A. Polo, S. Iliceto (Padua, IT; Bucharest, RO; Porto Alegre, BR)
Noninvasive and mainstream end-tidal carbon dioxide monitoring via nasal cannula is a unique and useful
technique for diagnosing pulmonary hypertension in patients with heart failure.
– O. Seguchi, A. Nakano, M. Hieda, T. Watanabe, T. Sato, H. Sunami, Y. Murata, M. Yanase, M. Kitakaze,
T. Nakatani (Osaka, JP)
VO2max/kg in heart failure patients is an unreliable indicator of the severity of cardiac dysfunction.
– S. Hothi, D.K. Tan, S. Chinnappa, N. Lewis, L.-B. Tan (Cambridge, Newcastle and Leeds, GB)
Copper serum levels in patients with heart failure correlate with parameters of left ventricular systolic
and diastolic dysfunction.
– I. Alexanian, J. Parissis, S. Athanaselis, L. Pappas, G. Gavrielatos, C. Michas, A. Sideris, D. Kremastinos,
M. Anastasiou-Nana, G. Filippatos (Athens, GR)
The effects of blood components modulation on load-dependent cardiac function during an acute
hemodilution.
– S. Chatpun, P. Cabrales (Hatyai, TH; La Jolla, US)
Changes of portal vein flow in heart failure patients with liver congestion.
– E. Goncalvesova, I. Varga, M. Tavacova, P. Lesny (Bratislava, SK)
Impact of stress on myocardial function in postmenopausal women and its relationship with endothelial
dysfunction.
– K.I. Cho, I.K. Shim, J.H. Heo, H.S. Kim, T.J. Cha, J.W. Lee (Busan, KR)
Pulmonary hypertension in patients with left heart disease: the relationship with left ventricular systolic
function.
– T. Ibe, H. Wada, K. Sakakura, N. Ikeda, Y. Sugawara, J. Ako, S. Momomura (Saitama, JP)
Acute effects of adaptive servo-ventilation on hemodynamics in advanced chronic heart failure patients.
– M. Hieda, Y. Murata, M. Yanase, O. Seguchi, T. Sato, H. Sunami, T. Watanabe, T. Shishido, T. Nakatani
(Suita, JP)
Adults with growth hormone deficiency have subclinical left ventricular dysfunction without vascular
dysfunction, suggesting intrinsic myocardial disease.
– S. Mihaila, R. Mincu, R.C. Rimbas, N. Patrascu, M. Cinteza, C. Badiu, D. Vinereanu (Bucharest, RO)
Hypoperfused interventricular septum in left bundle branch block is due to reduced septal work.
– K. Russell, M. Eriksen, J.G. Fjeld, S.I. Sarvari, T. Edvardsen, O.A. Smiseth (Oslo, NO)
Cardiac functional consequences of chronic kidney disease: direct evidence of uraemic cardiomyopathy.
– S. Chinnappa, S.S. Hothi, A. Mooney, M. El Nahas, L.-B. Tan (Leeds, Cambridge and Sheffield, GB)
The fibroblast growth factor-23/vitamin D axis, left ventricular mass and mortality in elderly people.
– S. Masson, R. Latini, G.F. Mureddu, N. Agabiti, M. Miceli, F. Forastiere, G. Cesaroni,
U.H. Wienhues-Thelen, T. Vago, A. Boccanelli (Milan and Rome, IT; Penzberg, DE)
Prognostic value of pulmonary hypertension in ambulatory patients with non-ischemic left ventricular
systolic dysfunction.
– A.Hirashiki,T.Kondo,T.Okumura,S.Adachi,R.Morimoto,S.Shimazu,S.Shimizu,T.Murohara(Nagoya,
JP)
Renal arterial resistance index is independently associate to high diuretic dose in chronic heart failure
outpatients.
– A. Doronzo, M.M. Ciccone, M. Iacoviello, A. Puzzovivo, F. Monitillo, V. Antoncecchi, G. Citarelli, V. Paradies,
N. Corrieri, S. Favale (Bari, IT)
Renal resistance index: a new marker reflecting cardiorenal syndrome independently associated with
heart failure progression.
– A. Puzzovivo, M.M. Ciccone, M. Iacoviello, A. Doronzo, V. Antoncecchi, F. Monitillo, G. Citarelli, V. Paradies,
N. Corrieri, S. Favale (Bari, IT)
Structural abnormality of the hippocampus and depressive symptoms in a rat model of heart failure.
– H. Suzuki, A. Sumiyoshi, Y. Matsumoto, T. Yoshikawa, Y. Fukumoto, K. Yanai, Y. Taki, R. Kawashima,
H. Shimokawa (Sendai, JP)
Longitudinal strain in Friedreich Ataxia: a potential marker for early left ventricular dysfunction.
– M. St John Sutton, B.K. Ky, S.R. Regner, K.S. Schadt, T.P. Plappert, B.D. D’Souza, D.R.L. Lynch
(Philadelphia, US)
Long-term therapy with Bendavia (MTP-131), a novel mitochondria-targeting peptide, reverses
mitochondrial abnormalities in left ventricular myocardium of dogs with advanced heart failure.
– H.N. Sabbah, R.C. Gupta, S. Rastogi, M. Wang, K. Zhang (Detroit, US)
P619
P620
P621
P622
P623
P624
P625
P626 (W)
P627
P628
P629
P630
P631
P632
P633
P634
P635
P636
P637
P638
P639
P640
52

SATURDAY, 31 AUGUST 2013 – AFTERNOON POSTERS
HEART FAILURE CARE AND QUALITY OF LIFE
Discussant(s): Heart failure care and quality of life.
–A.N.Neskovic(Belgrade,RS)
P641
Quality of life and heart rate according to the presence of sinus rhythm or atrial fibrillation in heart failure
patients.
– M. De Antonio, J. Lupon, M. Domingo, R. Cabanes, B. Gonzalez, L. Cano, A. Urrutia, E. Zamora, R. Coll,
A. Bayes-Genis (Badalona, ES)
Nurse-based educational intervention in a heart failure unit improves outcomes in self-care, quality of life
and depression of high-risk patients with chronic heart failure.
– S. Lopez-Fernandez, M. Puga-Martinez, M. Jimenez-Fernandez, M.J. Molina-Lerma, V. Alcalde-Martinez,
E. Lopez-Moreno, R. Melgares-Moreno (Granada, ES)
Disease management program in implementing the guidelines of heart failure.
– C.P.Amorim,R.Bosquetti,E.P.V.Felix,F.Dalpicolo,R.B.Madeo,J.Dinkhuysen,V.S.Issa,F.Ramires
(São Paulo, BR)
Renal failure in patients with heart failure - analysis based on ESC-HF Pilot survey.
– M.M.Stasiak,P.Rozentryt,E.Jankowska,A.Retwinski, E. Straburzynska-Migaj, E. Nowalany-Kozielska,
P. Ponikowski, E. Mirek-Bryniarska, L. Polonski, J. Drozdz (Lodz, Zabrze, Wroclaw, Poznan and Krakow,
PL)
Heart rate control in chronic systolic heart failure patients in Germany: results of a nationwide survey.
– C. Zugck, P. Martinka, G. Stoeckl, C. Tschoepe, S. Stoerk (Straubing, Munich, Berlin and Würzburg, DE)
Guiding decongestion treatment in chronic heart failure patients. Clinical assessment or serial laboratory
evaluation?
– A. Karavidas, K. Konstantinou, M. Nikolaou, V. Matzaraki,N.Papoutsidakis,V.Pyrgakis,J.Parissis(Athens,
GR)
Self-care and renal dysfunction in patients with chronic heart failure.
– D.E.F. Kessing, J. Denollet, J. Widdershoven, N. Kupper (Tilburg, NL)
Comparison of in-hospital course and long-term follow-up in apical and mid-ventricular takotsubo
patients.
– M. Pawlak, M. Roik, Z. Huczek, J. Kochanowski, R. Piatkowski, P. Scislo, R. Kowalik, M. Krakowian,
G. Opolski (Warsaw, PL)
Impaired LV systolic function in lymphoma survivors after mediastinal radiotherapy.
– K. Murbraech, K.H. Smeland, J.H. Loge, H. Holte, C.E. Kiserud, S. Aakhus (Oslo, NO)
The effect of heavy meal on left ventricular function during exercise in patients with stable coronary
artery disease.
– J. Patel, S.A. Wayangankar, P. Lozano, J. Stoner, H.D. Dao, U. Thadani (Oklahoma City, US)
Quality of life and frailty in an outpatient population with heart failure.
– P. Gastelurrutia, J. Lupon, M. De Antonio, B. Gonzalez, R. Cabanes, L. Cano, A. Urrutia, M. Domingo,
S. Altimir, A. Bayes-Genis (Badalona, ES)
Clinical features of patients with decompensated heart failure after the Great East Japan Earthquake.
– Y. Hiroyuki, A. Yoshihisa, T. Owada, T. Yamaki, K. Sugimoto, H. Kunii, K. Nakazato, H. Suzuki, S. Saitoh,
Y. Takeishi (Fukushima City, JP)
The state of reduced glutathione in patients with impaired glycemic states and coronary heart disease.
– O. Shyshko, T. Mokhort, I. Buko, E. Konstantinova, N. Tsapaeva, I. Lazareva (Minsk, BY)
Can we improve quality of life in heart failure - results of the national educational study.
– T.Rywik,P.Kurjata,M.Fedyk-Lukasik,P.Leszek,W.Piotrowski,R.Targonski,J.Korewicki,H.Rywik,
G.Broda(Warsaw,KrakowandOlsztyn,PL)
Ability of non-dependent elderly patients hospitalized for heart failure to perform the tasks required for
self-care.
– M.T. Vidan, D. Cimera, E. Sanchez-Garcia, G. Ferreira, F.J. Ortiz-Alonso, J.A. Serra, F. Fernandez-Aviles,
H. Bueno (Madrid, ES)
Prevalence of frailty in elderly non-dependent patients hospitalized for heart failure, and characteristics of
frail patients.
– M.T. Vidan, D. Cimera, E. Sanchez-Garcia, G. Mendieta, F.J. Ortiz-Alonso, J.A. Serra, F. Fernandez-Aviles,
H. Bueno (Madrid, ES)
The relationship of tissue Doppler Tei index with invasive hemodynamic parameters in patients with heart
failure.
– M. Meric, O. Yesildag, S. Yuksel, I. Dursun, M. Arslandag, D. Koprulu, K. Soylu, O. Yilmaz
(Kurupelit-Samsun, TR)
Right ventricular systolic echocardiographic parameters in chronic systolic heart failure and prognosis.
– K. Darahim (Cairo, EG)
A novel minimally-invasive technique to predict pulmonary capillary wedge pressure utilizing jugular
venous pressure and the tissue Doppler tricuspid/mitral annular velocities.
– K. Uemura, T. Kawada, M. Sugimachi (Suita, JP)
Noninvasive estimation of pulmonary capillary wedge pressure using speckle tracking echocardiography
in patients with preserved or reduced ejection fraction.
– M. Kawasaki, R. Tanaka, H. Yagasaki, K. Ono, T. Watanabe, M. Iwama, M. Arai, T. Noda, S. Watanabe,
S. Minatoguchi (Gifu, JP)
Regional cardiac dysfunction and outcome in patients with left ventricular dysfunction, heart failure, or
both after myocardial infarction.
Top Score Poster
– N. Wang, A. Shah, G. Querejeta, D. Gupta, E. Velazquez, R. Califf, J. McMurray, M. Pfeffer, S. Solomon
(Boston and Durham, US)
P642
P643
P644
P645
P646
P647
P648
P649
P650
P651
P652
P653
P654
P655
P656
P657
P658
P659
P660
P661
P662
SATURDAY – AFTERNOON
53

SATURDAY, 31 AUGUST 2013 – AFTERNOON POSTERS
DIAGNOSTIC TOOLS IN HEART FAILURE
Discussant(s): Diagnostic tools in heart failure.
– G. Ertl (Würzburg, DE)
Barriers to accurate diagnosis and effective management of heart failure have not changed in 10 years.
– H.C. Hancock, H. Close, A. Fuat, J.J. Murphy, A.P.S. Hungin, J.M. Mason (Durham and Darlington, GB)
Pulmonary congestion evaluated by lung ultrasound predicts admission in patients with heart failure.
– M.H. Miglioranza, L. Gargani, R.T. Sant’anna, M. Rover, V.M. Martins, L.P. Badano, R. Sicari, E. Picano,
R.A.K. Kalil, T.L. Leiria (Porto Alegre, BR; Pisa and Padua, IT)
Breathless catastrophizing score in heart failure patients: development and validation.
– J.Hunt,G.Lloyd(Eastbourne,GB)
Development of a European heart failure risk score in the general population.
– A. Jagodzinski, F. Ojeda, T. Zeller, K. Sydow, S. Blankenberg, T. Jorgensen, K. Kuulasma, R.B. Schnabel,
V. Salomaa (Hamburg, DE; Copenhagen, DK; Helsinki, FI)
Suboptimal accuracy of the ED physician and NT-proBNP levels to diagnose heart failure in elderly
patients with dyspnoea: the Akershus Cardiac Examination (ACE) 2 Study.
– J. Brynildsen, A.D. Hoiseth, S. Nygard, T.A. Hagve, G. Christensen, T. Omland, H. Rosjo (Lørenskog and
Oslo, NO)
Repeated echocardiography after first ever ST segment elevation myocardial infarction treated with
primary percutaneous coronary intervention, is it necessary.
– H. Soeholm, J. Loenborg, M.J. Andersen, N. Vejlstrup, T. Engstroem, J.E. Moller, C. Hassager
(Copenhagen, DK)
Echocardiographic indices of right heart function affecting ventilatory efficiency during exercise in left
and right ventricular failure.
– M. Jasiewicz, M. Knapp, K. Ptaszynska, A. Szpakowicz, W.J. Musial, K. Kaminski (Bialystok, PL)
The role of heart failure in hospital management program upon mortality.
– C.P. Amorim, R. Bosquetti, E.P.V. Felix, M.B. Carli, R.A. Gomes, V.S.G. Ribeiro, V.S. Issa, F.J.A. Ramires
(São Paulo, BR)
Defining the best echocardiographic parameter to predict acute rejection after heart transplantation.
– S. Mingo Santos, V. Monivas Palomero, C. Mitroi, I. Garcia Lunar, M. Sanchez Garcia, E. Gonzalez Lopez,
P. Beltran Correas, J. Gonzalez Mirelis, B. Rivero, J. Segovia Cubero (Madrid, ES)
Multiple circulating microRNAs improve prognostication in subjects with stable heart failure.
– A.Bayes-Genis,J.Lupon,J.Lenders,S.J.Pinto-Sietsma, Y.M. Pinto (Badalona, ES; Amsterdam, NL)
N-terminal proB-type natriuretic peptide testing: practical diagnostic value in a emergency department.
– P. Villa, R. Dominici, A. Dolci, M. Panteghini, S. Guzzetti (Milan, IT)
Evaluation of plasma brain natriuretic peptid levels in patients with isolated left bundle branch block and
preserved left ventricular systolic function.
– H. Hamur, M. Acikel, E.M. Bakirci, H. Degirmenci, H. Duman, S. Demirelli, F. Erol, M.H. Tas, E. Aksakal,
S. Karakelleoglu (Erzurum, TR)
Early detection and prediction of taxanes-induced cardiac dysfunction by assessment of myocardial
deformation.
– M. Florescu, D. Mihalcea, O.A. Enescu, L.S. Magda, L. Trasca, P. Balanescu, R.C. Rimbas, E. Radu,
D. Jinga, D. Vinereanu (Bucharest, RO)
Left ventricular performance and dyssynchrony in heart failure and normal ejection fraction: assessment
by stress echocardiography.
– J.I.N.G. Wang, F.A.N.G. Fang, W.E.I. Feng, C.M. Yu, Y.-Y. Lam (Hong Kong, CN)
P663
P664
P665
P666
P667
P668
P669
P670
P671
P672
P673
P674
P675
P676
P677
LIPID LOWERING STRATEGIES
Discussant(s): Lipid lowering strategies.
– Z. Reiner (Zagreb, HR)
Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease
patients with baseline elevations in alanine aminotransferase levels.
– M.J. Tikkanen, R. Fayyad, O. Faergeman, A.G. Olsson, C.-C. Wun, R. Laskey, J.J. Kastelein, I. Holme,
T.R. Pedersen (Helsinki, FI; New York, US; Aarhus, DK; Linköping, SE; Amsterdam, NL; Oslo, NO)
The effect of high dose Cilostazol and Rosuvastatin on myocardial damage in patients with elective
percutaneous coronary intervention (PREVENT trial).
– H.Ari,N.Emlek,S.Cosar,C.Aydin,K.Doganay,A.Karakus,I.Zengin,T.Bozat,M.Melek(Bursa,TR)
Statin therapy is a major determinant of PCSK9 plasma concentration: data from four clinical trials with
AMG 145.
– F. Civeira Otermin, F. Raal, E.A. Stein, M.B. Schou, D.C. Basart, M.J. Koren, R. Ceska, R. Somaratne,
J. Yang, M.S. Sabatine (Zaragoza, ES; Johannesburg, ZA; Cincinnati, Jacksonville, Thousand Oaks and
Boston, US; Ballerup, DK; Holland, NL; Prague, CZ)
Intolerance to statins and response to PCSK9 inhibition with AMG 145.
– D. Sullivan, F. Civeira, G.F. Watts, M.B. Shou, M.J. Tikkanen, L.A. Simons, L. Masana, J.B. Kim, A. Xue,
E.A. Stein (Camperdown, New South Wales, Perth and Sydney, AU; Zaragoza and Reus, ES; Ballerup, DK;
Helsinki, FI; Thousand Oaks and Cincinnati, US)
Safety of AMG 145, a fully human monoclonal antibody to PCSK9: Data from four phase 2 studies in 1314
patients.
– R.P. Giugliano, F. Raal, M.J. Koren, D. Sullivan, E.M. Roth, R. Weiss, R. Somaratne, J. Yang,
M.S. Sabatine, E.A. Stein (Boston, Jacksonville, Cincinnati, Auburn and Thousand Oaks, US;
Johannesburg, ZA; Camperdown, New South Wales, AU)
P678
P679
P680
P681
P682
P683
54

SATURDAY, 31 AUGUST 2013 – AFTERNOON POSTERS
Impact of low-density lipoprotein cholesterol/high-density lipoprotein cholesterol ratio as a risk factor of
cardiovascular event after percutaneous coronary intervention in men.
– I. Matsumoto, R. Kawakami, M. Kurozumi, Y. Tagagi (Takamatsu, JP)
Lipid-lowering therapy modification and LDL-C Goal achievement after an acute coronary syndrome: a
prospective Swiss cohort.
– B. Gencer, F. Mach, R. Auer, L. Raeber, D. Nanchen, P. Meyer, C.M. Matter, S. Windecker, T.F. Luescher,
N. Rodondi (Geneva, Berne, Lausanne and Zurich, CH; San Francisco, US)
Safety and tolerability of intensive lipid-lowering therapy after acute coronary syndromes: defining the
role of ezetimibe in a comprehensive secondary prevention program.
– F. Colivicchi, A. Aiello, M. Tubaro, M. Santini (Rome, IT)
LDL goal achievement in 766 consecutive, unselected coronary heart disease patients, a comparison
between usual care and a structured follow-up program in out of hospital cardiology practice.
– M. Heldal, T.R. Pedersen (Oslo, NO)
ROsuvastatin LOading and Clinical Outcomes (ROLOCO) trial.
– S. Cay, G. Cagirci, S. Topaloglu, D. Aras, S. Aydogdu (Ankara and Antalya, TR)
Eicosapentaenoic acid reduced the progression of the coronary atherosclerosis in the patients with
optimal LDL cholesterol lowering therapy.
– T.Domei,K.Amemiya,S.Enomoto,K.Ichihashi,H.Yokoi,M.Iwabuchi,M.Nobuyoshi(Kitakyusyu,JP)
The statins benefit in prognosis after an acute coronary syndrome is independent of baseline
LDL-cholesterol levels.
– A. Cordero, D. Sirera, B. Miralles, M.D. Masia, P. Carrillo, V. Bertomeu-Gonzalez, J. Moreno-Arribas,
R. Lopez-Palop, V. Bertomeu-Martinez (Alicante, ES)
Assessment of lipophilic vs. hydrophilic statin therapy in Acute Myocardial Infarction (The ALPS-AMI
study).
– A.Izawa,Y.Kashima,S.Ebisawa,T.Miura,T.Saigusa,Y.Shiba,Y.Miyashita,T.Tomita,J.Koyama,
U. Ikeda (Matsumoto, JP)
Coronary artery calcium score to guide statin therapy in patients with elevated C-reactive protein and low
LDL cholesterol levels: a cost-effectiveness analysis.
– A. Silva Ferreira, P. De Araujo Goncalves, H. Marques, N. Cardim, F.P. Machado (Lisbon, PT)
The association of elevated HDL levels (>70 mg/dl) with carotid atherosclerosis in middle-aged women
with first diagnosed and untreated essential hypertension.
– H. Triantafyllidi, I. Ikonomidis, P. Trivilou, K. Kontsas, S. Tzortzis, G. Pavlidis, F. Hlia, M. Anastasiou-Nana,
J. Lekakis (Athens, GR)
P684
P685
P686
P687
P688
P689
P690
P691
P692
P693
SATURDAY – AFTERNOON
LIPIDS: RISK AND MANAGEMENT
Discussant(s): Lipids: risk and management.
– F.T. Lanas Zanetti (Temuco, CL)
Highly purified eicosapentaenoic acid may increase the low-density lipoprotein particle size by improving
triglyceride metabolism in patients with hypertriglyceridemia.
– S. Tani, K. Nagao, M. Matsumoto, M. Onikura, T. Ashida, K. Kawauchi, A. Hirayama (Tokyo, JP)
Association of a polymorphism of BTN2A1 with dislipidemia in community-dwelling Japanese individuals.
– H. Horibe, T. Ueyama, T. Kawamiya, T. Fujimaki, M. Oguri, K. Kato, K. Yokoi, T. Murohara, S. Ichihara,
Y. Yamada (Tajimi, Yokkaichi, Inabe, Nagoya and Tsu, JP)
What factors affect the improvement of coronary artery lipid composition most? - assessed by
integrated-backscatter intravascular ultrasound.
– R. Kawakami, M. Kurozumi, I. Matsumoto, Y. Takagi (Takamatsu, JP)
Does the determination of lipoprotein(a) help in the prediction of cardiovascular events?
– Y.A. Kesaniemi, M. Santaniemi, 0. Ukkola (Oulu, FI)
Sharp increase in statin use and large changes in lipids and hsCRP in adults >=55 years of age in Poland
during the last decade.
– P. Bandosz, T. Zdrojewski, M. Pencina, M. Rutkowski, B. Wyrzykowski (Gdansk, PL; Boston, US)
Impact of the hypertriglyceridemic waist phenotype as a simplified model of screening to identify
asymptomatic subjects at high cardiometabolic risk with increased subclinical atherosclerosis.
– D.E. Monopoli, L. Bertelli, K. Rampino, G. Gorlato, A. Lattanzi, F. Coppi, F. Sgura, R. Rossi (Modena, IT)
Lipoprotein associated phospholipase A2 and C-reactive protein as predictors of metabolic syndrome in
subjects without cardiovascular disease.
– M. Acevedo, P. Varleta, V. Kramer, T. Quiroga, C. Prieto, J. Parada, C. Navarrete (Santiago and La Serena,
CL)
Concordance and discordance between apolipoprotein B, LDL-C and Non-HDL-C in statin-treated
subjects presenting with chest pain and elevated troponin.
– R. Pitts, V. Varghese, K. Bhatt, J. Parag, Z. Qian, W. Odeh, J. Lee, S. Rinehart, J. Miller (Atlanta and
Baltimore, US)
High level of low density lipoprotein cholesterol in younger children of patients with premature coronary
artery disease: relation to own and parental risk factors.
– M.V. Konov, A.D. Deev, N.A. Gratsiansky (Moscow, RU)
Dissecting the protective IgG anti-malondialdehyde-LDL (MDA-LDL) antibody response in a substudy of
the Anglo Scandinavian Cardiac Outcomes Trial (ASCOT).
– R. Khamis, T. Batty, I. Wong, M. Johns, S. Thom, J. Mayet, A. Stanton, A.L. Hughes, D.O. Haskard
(London, GB; Dublin, IE)
P694
P695
P696
P697
P698
P699
P700
P701
P702
P703
P704
55

SATURDAY, 31 AUGUST 2013 – AFTERNOON POSTERS
Supplementation with a pomegranate extract abrogates hypercholesterolemia-induced coronary
endothelial dysfunction in swine.
– G. Vilahur, T. Padro, L. Casani, G. Mendieta, J.A. Lopez, M. Penalver, L. Badimon (Barcelona and Murcia,
ES)
Fasting triglyceridemia influences postprandial endothelial response to a single Mediterranean-type meal
compared to a high-saturated fat meal.
– S. Lacroix, C. Desrosiers, M. Gayda, J.C. Tardif, A. Nigam (Montreal, CA)
Incidence of simvastatin and strong CYP3A4 inhibitors co-prescription during hospital admission.
– C.M. Santos, T. Laranjeira, L. Calixto, H. Dores, S. Madeira, A. Parrinha, A. Mirco, C. Aguiar, M. Mendes,
F. Falcao (Lisbon, PT)
Role of the relationship between dyslipidemia and genetic factors in the development of atherosclerosis.
– S. Hata, M. Nakazato, T. Sekita, T. Maeda, T. Kanda (Sasebo, Goto and Nagasaki, JP)
Impact of hyperlipidemia on development of new-onset diabetes mellitus in Asian population: 5-year
clinical outcomes.
– S.H.Park,S.W.Rha,W.Y.Shin,B.G.Choi,S.Y.Choi,C.U.Choi,E.J.Kim,C.G.Park,H.S.Seo,D.J.Oh
(Cheonan and Seoul, KR)
P705
P706
P707
P708
P709
OBESITY: LOWERING RISK
Discussant(s): Obesity: lowering risk.
– W.J. Kop (Tilburg, NL)
Leptin-adiponectin ratio and the extent of CAD in pre-diabetic patients undergoing PCI.
– W.A. Heggermont, P.A.H. Nguyen, C. Dubois, T. Vydt, M. Coosemans, T. Adriaenssens, B. Ferdinande,
W. Desmet, P.R. Sinnaeve (Leuven, BE)
Does adiponectin protect against the cardiovascular dysfunction associated with central adiposity in
young women with polycystic ovary syndrome?
– E. Rees, R. Hocking, F. Dunstan, M. Lewis, K. Tunstall, J.P. Halcox, A.G. Fraser, D.A. Rees (Swansea and
Cardiff, GB)
Analysis of the obesity paradoxic according to the sex: relation between body mass index and mortality in
the first year after an acute coronary syndrome.
– S. Raposeiras Roubin, E. Abu Assi, N. Bouzas Cruz, A. Lopez Lopez, M. Castineiras Busto, E. Pereira
Lopez, S. Gestal Romari, J.M. Garcia Acuna, J.R. Gonzalez Juanatey (Santiago de Compostela, ES)
Despite a mixed reactivity to antiplatelet agents, obese patients have no benefit of platelet function
monitoring: insight from the ARCTIC study.
– E. Van Belle, J.P. Collet, S. O’Connor, J. Abtan, C. Saint-Etienne, M. Kerneis, H. Rousseau, J. Sylvain,
E. Vicaut, G. Montalescot (Lille, Paris and Tours, FR)
Serum omentin significantly predicts cardiovascular events both in patients with the metabolic syndrome
and in subjects who do not have the metabolic syndrome.
Top Score Poster
– C.H. Saely, A. Leiherer, A. Muendlein, A. Vonbank, D. Zanolin, K. Geiger, H. Drexel (Feldkirch, AT; Triesen,
LI; Philadelphia, US)
Association of current carotid elastic modulus and prior body mass index in elderly people - results from
the SAPALDIA cohort study.
– S. Caviezel, J. Dratva, E. Schaffner, C. Schindler, N. Kuenzli, J.M. Gaspoz, T. Rochat, N. Probst-Hensch,
A. Schmidt-Trucksaess (Basel and Geneva, CH)
Volume-rendered regional adipose tissue depots correlated with circulating hs-CRP as an independent
clinical predictor for left atrial remodeling beyond BMI in asymptomatic population.
– Y.H. Lai, C.H. Yun, J.Y. Kuo, T.C. Hung, Y.J. Wu, H.I. Yeh, C.L. Hung (Taipei, TW)
Increased levels of circulating arginase I in adolescents with overweight.
– C. Jung, H.R. Figulla, M. Lichtenauer, M. Franz, J. Pernow (Stockholm, SE; Jena, DE)
Association between erectile dysfunction severity and major adverse cardiovascular events in men with
metabolic syndrome.
– A. Aggelakas, C. Vlachopoulos, I. Iona, N. Ioakeimidis, M. Abdelrasoul, A. Aggelis, D. Terentes-Printzios,
P. Pietri, S. Vaina, C. Stefanadis (Athens, GR)
Risk factors for cardiovascular disease, metabolic syndrome and sleepiness in truck drivers.
– A.P. Mansur, J.Y. Takada, S.D. Avakian, S.M.B. Lins, M.A.B.S. Rocha, A.J. Santos, A.M.C.A. Andrade,
J.R. Vasconcelos Jr, L.B.M. Monteiro, V. Leyton (São Paulo and Brasilia, BR)
Association of epicardial adipose tissue with cardiovascular risk factors in subjects free from clinical
symptoms of coronary artery disease.
– A.Jermendy,R.Vadas,A.Bartykowszki,Z.S.Bagyura,M.Karolyi,P.Soos,Z.S.Szelid,B.Merkely,
P. Maurovich-Horvat (Budapest, HU)
Lean mass, fat mass and eccentric left ventricular remodelling in obesity.
– B. Corden, N.G. Keenan, T.J.W. Dawes, A.S.M. De Marvao, G. Durighel, T. Diamond, S.A. Cook,
D.P. O’Regan (London, GB)
Resting heart rate is an independent predictor of left ventricular diastolic dysfunction in obese patients
with or without arterial hypertension.
– F.L. Dini, F. Santini, D. Morrone, A. Huqi, G. Guarini, A. Simioniuc, V. Di Bello, M. Marzilli (Pisa, IT)
Impact of serum adipocyte fatty acid-binding protein on clinical outcome in patients with stable angina
undergoing percutaneous coronary intervention.
– W. Takagi, T. Miyoshi, M. Kajiya, M. Iwamoto, K. Ohkawa, K. Nosaka, R. Nakayama, K. Takeda,
S. Hirohata, M. Doi (Takamatsu and Okayama, JP)
P710
P711
P712
P713
P714
P715
P716
P717
P718
P719
P720
P721
P722
P723
P724
56

SATURDAY, 31 AUGUST 2013 – AFTERNOON POSTERS
Differential responses of distinct adipose tissue depots to acute and chronic inflammation: novel insights
into the complex mechanisms regulating adiponectin biosynthesis in humans.
– A. Antonopoulos, R. Patel, M. Demosthenous, M. Margaritis, J. Digby, R. Sayeed, D. Tousoulis,
C. Stefanadis, K.M. Channon, C. Antoniades (Oxford, GB; Athens, GR)
P725
OBESITY
Discussant(s): Obesity.
– N.Sattar(Glasgow,GB)
Comparative effectiveness of weight loss interventions and prevention of cardiovascular disease in
patients with abdominal obesity.
– A. Berezina, O. Belyaeva, O. Berkovich, E. Baranova, E. Shlyakhto (St. Petersburg, RU)
Waist circumference versus other obesity parameters as predictors of coronary artery disease in
essential hypertensive patients: a 6-year-follow-up study.
– K. Kintis, C. Tsioufis, K. Dimitriadis, I. Bafakis, A. Kefala, A. Kasiakogias, P. Vasileiou, A. Kordalis,
I. Kallikazaros, C. Stefanadis (Athens, GR)
Visceral fat is stronger associated with electrocardiographic measures of sympathetic activation than
subcutaneous fat in individuals with structurally normal hearts: the NEO study.
– S. Hillebrand, T. Christen, A.C. Maan, J.W. Jukema, H.J. Lamb, A. De Roos, F.R. Rosendaal, M. Den
Heijer, C.A. Swenne, R. De Mutsert (Leiden and Amsterdam, NL)
Successful long-term weight reduction improves left ventricular diastolic function and physical
performance in severe obesity.
– S. Fenk, A. Baessler, E. Rousseva, C. Strack, M. Manka, G. Schmitz, G. Riegger, T. Loew, C. Lahmann,
M. Fischer (Regensburg and Munich, DE)
Reclassification of LV geometric patterns in morbidly obese patients. A CRM study.
– M. Luaces Mendez, V. Cachofeiro, L. Perez-Isla, A. Antequera-Perez, M. Medina-Garcia, A. Garcia-Munoz
Najar, J.J. Gomez De Diego, J. Cabezudo, T. Matajira, C. Macaya (Madrid and Fuenlabrada, ES)
Steeper increase of body weight and BMI in acute myocardial infarction patients than in control subjects
from the general population: learning from a case control study.
– G. Nilsson, A. Rosenblad, P.O. Hedberg, J. Leppert (Västerås, SE)
Long term effects of bariatric surgery on peripheral endothelial function and on coronary microvascular
function.
– P. Tarzia, A. Villano, S. Figliozzi, G. Russo, R. Parrinello, P. Lamendola, A. Sestito, G.A. Lanza, F. Crea
(Rome, IT)
Short-term impact of bariatric surgery on structural and functional parameters of arterial remodeling in
morbidly obese patients.
– J. Domienik, O. Dzikowska-Diduch, W. Lisik, A. Chmura, P. Pruszczyk (Warsaw, PL)
Clinic, metabolic and hemodynamic benefits of bariatric surgery.
– M. Faustino, S. Baptista, E. Lourenco, P. Leal, C. Monteiro, R. Cabaco, M. Nedio, V. Gil (Amadora, PT)
The impact of central obesity on accelerated progression of noncalcified coronary plaque assessed by
coronary CT angiography: a 4-year-follow-up study.
– A. Imai, S. Komatsu, T. Ohara, T. Kamata, J. Yoshida, K. Miyaji, M. Takewa, Y. Kobayashi, R. Ohe,
K. Kodama (Amagasaki and Suita, JP)
Cardiac structure and function and insulin resistance in morbid obese patients: does superobesity play a
further role?
– F. Antonini-Canterin, A.D. Mateescu, V. Di Bello, S. Carerj, C. Zito, S. La Carrubba, O. Vriz, C. Ginghina,
B.A. Popescu, G.L. Nicolosi (Pordenone, Pisa, Messina, Palermo and San Daniele del Friuli, IT; Bucharest,
RO)
Association of cause-specific mortality with body mass index in Russian population.
– S.A. Shalnova, A.D. Deev, A.V. Kapustina, J.A. Balanova (Moscow, RU)
Age at first detection of overweight and adult lfe course BMI are associated with future increased left
ventricular mass index.
– A.K. Ghosh, R. Hardy, D.P. Francis, J. Mayet, N. Chaturvedi, D. Kuh, J. Deanfied, D. Pellerin, A.D. Hughes
(London, GB)
Age at first detection of overweight and adult life course BMI are associated with future diastolic
dysfunction.
– A.K. Ghosh, A.D. Hughes, D.P. Francis, N. Chaturvedi, J. Mayet, D. Kuh, J. Deanfield, D. Pellerin, R. Hardy
(London, GB)
Sex differences in the relationship between adiposity and left ventricular morphology.
– B. Corden, N.G. Keenan, A.S.M. De Marvao, T.J.W. Dawes, T. Diamond, G. Durighel, S.A. Cook,
D.P. O’Regan (London, GB)
P726
P727
P728
P729
P730
P731
P732
P733
P734
P735
P736
P737
P738
P739
P740
P741
SATURDAY – AFTERNOON
57

58
NOTES